Author: "Begun A" / Topic: business - Searchworks@Jio Institute Digital Library Search Results

311 results on '"Begun A"'

1. Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement

Author: Heba Al-Farhan, Thomas M Goodsall, Dan Carter, Stephanie R. Wilson, Tawnya Hansen, Torsten Kucharzik, Jakob Begun, Christian Maaser, Cathy Lu, Krisztina B Gecse, Britt Christensen, Kim Nylund, Jakob Benedict Seidelin, Marla Dubinsky, Rune Wilkens, Carolina Palmela, Giovanni Maconi, Kerri L. Novak, Robert V Bryant, Mariangela Allocca, Johan F.K.F. Ilvemark, Gastroenterology and Hepatology, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
Subjects: medicine.medical_specialty, Treatment response, Consensus, Treatment outcome, transmural healing, Inflammatory bowel disease, Ultrasound treatment, inflammatory bowel disease, medicine, Humans, Prospective Studies, Intensive care medicine, Prospective cohort study, Ultrasonography, business.industry, Gastroenterology, treatment response, Expert consensus, transmural remission, General Medicine, Inflammatory Bowel Diseases, medicine.disease, Intestinal ultrasound, Intestines, Clinical trial, Response assessment, Chronic Disease, business
Abstract: Background and Aims No consensus exists on defining intestinal ultrasound response, transmural healing, or transmural remission in inflammatory bowel disease, nor clear guidance for optimal timing of assessment during treatment. This systematic review and expert consensus study aimed to define such recommendations, along with key parameters included in response reporting. Methods Electronic databases were searched from inception to July 26, 2021, using pre-defined terms. Studies were eligible if at least two intestinal ultrasound [IUS] assessments at different time points during treatment were reported, along with an appropriate reference standard. The QUADAS-2 tool was used to examine study-level risk of bias. An international panel of experts [n = 18] rated an initial 196 statements [RAND/UCLA process, scale 1–9]. Two videoconferences were conducted, resulting in additional ratings of 149 and 13 statements, respectively. Results Out of 5826 records, 31 full-text articles, 16 abstracts, and one research letter were included; 83% [40/48] of included studies showed a low concern of applicability, and 96% [46/48] had a high risk of bias. A consensus was reached on 41 statements, with clear definitions of IUS treatment response, transmural healing, transmural remission, timing of assessment, and general considerations when using intestinal ultrasound in inflammatory bowel disease. Conclusions Response criteria and time points of response assessment varied between studies, complicating direct comparison of parameter changes and their relation to treatment outcomes. To ensure a unified approach in routine care and clinical trials, we provide recommendations and definitions for key parameters for intestinal ultrasound response, to incorporate into future prospective studies.
Published: 2021

2. Factors Associated With Corporoglandular Shunting for Patients With First-time Ischemic Priapism

Author: Evan Begun, Joshua Palka, William DuComb, and Omar E. Soto-Aviles
Subjects: Adult, Male, Time Factors, Ischemic priapism, Urology, 030232 urology & nephrology, Risk Assessment, Phenylephrine, 03 medical and health sciences, 0302 clinical medicine, Erectile Dysfunction, Ischemia, Risk Factors, Diabetes mellitus, medicine, Humans, Priapism, Retrospective Studies, Receiver operating characteristic, business.industry, Penile Erection, medicine.disease, Shunting, Treatment Outcome, 030220 oncology & carcinogenesis, Anesthesia, Etiology, business, Vascular Surgical Procedures, Body mass index, Shunt (electrical), Penis, medicine.drug
Abstract: Objective To establish predictive factors of patients who failed intra-cavernosal injection therapy and ultimately required corporoglandular shunting during first-time ischemic priapism episodes. Methods A retrospective review was performed of all patients over the age of 18 who presented to our institution with first-time episode of ischemic priapism from 2009 to 2019. Variables assessed included: body mass index, diabetes, hypertension, race, insurance-type, hypertension, etiology, age, duration of erection prior to evaluation, total amount of phenylephrine injected, and use of corporal irrigation. A receiver operating characteristic (ROC) curve was performed utilizing duration of erection and amount of phenylephrine. Results One-hundred and forty-seven patients met inclusion criteria of which 24 patients required surgical intervention. There were differences associated with mean total phenylephrine used, duration of erection between shunted patients and non–shunted patients with regards to age (P = .38) or etiology (P = .81). Multivariable analysis revealed differences between duration of erection and BMI greater than 25 kg/m2. ROC curve analyses revealed total amount of phenylephrine injected and duration of erection were acceptable and excellent predictors of need for shunt procedures with area under the curves of 0.72 and 0.90, respectively. Optimal cut-off values for each were found to be 950 mcg and 15.5 hours. Conclusion Our study suggests that patients who require greater than 950 mcg of total phenylephrine or present with erections lasting greater than 15.5 hours are significantly more likely to require corporoglandular shunting and should be counseled appropriately as such.
Published: 2021

3. Diseases of the Endocrine System in the Population of the Orenburg Region

Author: DS Karmanova, MV Boev, IG Sidorova, DN Begun, and EL Borshchuk
Subjects: education.field_of_study, business.industry, Incidence (epidemiology), Population, Adult population, 030209 endocrinology & metabolism, Medical information, Disease, 03 medical and health sciences, 0302 clinical medicine, Endocrine system, Medicine, Russian federation, 030212 general & internal medicine, education, business, Demography
Abstract: Introduction. The increase in the rates of diseases of the endocrine system has been observed in the Russian Federation for many years. Unfavorable trends, including increasing growth rates and rising incidence and prevalence, are also registered in the Orenburg Region. The prevalence and structure of endocrine disorders in children and adolescents differ significantly from those in adults. The objective of our study was to establish regional features of the structure, dynamics and rates of endocrine morbidity in the population of the Orenburg Region. Materials and methods. We conducted correlation and regression analyses of data extracted from summary statistical reports for 2006–2019 issued by the State Budgetary Health Care Institution for the Orenburg Region “Medical Information and Analytical Center”. Results. In 2006–2019, the incidence rate of diseases of the endocrine system increased by 1.6 and 1.7 times in the Russian Federation and the Orenburg Region, respectively. In 2019, the growth rate in the Orenburg Region was 2.6 %. We observed age-specific differences in disease growth rates: the prevalence in the adult population increased by 1.7 times while in children aged 0–14 years this increase was already by 2.4 times. The incidence rate of endocrine disorders in the population of the Russian Federation and the Volga Federal District increased by 1.2 times, and in the Orenburg Region – by 1.5 times. By 2024, there is a 95 % probability that the prevalence of diseases of the endocrine system will range from 124.3 to 143.3 % while the incidence rates might range from 20.6 to 38.6 % with the same confidence level. Conclusions. Our findings indicate unfavorable trends in the rates of diseases of the endocrine system among both adults and children.
Published: 2021

4. Epidemiological Surveillance of the Impact of the COVID-19 Pandemic on Stroke Care Using Artificial Intelligence

Author: Fadi Nahab, Michael Frankel, Thomas Devlin, Christopher P. Kellner, Wondwossen G Tekle, Tudor G Jovin, Raul G Nogueira, Dina Begun, Diogo C Haussen, Don Frei, Jason M Davies, Nadia Mordenfeld, J Mocco, Adnan H. Siddiqui, Rishi Gupta, K Owada, Ameer E Hassan, Adam S Arthur, Mukund Narayan, Lucas Elijovich, and Mahmoud H Mohammaden
Subjects: Advanced and Specialized Nursing, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Stroke care, medicine.disease, Emergency medicine, Pandemic, medicine, Epidemiological surveillance, Neurology (clinical), Cardiology and Cardiovascular Medicine, business, Stroke
Abstract: Background and Purpose: The degree to which the coronavirus disease 2019 (COVID-19) pandemic has affected systems of care, in particular, those for time-sensitive conditions such as stroke, remains poorly quantified. We sought to evaluate the impact of COVID-19 in the overall screening for acute stroke utilizing a commercial clinical artificial intelligence platform. Methods: Data were derived from the Viz Platform, an artificial intelligence application designed to optimize the workflow of patients with acute stroke. Neuroimaging data on suspected patients with stroke across 97 hospitals in 20 US states were collected in real time and retrospectively analyzed with the number of patients undergoing imaging screening serving as a surrogate for the amount of stroke care. The main outcome measures were the number of computed tomography (CT) angiography, CT perfusion, large vessel occlusions (defined according to the automated software detection), and severe strokes on CT perfusion (defined as those with hypoperfusion volumes >70 mL) normalized as number of patients per day per hospital. Data from the prepandemic (November 4, 2019 to February 29, 2020) and pandemic (March 1 to May 10, 2020) periods were compared at national and state levels. Correlations were made between the inter-period changes in imaging screening, stroke hospitalizations, and thrombectomy procedures using state-specific sampling. Results: A total of 23 223 patients were included. The incidence of large vessel occlusion on CT angiography and severe strokes on CT perfusion were 11.2% (n=2602) and 14.7% (n=1229/8328), respectively. There were significant declines in the overall number of CT angiographies (−22.8%; 1.39–1.07 patients/day per hospital, P P P P P =0.9) and comprehensive stroke center hospitalizations (18.8% versus 11.0%, P =0.4). Conclusions: A significant decline in stroke imaging screening has occurred during the COVID-19 pandemic. This analysis underscores the broader application of artificial intelligence neuroimaging platforms for the real-time monitoring of stroke systems of care.
Published: 2021

5. Pharmacokinetics of low molecular weight heparins in thrombosis, complicate the treatment of children with cancer

Author: V. V. Dmitriev, N. V. Lipay, N. V. Migal, I. V. Begun, and E. V. Dmitriev
Subjects: medicine.medical_specialty, medicine.drug_class, Urology, Low molecular weight heparin, 030204 cardiovascular system & hematology, malignant neoplasms, 03 medical and health sciences, Subcutaneous injection, 0302 clinical medicine, children, Pharmacokinetics, medicine, Diseases of the blood and blood-forming organs, adolescents, anticoagulant therapy, Dalteparin sodium, business.industry, low molecular weight heparin, Anticoagulant, Hematology, Nadroparin calcium, medicine.disease, Venous thrombosis, Oncology, 030220 oncology & carcinogenesis, Nadroparin, venous thrombosis, RC633-647.5, business, medicine.drug
Abstract: Objective: to evaluate the pharmacokinetics of nadroparin and dalteparin in thrombosis complicating the treatment of children with malignant neoplasms.Materials and methods. The results of 52 pharmacokinetic studies performed in 34 patients with malignant neoplasms, whose treatment was complicated by venous thrombosis, were analyzed. The age of the patients is from 7 to 18 years, he median is 14.5 years. Depending on the value of daily dose and type of heparin administered, the results of pharmacokinetic studies were divided into 6 groups. Dalteparin sodium: during period of chemotherapy induced thrombocytopenia, subcutaneous injection at a dose of 51.0 (40.0-72.0) anti Xa IU/kg every 12 hours - 6 studies; subcutaneous injection every 12 hours at a dose of 100.5 (91.0-141.0) anti Xa IU/kg - 18 observations; long-term continuous administration at a constant rate at a daily dose of 201.0 (180.0-265.0) anti Xa IU/kg - 6 pharmacokinetic observations. Nadroparin calcium: 62.0 (53.0-71.0) anti Xa IU/kg every 12 hours - 6 studies; 93.5 (80.0-117.0) anti Xa IU/kg every 12 hours - 10 observations; subcutaneous injection at a dose of 203.0 (170.0-236.0) anti Xa IU/kg once a day - 6 pharmacokinetic observations.Results. At steady-state, the area under the pharmacokinetic curve (AUC) of dalteparin and nadroparin, regardless of the mode of administration, depended on the maximum specific activity and half-life. No relationship was found for dalteparin between AUC and endogenous creatinine clearance. In contrast to dalteparin, the AUC after administration of na-droparin was closely related to endogenous creatinine clearance. The increase in chronometric indices indirectly reflected the presence of an anticoagulant in the blood, but did not allow an objective assessment of therapeutic effect achievement, recorded by the degree of thrombin generation inhibition.Conclusion. There were no significant advantages of nadroparin compared with dalteparin when using in comparable doses in the case of venous thrombosis, complicated the treatment of children with malignant neoplasms. Subcutaneous administration of 50 % nadroparin calcium daily dose with 12 hours interval is preferred over a single administration of 100 % daily dose every 24 hours. It is mandatory to monitor the administration of low molecular weight heparins in children with oncological diseases in order to make a decision on the adequacy of anticoagulant dose to the therapeutic range.
Published: 2021

6. An investment compliance methodology for electric grid companies

Author: Vilena Yakimova and Anastasiya А. Begun
Subjects: Finance, business.industry, 0502 economics and business, 05 social sciences, 050201 accounting, Business, 010501 environmental sciences, Investment (macroeconomics), Grid, 01 natural sciences, 0105 earth and related environmental sciences, Compliance (psychology)
Abstract: Subject. We consider the investment compliance methodology for power grid companies. Objectives. The purpose is to develop a methodology for investment compliance and test it, using the case of a power grid company engaged in investment activities. Methods. The study rests on methods of generalization, systematization, grouping, analysis, working documentation modeling, and planning methods. Results. The developed methodology includes an algorithm for compliance procedures grouped by stage of the life cycle of investment projects, a compliance program, and forms of working documentation. The investment compliance methodology is based on assessment procedures and comparison of information, identification and assessment of the risks of power grid companies, methods of investment analysis and predictive audit. Conclusions. The proposed methodology enables to review the schedule of works according to approved deadlines, to confirm the investment value, and to assess the accuracy of macroeconomic indicators that are chosen as a basis for evaluating the economic efficiency of projects.
Published: 2021

7. Decreasing malpractice claims by reducing preventable perinatal harm

Author: Riley, William, Meredith, Les W., Price, Rebecca, Miller, Kristi K., Begun, James W., McCullough, Mac, and Davis, Stanley
Subjects: Insurance industry -- Rankings -- Health aspects, Evidence-based medicine -- Health aspects, Health care industry -- Rankings -- Health aspects, Medical malpractice insurance -- Rankings -- Health aspects, Patient care -- Health aspects, Medical malpractice -- Health aspects, Health care reform -- Health aspects, Health care industry, Insurance industry, Business
Abstract: Objective. To evaluate the association of improved patient safety practices with medical malpractice claims and costs in the perinatal units of acute care hospitals. Data Sources. Malpractice and harm data from participating hospitals; litigation records and medical malpractice claims data from American Excess Insurance Exchange, RRG, whose data are managed by Premier Insurance Management Services, Inc. (owned by Premier Inc., a health care improvement company). Study Design. A quasi-experimental prospective design to compare baseline and postintervention data. Statistical significance tests for differences were performed using chi-square, Wilcoxon signed-rank test, and i-test. Data Collection. Claims data were collected and evaluated by experienced senior claims managers through on-site claim audits to evaluate claim frequency, severity, and financial information. Data were provided to the analyzing institution through confidentiality contracts. Principal Findings. There is a significant reduction in the number of perinatal malpractice claims paid, losses paid, and indemnity payments (43.9 percent, 77.6 percent, and 84.6 percent, respectively) following interventions to improve perinatal patient safety and reduce perinatal harm. This compares with no significant reductions in the nonperinatal claims in the same hospitals during the same time period. Conclusions. The number of perinatal malpractice claims and dollar amount of claims payments decreased significantly in the participating hospitals, while there was no significant decrease in nonperinatal malpractice claims activity in the same hospitals. Key Words. Perinatal malpractice claims, patient safety, perinatal outcomes, care bundles, in situ simulation training, There is a recognized link between perinatal harm, malpractice claims, and malpractice payments. However, few studies have quantified this relationship and even fewer studies have undertaken efforts to improve perinatal [...]
Published: 2016
Full Text: View/download PDF

8. Integrated approach to reduce perinatal adverse events: standardized processes, interdisciplinary teamwork training, and performance feedback

Author: Riley, William, Begun, James W., Meredith, Les, Miller, Kristi K., Connolly, Kathy, Price, Rebecca, Muri, Janet H., McCullough, Mac, and Davis, Stanley
Subjects: Work groups -- Usage, Medical care -- Quality management, Evidence-based medicine -- Usage, Business, Health care industry
Abstract: Objective. To improve safety practices and reduce adverse events in perinatal units of acute care hospitals. Data Sources. Primary data collected from perinatal units of 14 hospitals participating in the intervention between 2008 and 2012. Baseline secondary data collected from the same hospitals between 2006 and 2007. Study Design. A prospective study involving 342,754 deliveries was conducted using a quality improvement collaborative that supported three primary interventions. Primary measures include adoption of three standardized care processes and four measures of outcomes. Data Collection Methods. Chart audits were conducted to measure the implementation of standardized care processes. Outcome measures were collected and validated by the National Perinatal Information Center. Principal Findings. The hospital perinatal units increased use of all three care processes, raising consolidated overall use from 38 to 81 percent between 2008 and 2012. The harms measured by the Adverse Outcome Index decreased 14 percent, and a run chart analysis revealed two special causes associated with the interventions. Conclusions. This study demonstrates the ability of hospital perinatal staff to implement efforts to reduce perinatal harm using a quality improvement collaborative. Findings help inform the relationship between the use of standardized care processes, teamwork training, and improved perinatal outcomes, and suggest that a multiplicity of integrated strategies, rather than a single intervention, may be essential to achieve high reliability. Key Words. High reliability, perinatal outcomes, quality improvement collaborative, standardized care processes, in situ simulation team training, Labor and delivery pose substantial risk for unintended harm to mothers and newborns. Perinatal complications are reported from 3 to 10.7 percent of all deliveries, ranging from catastrophic events, including [...]
Published: 2016
Full Text: View/download PDF

9. On the possibility of assessment of the level of safety culture automation on the basis of observation of current parameters

Author: P.O. Voloshyn, V.V. Begun, and Systems Problems
Subjects: Basis (linear algebra), business.industry, Computer science, Systems engineering, Safety culture, Current (fluid), business, Automation
Abstract: Safety culture (SC) is a modern paradigm of safety management of ultra-complex technical systems, primarily NPPs. According to the latest researches, the probability of an error made by a human, who professes the principles of safety culture, and the occurrence of accidents in general, compared to previ-ous methods of safety management, is reduced by hundreds of times. Therefore, it is necessary to pro-vide support as much as possible at all levels of government, to train all specialists and explore new pos-sibilities of this paradigm. This article is aimed at developing offers for an algorithm for automated as-sessment of the level of SC power units based on current indicators and indicators of structural units with a selected discreteness in order to further develop an appropriate cloud-based software which will eliminate subjectivism and record the smallest deviations, which, in its turn, will allow to take appropri-ate measures to improve the safety of nuclear power plants in the early stages of negative processes. The term «safety culture» was first formulated by the IAEA in 1986 in the course of the analysis of the causes of the Chernobyl disaster, and published in INSAG-1. The report stated that the lack of safety culture was one of the main causes of the disaster. Safety culture is defined as a set of values and ac-tions that occur as a result of an agreement reached in the team between the top managers and employ-ees to give security the highest priority in order to protect people and the environment. Further under-standing of this concept has led to a new perspective on the causes of other accidents and incidents at nuclear power plants that occurred in the past. The experience of NPP operation shows that their occur-rence is somehow related to people's behavior (namely, their attitude to safety issues), i.e., the current state of the level of safety culture. But as a current safety parameter (SC) it is estimated with a long pe-riod of time. The article offers automation of the assessment process.
Published: 2021

10. A Nucleotide Analog Prevents Colitis-Associated Cancer via Beta-Catenin Independently of Inflammation and AutophagySummary

Author: Iulia Oancea, Andy Wu, Michael A. McGuckin, Sumaira Z. Hasnain, Rabina Giri, John D. Hooper, Veronika Schreiber, Brett C McWhinney, Julie M. Davies, Jakob Begun, Yonghua Sheng, David P. Fairlie, Saleh Y. Alabbas, Gregor Kijanka, Yaowu He, Ramya Movva, Andrew J. Lucke, and Timothy H. Florin
Subjects: rac1 GTP-Binding Protein, 0301 basic medicine, TGTP, thioguanine nucleotide triphosphate, TCF/LEF, T-cell factor/lymphoid enhancer factor, Colorectal cancer, MP, mercaptopurine, TGN, thioguanine nucleotides, medicine.disease_cause, Autophagy-Related Protein 7, Inflammatory bowel disease, BrdU, bromodeoxyuridine, Mice, chemistry.chemical_compound, AOM, azoxymethane, 0302 clinical medicine, GTP, guanosine triphosphate, GTPase, guanosine triphosphatase, DSS, dextran sodium sulfate, Intestinal Mucosa, Wnt Signaling Pathway, beta Catenin, Original Research, GDP, guanosine diphosphate, IBD, inflammatory bowel disease, Colon Cancer, Mercaptopurine, Dextran Sulfate, Gastroenterology, Wnt signaling pathway, Colitis, Atg7ΔIEC, intestinal epithelial cell–specific deletion of autophagy related 7 gene, Editorial, Gene Knockdown Techniques, CRC, colorectal cancer, 030211 gastroenterology & hepatology, Colon, β-Catenin, CAC, colitis-associated cancer, Azoxymethane, Mice, Transgenic, DAI, disease activity index scores, IMPDH, inosine-5′-monophosphate dehydrogenase, 03 medical and health sciences, Administration, Rectal, Anseriformes, medicine, Autophagy, Animals, Humans, lcsh:RC799-869, Thioguanine, IC50, inhibitory concentration of 50%, Hepatology, business.industry, Neuropeptides, Cancer, DMEM, Dulbecco modified Eagle medium, PBS-T, phosphate-buffered saline with 0.1% Tween-20, HCT116 Cells, medicine.disease, WT, wild-type, TG, thioguanine, 030104 developmental biology, chemistry, siRNA, small interfering RNA, Cancer research, BSA, bovine serum albumin, lcsh:Diseases of the digestive system. Gastroenterology, Caco-2 Cells, Colitis-Associated Neoplasms, business, Carcinogenesis, HPRT, hypoxanthine phosphoribosyltransferase gene
Abstract: Background & Aims Chronic bowel inflammation increases the risk of colon cancer; colitis-associated cancer (CAC). Thiopurine treatments are associated with a reduction in dysplasia and CAC in inflammatory bowel disease (IBD). Abnormal Wnt/β-catenin signalling is characteristic of >90% of colorectal cancers. Immunosuppression by thiopurines is via Rac1 GTPase, which also affects Wnt/β-catenin signalling. Autophagy is implicated in colonic tumors, and topical delivery of the thiopurine thioguanine (TG) is known to alleviate colitis and augment autophagy. This study investigated the effects of TG in a murine model of CAC and potential mechanisms. Methods Colonic dysplasia was induced by exposure to azoxymethane (AOM) and dextran sodium sulfate (DSS) in wild-type (WT) mice and mice harboring intestinal epithelial cell–specific deletion of autophagy related 7 gene (Atg7ΔIEC). TG or vehicle was administered intrarectally, and the effect on tumor burden and β-catenin activity was assessed. The mechanisms of action of TG were investigated in vitro and in vivo. Results TG ameliorated DSS colitis in wild-type but not Atg7ΔIEC mice, demonstrating that anti-inflammatory effects of locally delivered TG are autophagy-dependent. However, TG inhibited CAC in both wild-type and Atg7ΔIEC mice. This was associated with decreased β-catenin activation/nuclear translocation demonstrating that TG’s inhibition of tumorigenesis occurred independently of anti-inflammatory and pro-autophagic actions. These results were confirmed in cell lines, and the dependency on Rac1 GTPase was demonstrated by siRNA knockdown and overexpression of constitutively active Rac1. Conclusions Our findings provide evidence for a new mechanism that could be exploited to improve CAC chemoprophylactic approaches., Graphical abstract
Published: 2021

11. Overview of key technological trends of ticket sales at spectacular events

Author: Alexander Urdenko, Maxim Plakhtiy, Anatoly Begun, and Olga Osipova
Subjects: Ticket, Key (cryptography), General Medicine, Business, Marketing
Published: 2020

12. Crohn’s Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease

Author: Graham L. Radford-Smith, David William Carter, Anna McMahon, Australia, Sally Bell, Jane M. Andrews, Alissa Walsh, Rachel Grafton, Krupa Krishnaprasad, Jakob Begun, Susan J. Connor, Alexandra Sechi, Karen Sewell, and Crohn’s Colitis Cure
Subjects: Telemedicine, medicine.medical_specialty, Crohn's colitis, Cloud computing, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, eHealth, Humans, Medicine, Intensive care medicine, Electronic systems, Bespoke, business.industry, Australia, Gastroenterology, Cloud Computing, Colitis, Inflammatory Bowel Diseases, medicine.disease, digestive system diseases, Healthcare utilization, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, business, Software
Abstract: Adherence to evidence-based management is variable in inflammatory bowel disease (IBD), which leads to worse patient outcomes and higher healthcare utilization. Solutions include electronic systems to enhance care, but these have often been limited by lack of clinician design input, poor usability, and low perceived value. A cloud-based IBD-specific clinical management software - 'Crohn's Colitis Care' (CCCare) was developed by Australia and New Zealand Inflammatory Bowel Disease Consortium clinicians and software developers to improve this.CCCare captures patient-reported disease activity and medical assessment, medication monitoring, cancer screening, preventative health, and facilitates communication with the IBD team and referring doctor. De-identified longitudinal data are stored separately in a clinical quality registry for research. CCCare was tested for feasibility and usability in routine clinical settings at two large Australian hospitals. Users' experience was evaluated with System Usability Scale (SUS). Value to clinicians and patients was assessed by qualitative feedback. Security was assessed by penetration testing.Users (Initial evaluation demonstrates CCCare is usable, secure, and valued in clinical use. It is designed to measure outcomes of clinical care, including efficacy, quality, cost, and complications for individuals, and to audit these at hospital and national level.
Published: 2020

13. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study

Author: Ashish Srinivasan, Daniel R. van Langenberg, Lena Thin, Yoon-Kyo An, Sherman Picardo, Jakob Begun, Shankar Menon, Simon Ghaly, and Craig Haifer
Subjects: musculoskeletal diseases, medicine.medical_specialty, Crohn's disease, business.industry, Biosimilar, General Medicine, medicine.disease, Inflammatory bowel disease, Infliximab, Discontinuation, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Cohort, medicine, 030212 general & internal medicine, skin and connective tissue diseases, Adverse effect, business, Cohort study, medicine.drug
Abstract: Objective To examine whether non-medical switching of patients with inflammatory bowel disease (IBD) from originator infliximab to a biosimilar (CT-P13, Inflectra) is safe and clinically non-inferior to continued treatment with originator infliximab. Design Prospective, open label, multicentre, parallel cohort, non-inferiority study in seven Australian hospitals over 48 weeks, May 2017 - October 2019. Participants Adults (18 years or older) with IBD receiving maintenance originator infliximab (Remicade) who had been in steroid-free clinical remission for at least 12 weeks. Intervention Managed program for switching patients in four hospitals from originator to biosimilar infliximab (CT-P13); patients in three other hospitals continued to receive originator infliximab (control). Main outcome measures Clinical disease worsening requiring infliximab dose escalation or change in therapy. Results The switch group included 204 patients, the control group 141 patients with IBD. Ten patients in the control group (7%) and 16 patients switched to CT-P13 (8%) experienced clinical deterioration; the adjusted risk difference (control v switch group) was -1.1 percentage points (95% CI, -6.1 to 8.2 percentage points), within our pre-specified non-inferiority margin of 15 percentage points. Serious adverse events leading to infliximab discontinuation were infrequent in both the switch (six, 3%) and control (six, 4%) groups. Conclusion Switching patients with IBD from originator to biosimilar infliximab is safe and non-inferior to continuing treatment with originator infliximab. Moreover, the introduction of biosimilar infliximab, by increasing market competition, has resulted in substantial cost savings for the Pharmaceutical Benefits Scheme.
Published: 2020

14. ФАКТОРНИЙ АНАЛІЗ ФІНАНСОВИХ РЕЗУЛЬТАТІВ ДІЯЛЬНОСТІ ПІДПРИЄМСТВА: СТАТИСТИЧНА ОЦІНКА

Author: Svitlana Begun
Subjects: Microeconomics, lcsh:HB1-3840, 03 medical and health sciences, детермінований факторний аналіз, прибуток, статистичні методи, мультиплікативна модель, індексна модель, ланцюгові підстановки, ізольований вплив факторів, 0302 clinical medicine, lcsh:Finance, lcsh:HG1-9999, lcsh:Economic theory. Demography, 030206 dentistry, Business, Multiplicative model, Profit (economics)
Abstract: Формування прибутку підприємства залежить від низки чинників, серед яких є ті, що сприяють його зростанню та ті, що призводять до зменшення. Прийняття ефективних управлінських рішень, спрямованих на збільшення розміру доходів та прибутків, можливо на основі факторного аналізу. Методи факторного аналізу дозволяють визначити кількісний внесок кожного фактора у зміні обсягу фінансових результатів. У статті розглянуто особливості детермінованого факторного аналізу на основі статистичних мультиплікативних моделей. Проаналізовано переваги та недоліки методів ланцюгових підстановок і ізольованого впливу факторів. Розраховано чотирьохфакторні індексні моделі валового прибутку виробничого підприємства за 2016-2019 роки. Здійснено порівняльний аналіз величини абсолютного та відносного впливу кожного фактора на валовий прибуток за двома методами.
Published: 2020

15. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford

Author: Emma Flanagan, Peter De Cruz, A. Srinivasan, Susan J. Connor, Paola Chivers, Sally Bell, Ian C. Lawrance, Simon Ghaly, E Sawyer, Tamara Mogilevski, Daniel Cheng, G. Radford-Smith, Simon Travis, Quart Ul Ain Rizvi, Jane M. Andrews, Daniel R. van Langenberg, Peter A. Bampton, Samba Siva Reddy Pulusu, Jakob Begun, Krupa Krishnaprasad, Lena Thin, Gillian Mahy, Charlotte Keung, Soleiman Kashkooli, and Miles P. Sparrow
Subjects: Adult, medicine.medical_specialty, Outcomes, Antibodies, Monoclonal, Humanized, Vedolizumab, 03 medical and health sciences, 0302 clinical medicine, Gastrointestinal Agents, Maintenance therapy, Internal medicine, medicine, Adalimumab, Humans, Retrospective Cohort Study, Retrospective Studies, Gastrointestinal agent, Tumor Necrosis Factor-alpha, business.industry, Australia, Gastroenterology, Retrospective cohort study, General Medicine, medicine.disease, Ulcerative colitis, United Kingdom, Infliximab, Treatment Outcome, 030220 oncology & carcinogenesis, Cohort, Colitis, Ulcerative, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract: BACKGROUND Vedolizumab (VDZ), a humanised monoclonal antibody that selectively inhibits alpha4-beta7 integrins is approved for use in adult moderate to severe ulcerative colitis (UC) patients. AIM To assess the efficacy and safety of VDZ in the real-world management of UC in a large multicenter cohort involving two countries and to identify predictors of achieving remission. METHODS A retrospective review of Australian and Oxford, United Kingdom data for UC patients. Clinical response at 3 mo, endoscopic remission at 6 mo and clinical remission at 3, 6 and 12 mo were assessed. Cox regression models and Kaplan Meier curves were performed to assess the time to remission, time to failure and the covariates influencing them. Safety outcomes were recorded. RESULTS Three hundred and three UC patients from 14 centres in Australia and United Kingdom, [60% n = 182, anti-TNF naïve] were included. The clinical response was 79% at 3 mo with more Australian patients achieving clinical response compared to Oxford (83% vs 70% P = 0.01). Clinical remission for all patients was 56%, 62% and 60% at 3, 6 and 12 mo respectively. Anti-TNF naive patients were more likely to achieve remission than exposed patients at all the time points (3 mo 66% vs 40% P < 0.001, 6 mo 73% vs 46% P < 0.001, 12 mo 66% vs 51% P = 0.03). More Australian patients achieved endoscopic remission at 6 mo compared to Oxford (69% vs 43% P = 0.01). On multi-variate analysis, anti-TNF naïve patients were 1.8 (95%CI: 1.3-2.3) times more likely to achieve remission than anti-TNF exposed (P < 0.001). 32 patients (11%) had colectomy by 12 mo. CONCLUSION VDZ was safe and effective with 60% of UC patients achieving clinical remission at 12 mo and prior anti-TNF exposure influenced this outcome.
Published: 2020

16. Practical management of inflammatory bowel disease patients during the <scp>COVID</scp> ‐19 pandemic: expert commentary from the Gastroenterological Society of Australia <scp>Inflammatory Bowel Disease</scp> faculty

Author: Al Ani Aysha, Jakob Begun, Robert V Bryant, Britt Christensen, Mark G. Ward, Doug Johnson, Simon Ghaly, Clarissa Rentsch, Samuel P Costello, Ralley E Prentice, Susan J. Connor, and Peter Lewindon
Subjects: medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Clinical Perspectives, Pneumonia, Viral, Change Management, Context (language use), 030204 cardiovascular system & hematology, Inflammatory bowel disease, SARS‐CoV‐2, Betacoronavirus, 03 medical and health sciences, 0302 clinical medicine, COVID‐19, inflammatory bowel disease, Pandemic, Internal Medicine, medicine, Humans, Immunologic Factors, 030212 general & internal medicine, Disease management (health), Intensive care medicine, Pandemics, ulcerative colitis, Risk Management, immunosuppression, SARS-CoV-2, business.industry, Public health, Australia, Gastroenterology, Crohn disease, COVID-19, Disease Management, Immunosuppression, Inflammatory Bowel Diseases, medicine.disease, Ulcerative colitis, Patient Care Management, Practice Guidelines as Topic, Coronavirus Infections, business
Abstract: The COVID‐19 pandemic, caused by the novel coronavirus SARS‐CoV‐2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS‐CoV‐2 manifests with a severe acute respiratory illness and currently there are insufficient data regarding the virulence of COVID‐19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease (IBD) patients in the context of the COVID‐19 pandemic in the Australasian setting.
Published: 2020

17. 'This Research Is Cool': Engaging Youth Experiencing Homelessness in Research on Reproductive and Sexual Health

Author: Cressida Frey, Joshua Spring, Alicia Fortin, Simran R A Arora, Ariel Weber, and Stephanie Begun
Subjects: medicine.medical_specialty, Biomedical Research, Health (social science), Adolescent, Social work, business.industry, Health Policy, Public health, media_common.quotation_subject, Taboo, Public Health, Environmental and Occupational Health, Face (sociological concept), Citizen journalism, Criminology, Homeless Youth, Homeless youths, medicine, Humans, Narrative, Sexual Health, Psychology, business, media_common, Reproductive health
Abstract: Youth experiencing homelessness face myriad barriers and inequities regarding their reproductive and sexual health and rights. Moreover, homeless youth are often characterized as "disaffiliated" and depicted as difficult to engage in research. This study qualitatively explored homeless youths' attitudes, beliefs, and needs regarding reproductive and sexual health, and sought their perspectives on being involved in research on such topics, which are often thought of as "taboo" or sensitive. Youth were enthusiastic about openly discussing such issues, which they deemed as highly relevant to their daily lives. Youth identified that how they were engaged in such research, and having opportunities for longer-term contributions to such efforts, were both important and exciting to them. Future social work and public health research efforts should seek to further disrupt narratives of homeless youth as "disaffiliated" and difficult to engage, and in doing so, develop more creative, participatory, and youth-led opportunities for including this group in reproductive and sexual health research.
Published: 2020

18. Aeromedical retrievals for gastrointestinal disorders in rural and remote Australia: the need for improved access to specialist advice

Author: Fergus W. Gardiner, Kathryn McMahon, Susan J. Connor, Lara Bishop, Jakob Begun, Jane M. Andrews, and Ezekiel Uba Nwose
Subjects: Rural Population, Service (business), Gastrointestinal Diseases, business.industry, Australia, Air Ambulances, 030204 cardiovascular system & hematology, medicine.disease, Medical care, Advice (programming), 03 medical and health sciences, 0302 clinical medicine, parasitic diseases, Internal Medicine, Humans, population characteristics, Medicine, Rural Health Services, 030212 general & internal medicine, Medical emergency, business, human activities
Abstract: The Royal Flying Doctor Service (RFDS) provides medical care to populations without access to traditional health-care services. From 2014 to 2018 the RFDS conducted 6007 (≈1201/year) aeromedical retrievals for gastrointestinal (GI) disorders. More detailed research is needed to determine specific GI disorders that contributed to this caseload, and in particular inform whether the establishment of a GI specialist service is justified.
Published: 2020

19. Monitoring Inflammatory Bowel Disease in Pregnancy Using Gastrointestinal Ultrasonography

Author: Jakob Begun, Yoon-Kyo An, Katerina V Kiburg, Emily K Wright, Robert V Bryant, Sally Bell, Alyson L Ross, and Emma Flanagan
Subjects: Adult, medicine.medical_specialty, Colon, Ileum, Sensitivity and Specificity, Severity of Illness Index, Gastroenterology, Inflammatory bowel disease, Feces, Predictive Value of Tests, Pregnancy, Internal medicine, Severity of illness, medicine, Humans, Correlation of Data, Ultrasonography, Crohn's disease, business.industry, Australia, Patient Acuity, General Medicine, Inflammatory Bowel Diseases, medicine.disease, Faecal calprotectin, Pregnancy Complications, medicine.anatomical_structure, Predictive value of tests, Feasibility Studies, Gestation, Female, business, Leukocyte L1 Antigen Complex, Procedures and Techniques Utilization
Abstract: Background and Aims Inflammatory bowel disease [IBD] affects women during their childbearing years. Gastrointestinal ultrasonography [GIUS] accurately identifies disease activity in non-pregnant patients with IBD. The utility of GIUS in pregnancy has not been established. We aimed to determine the feasibility and accuracy of GIUS in the assessment of IBD during pregnancy progression. Methods A multicentre observational study of women with IBD undergoing GIUS during pregnancy. Clinicians assessed the adequacy of bowel views and disease activity in four colonic segments and the terminal ileum. Location[s] in which views were impeded by the uterus were documented. GIUS disease activity [bowel wall thickness >3 mm] was compared with biochemical disease activity [faecal calprotectin >100 μg/g]. Results Ninety patients and 127 GIUS examinations were included [median gestation 19 weeks, range 4–33]. Adequate colonic views were obtained in 116/127 [91%] scans. Adequate ileal views were obtained in 62/67 [93%] scans Conclusions GIUS is a feasible and accurate modality for monitoring IBD in pregnancy. Adequate GIUS views of the colon and terminal ileum can be obtained in the majority of patients up to 20 weeks of gestation. Beyond 20 weeks, GIUS provides good views of the colon but the terminal ileum becomes difficult to assess.
Published: 2020

20. Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease‐related knowledge

Author: Lucinda Van De Ven, Yoon-Kyo An, Serena Martin, Samuel P Costello, Robert V Bryant, James Fon, Jakob Begun, Arvind Rajagopalan, and Dharshan Sathananthan
Subjects: medicine.medical_specialty, Visual analogue scale, Population, Colonoscopy, RC799-869, Disease, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, inflammatory bowel disease, Internal medicine, medicine, point‐of‐care ultrasound, Prospective cohort study, education, education.field_of_study, Hepatology, medicine.diagnostic_test, business.industry, patient perceptions, Gastroenterology, Original Articles, Diseases of the digestive system. Gastroenterology, medicine.disease, digestive system diseases, inflammatory bowel disease imaging, Tolerability, 030220 oncology & carcinogenesis, Original Article, 030211 gastroenterology & hepatology, business, gastrointestinal ultrasound, Blood sampling
Abstract: Background and Aim Objective monitoring of disease activity is integral to therapeutic decision‐making in inflammatory bowel disease (IBD). Data are sparse on patients' perspectives of tools used to monitor disease activity in IBD. To evaluate patients' perspectives of gastrointestinal ultrasound (GIUS) performed during routine IBD clinical care, along with its impact on IBD‐specific knowledge. Methods Patients with a formal diagnosis of IBD who underwent GIUS at two tertiary IBD services between March 2017 and January 2019 participated in this prospective study. Participants completed a questionnaire measuring the acceptability, tolerability, and usefulness of GIUS using a visual analogue scale (VAS) from 0 (disagree) to 10 (strongly agree). Comparative acceptability of IBD monitoring tools and the impact of GIUS on IBD‐specific knowledge was measured. Results A total of 121 participants completed the questionnaire, with a mean age of 42 years (range 17–78), 54 (45%) males, and 79 (65%) Crohn's disease patients. In the overall population, GIUS was scored as highly acceptable for monitoring IBD (mean 9.20 ± 1.37) compared to colonoscopy (7.94 ± 2.30), stool sampling (8.17 ± 1.96), blood sampling (8.87 ± 1.62), and imaging (8.67 ± 1.60); P, Gastrointestinal ultrasound (GIUS) is being increasingly used for disease monitoring in inflammatory bowel disease; however, patient perceptions of the different modalities available are sparse. This article evaluates patient perceptions, finding that GIUS was preferred to other modalities, and it was also found to have an impact on disease‐related knowledge.
Published: 2020

21. Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

Author: Rupert W. Leong, Michael A. Kamm, Samuel P Costello, Hiu Tat Chan, David van der Poorten, Paul D R Johnson, David Andresen, Andrew M. Redmond, Harsha Sheorey, Craig Haifer, Simon Ghaly, Daniel A. Lemberg, Sudarshan Paramsothy, Thomas J. Borody, Ramesh Paramsothy, Jane M. Andrews, Lito E. Papanicolas, Susan J. Connor, Genevieve McKew, Colleen R. Kelly, and Jakob Begun
Subjects: Male, medicine.medical_specialty, Consensus, Best practice, Donor Selection, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Multidisciplinary approach, medicine, Humans, Production (economics), Relevance (law), 030212 general & internal medicine, Grading (education), Intensive care medicine, business.industry, Donor selection, Australia, Gastroenterology, Fecal Microbiota Transplantation, Treatment Outcome, Practice Guidelines as Topic, New product development, Clostridium Infections, Female, 030211 gastroenterology & hepatology, Health Facilities, business
Abstract: ObjectiveFaecal microbiota transplantation (FMT) has proved to be an extremely effective treatment for recurrent Clostridioides difficile infection, and there is interest in its potential application in other gastrointestinal and systemic diseases. However, the recent death and episode of septicaemia following FMT highlights the need for further appraisal and guidelines on donor evaluation, production standards, treatment facilities and acceptable clinical indications.DesignFor these consensus statements, a 24-member multidisciplinary working group voted online and then convened in-person, using a modified Delphi approach to formulate and refine a series of recommendations based on best evidence and expert opinion. Invitations to participate were directed to Australian experts, with an international delegate assisting the development. The following issues regarding the use of FMT in clinical practice were addressed: donor selection and screening, clinical indications, requirements of FMT centres and future directions. Evidence was rated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.ResultsConsensus was reached on 27 statements to provide guidance on best practice in FMT. These include: (1) minimum standards for donor screening with recommended clinical selection criteria, blood and stool testing; (2) accepted routes of administration; (3) clinical indications; (4) minimum standards for FMT production and requirements for treatment facilities acknowledging distinction between single-site centres (eg, hospital-based) and stool banks; and (5) recommendations on future research and product development.ConclusionsThese FMT consensus statements provide comprehensive recommendations around the production and use of FMT in clinical practice with relevance to clinicians, researchers and policy makers.
Published: 2020

22. Early identification of tubulointerstitial renal injury in hypertensive patients: a comparative evaluation of the urine biomarkers NGAL and KIM 1

Author: D. N. Begun, O. B. Kuzmin, V. V. Zhezha, V. A. Tsareva, and T. G. Gubanova
Subjects: medicine.medical_specialty, Kidney, business.industry, Renal function, Urine, 030204 cardiovascular system & hematology, medicine.disease, Gastroenterology, Confidence interval, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Internal medicine, Diabetes mellitus, Concomitant, Internal Medicine, Albuminuria, Medicine, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Kidney disease
Abstract: Objective. The aim of the study was a comparative assessment of urine NGAL (neutrophil gelatinase associated lipocalin) and KIM‑1 (kidney injury molecule‑1) as biomarkers of early detection of tubulointerstitial renal damage in patients with arterial hypertension (HTN) without concomitant diabetes mellitus and kidney disease.Design and methods. The study involved 52 patients of both sexes (17 man and 35 women, mean age 60,2 ± 6,54 years) hospitalized for aggravation of HTN 1–3 degrees, which were divided into 3 groups with glomerular filtration rate (GFR) > 90 ml/min/1,73 m 2 (n = 21), 60–90 ml/min/1,73 m 2 (n = 19) and < 60 ml/min/1,73 m 2 (n = 12). In a separate group, patients with albuminuria in the range 10–29 mg/g urine creatinine were isolated. The comparison group consisted of 15 normotensive individuals (6 men and 9 women, mean age 49,8 ± 9,68 years) with no obvious signs of renal, cardiovascular or other diseases. All patients and controls underwent examination, and albumin, NGAL (Human NGAL ELISA kit) and KIM‑1 (Human KIM‑1 Immunoassay ELISA) levels were assessed in the first morning urine portion.Results. In the group of patients with GFR 67,7 ± 4,92 ml/min/1,73 m 2 (mildly reduced kidney function) and in the group of patients with GFR 55,8 ± 4,44 ml/min/1,73 m 2 (renal dysfunction) urine NGAL level increased by 3,43 (р < 0,05) and 3,92 times (р < 0,05), respectively, as compared with the control group. The urine concentration of KIM‑1 increased by 2,06 times (р < 0,05) was observed only in patients with renal dysfunction. Based on the ROC analysis AUC for the urine NGAL level in patients with mildly reduced kidney function is 0,78 (95 % confidence interval, 95 %CI: 0,70–0,86; p < 0,001), specificity — 89,6 %, sensitivity — 66,7 %. Similar indicators for KIM‑1 are 0,72 (95 % CI: 0,64–0,80; p < 0,001), specificity — 85,3 %, sensitivity — 16,7 %. In the group of patients with mildly reduced kidney function the urine level of NGAL correlated with the HTN severity (r = 0,8944, р < 0,001) and its duration (r = 0,8953, р < 0,001).Conclusions. Urine NGAL as compared with KIM‑1 is a more sensitive biomarker, which indicates tubulointerstitial injury in HTN patients without diabetes mellitus and kidney diseases in the early stage of impairment renal function.
Published: 2019

23. Malnutrition and quality of life among adult inflammatory bowel disease patients

Author: Jessica Pulley, Alwyn S Todd, Jakob Begun, and Christopher Flatley
Subjects: medicine.medical_specialty, Population, RC799-869, malnutrition, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, Quality of life, inflammatory bowel disease, Internal medicine, medicine, education, ulcerative colitis, education.field_of_study, Crohn's disease, Hepatology, business.industry, Gastroenterology, Original Articles, Odds ratio, Diseases of the digestive system. Gastroenterology, medicine.disease, Ulcerative colitis, Malnutrition, quality of life, 030220 oncology & carcinogenesis, Original Article, 030211 gastroenterology & hepatology, Underweight, medicine.symptom, business
Abstract: Background and Aim Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gut resulting in a significant risk for malnutrition. The reported prevalence of malnutrition in inflammatory disease patients varies from 5.7 to 82.8%. The aim of this study was to measure the prevalence of malnutrition and its association with quality of life (QOL) in a cohort of Australian IBD outpatients. Methods A total of 107 consecutive patients (68 Crohn's disease, 35 ulcerative colitis, 4 indeterminate colitis) were enrolled in this cross‐sectional study. Demographic data were collected, and patients underwent a malnutrition assessment using the patient‐generated subjective global assessment. The RAND 36‐item health survey was used to measure QOL. Results Mild to moderate malnutrition was detected in 17 patients (16%). Malnourished patients were more likely to be underweight (P ≤ 0.01), have active disease (P ≤ 0.01), and have been admitted to hospital in the preceding 12 months (P ≤ 0.05). Malnourished patients had a significantly lower QOL in physical (P ≤ 0.01) and mental (P ≤ 0.01) health components. Patients with active or recently active disease had reduced QOL compared to patients in remission. Malnutrition factors predictive of poor physical health‐related QOL were pain (odds ratio [OR] = 12.8, 95% confidence interval [CI] 2.0–80.4) and unintentional weight loss (OR = 3.1 per kg lost, 95% CI 1.2–7.9). The predictor of poor mental health‐related QOL was early satiety (OR = 7.7, 95% CI 1.7–33.9). Conclusions The malnutrition prevalence for this population was 16%. Malnutrition was associated with being underweight, active disease, and increased number of hospital admissions. Disease activity and malnutrition were associated with poorer QOL., In an outpatient cohort of inflammatory bowel disease patients, we found a malnutrition prevalence of 16%. Malnutrition was associated with being underweight, active disease, and an increased number of hospital admissions and was associated with poorer quality of life.
Published: 2019

24. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta‐analysis

Author: Ecushla C Linedale, Jakob Begun, Fergus W. Gardiner, Jane M. Andrews, Teresa Neeman, Susan J. Connor, David Prince, and Yoon-Kyo An
Subjects: Adult, medicine.medical_specialty, Population, Colonoscopy, Inflammatory bowel disease, Gastroenterology, Feces, Internal medicine, medicine, Humans, Child, education, Mass screening, Irritable bowel syndrome, education.field_of_study, medicine.diagnostic_test, business.industry, Area under the curve, General Medicine, Middle Aged, Inflammatory Bowel Diseases, medicine.disease, Faecal calprotectin, Child, Preschool, Meta-analysis, business, Leukocyte L1 Antigen Complex
Abstract: Objectives To assess the clinical effectiveness of faecal calprotectin (FC) testing for distinguishing between organic gastrointestinal diseases (organic GID), such as inflammatory bowel disease (IBD), and functional gastrointestinal disorders (functional GIDs). Study design Studies that assessed the accuracy of FC testing for differentiating between IBD or organic GID and functional GIDs were reviewed. Articles published in English during January 1998 - June 2018 that compared diagnostic FC testing in primary care and outpatient hospital settings with a reference test and employed the standard enzyme-linked immunosorbent FC assay method with a cut-off of 50 or 100 μg/g faeces were included. Study quality was assessed with QUADAS-2, an evidence-based quality assessment tool for diagnostic accuracy studies. Data sources MEDLINE and EMBASE; reference lists of screened articles. Data synthesis Eighteen relevant studies were identified. For distinguishing patients with organic GID (including IBD) from those with functional GIDs (16 studies), the estimated sensitivity of FC testing was 81% (95% CI, 74-86%), the specificity 81% (95% CI, 71-88%); area under the curve (AUC) was 0.87. For distinguishing IBD from functional GIDs (ten studies), sensitivity was 88% (95% CI, 80-93%), specificity 72% (95% CI, 59-82%), and AUC 0.89. Assuming a population prevalence of organic GID of 1%, the positive predictive value was 4.2%, the negative predictive value 100%. The difference in sensitivity and specificity between FC testing cut-offs of 50 μg/g and 100 μg/g faeces was not statistically significant (P = 0.77). Conclusions FC testing is clinically useful for distinguishing organic GID (including IBD) from functional GIDs, and its incorporation into clinical practice for evaluating patients with lower gastrointestinal symptoms could lead to fewer patients with functional GIDs undergoing colonoscopy, reducing costs for both patients and the health system. Prospero registration CRD4201810507.
Published: 2019

25. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1

Author: Klionsky, Daniel, Abdel-Aziz, Amal Kamal, Abdelfatah, Sara, Abdellatif, Mahmoud, Abdoli, Asghar, Abel, Steffen, Abeliovich, Hagai, Abildgaard, Marie, Abudu, Yakubu Princely, Acevedo-Arozena, Abraham, Adamopoulos, Iannis, Adeli, Khosrow, Adolph, Timon, Adornetto, Annagrazia, Aflaki, Elma, Agam, Galila, Agarwal, Anupam, Aggarwal, Bharat, Agnello, Maria, Agostinis, Patrizia, Agrewala, Javed, Agrotis, Alexander, Aguilar, Patricia, Ahmad, S Tariq, Ahmed, Zubair, Ahumada-Castro, Ulises, Aits, Sonja, Aizawa, Shu, Akkoc, Yunus, Akoumianaki, Tonia, Akpinar, Hafize Aysin, Al-Abd, Ahmed, Al-Akra, Lina, Al-Gharaibeh, Abeer, Alaoui-Jamali, Moulay, Alberti, Simon, Alcocer-Gómez, Elísabet, Alessandri, Cristiano, Ali, Muhammad, Alim Al-Bari, M Abdul, Aliwaini, Saeb, Alizadeh, Javad, Almacellas, Eugènia, Almasan, Alexandru, Alonso, Alicia, Alonso, Guillermo, Altan-Bonnet, Nihal, Altieri, Dario, Álvarez, Élida, Alves, Sara, Alves Da Costa, Cristine, Alzaharna, Mazen, Amadio, Marialaura, Amantini, Consuelo, Amaral, Cristina, Ambrosio, Susanna, Amer, Amal, Ammanathan, Veena, An, Zhenyi, Andersen, Stig, Andrabi, Shaida, Andrade-Silva, Magaiver, Andres, Allen, Angelini, Sabrina, Ann, David, Anozie, Uche, Ansari, Mohammad, Antas, Pedro, Antebi, Adam, Antón, Zuriñe, Anwar, Tahira, Apetoh, Lionel, Apostolova, Nadezda, Araki, Toshiyuki, Araki, Yasuhiro, Arasaki, Kohei, Araújo, Wagner, Araya, Jun, Arden, Catherine, Arévalo, Maria-Angeles, Arguelles, Sandro, Arias, Esperanza, Arikkath, Jyothi, Arimoto, Hirokazu, Ariosa, Aileen, Armstrong-James, Darius, Arnauné-Pelloquin, Laetitia, Aroca, Angeles, Arroyo, Daniela, Arsov, Ivica, Artero, Rubén, Asaro, Dalia Maria Lucia, Aschner, Michael, Ashrafizadeh, Milad, Ashur-Fabian, Osnat, Atanasov, Atanas, Au, Alicia, Auberger, Patrick, Auner, Holger, Aurelian, Laure, Autelli, Riccardo, Avagliano, Laura, Ávalos, Yenniffer, Aveic, Sanja, Aveleira, Célia Alexandra, Avin-Wittenberg, Tamar, Aydin, Yucel, Ayton, Scott, Ayyadevara, Srinivas, Azzopardi, Maria, Baba, Misuzu, Backer, Jonathan, Backues, Steven, Bae, Dong-Hun, Bae, Ok-Nam, Bae, Soo Han, Baehrecke, Eric, Baek, Ahruem, Baek, Seung-Hoon, Baek, Sung Hee, Bagetta, Giacinto, Bagniewska-Zadworna, Agnieszka, Bai, Hua, Bai, Jie, Bai, Xiyuan, Bai, Yidong, Bairagi, Nandadulal, Baksi, Shounak, Balbi, Teresa, Baldari, Cosima, Balduini, Walter, Ballabio, Andrea, Ballester, Maria, Balazadeh, Salma, Balzan, Rena, Bandopadhyay, Rina, Banerjee, Sreeparna, Banerjee, Sulagna, Bánréti, Ágnes, Bao, Yan, Baptista, Mauricio, Baracca, Alessandra, Barbati, Cristiana, Bargiela, Ariadna, Barilà, Daniela, Barlow, Peter, Barmada, Sami, Barreiro, Esther, Barreto, George, Bartek, Jiri, Bartel, Bonnie, Bartolome, Alberto, Barve, Gaurav, Basagoudanavar, Suresh, Bassham, Diane, Bast, Robert, Basu, Alakananda, Batoko, Henri, Batten, Isabella, Baulieu, Etienne, Baumgarner, Bradley, Bayry, Jagadeesh, Beale, Rupert, Beau, Isabelle, Beaumatin, Florian, Bechara, Luiz, Beck, George, Beers, Michael, Begun, Jakob, Behrends, Christian, Behrens, Georg, Bei, Roberto, Bejarano, Eloy, Bel, Shai, Behl, Christian, Belaid, Amine, Belgareh-Touzé, Naïma, Bellarosa, Cristina, Belleudi, Francesca, Belló Pérez, Melissa, Bello-Morales, Raquel, Beltran, Jackeline Soares de Oliveira, Beltran, Sebastián, Benbrook, Doris Mangiaracina, Bendorius, Mykolas, Benitez, Bruno, Benito-Cuesta, Irene, Bensalem, Julien, Berchtold, Martin, Berezowska, Sabina, Bergamaschi, Daniele, Bergami, Matteo, Bergmann, Andreas, Berliocchi, Laura, Berlioz-Torrent, Clarisse, Bernard, Amélie, Berthoux, Lionel, Besirli, Cagri, Besteiro, Sebastien, Betin, Virginie, Beyaert, Rudi, Bezbradica, Jelena, Bhaskar, Kiran, Bhatia-Kissova, Ingrid, Bhattacharya, Resham, Bhattacharya, Sujoy, Bhattacharyya, Shalmoli, Bhuiyan, Md Shenuarin, Bhutia, Sujit Kumar, Bi, Lanrong, Bi, Xiaolin, Biden, Trevor, Bijian, Krikor, Billes, Viktor, Binart, Nadine, Bincoletto, Claudia, Birgisdottir, Asa, Bjorkoy, Geir, Blanco, Gonzalo, Blas-Garcia, Ana, Blasiak, Janusz, Blomgran, Robert, Blomgren, Klas, Blum, Janice, Boada-Romero, Emilio, Boban, Mirta, Boesze-Battaglia, Kathleen, Boeuf, Philippe, Boland, Barry, Bomont, Pascale, Bonaldo, Paolo, Bonam, Srinivasa Reddy, Bonfili, Laura, Bonifacino, Juan, Boone, Brian, Bootman, Martin, Bordi, Matteo, Borner, Christoph, Bornhauser, Beat, Borthakur, Gautam, Bosch, Jürgen, Bose, Santanu, botana, luis, Botas, Juan, Boulanger, Chantal, Boulton, Michael, Bourdenx, Mathieu, Bourgeois, Benjamin, Bourke, Nollaig, Bousquet, Guilhem, Boya, Patricia, Bozhkov, Peter, Bozi, Luiz, Bozkurt, Tolga, Brackney, Doug, Brandts, Christian, Braun, Ralf, Braus, Gerhard, Bravo-Sagua, Roberto, Bravo-San Pedro, José, Brest, Patrick, Bringer, Marie-Agnès, Briones-Herrera, Alfredo, Broaddus, V Courtney, Brodersen, Peter, Brodsky, Jeffrey, Brody, Steven, Bronson, Paola, Bronstein, Jeff, Brown, Carolyn, Brown, Rhoderick, Brum, Patricia, Brumell, John, Brunetti-Pierri, Nicola, Bruno, Daniele, Bryson-Richardson, Robert, Bucci, Cecilia, Buchrieser, Carmen, Bueno, Marta, Buitrago-Molina, Laura Elisa, Buraschi, Simone, Buch, Shilpa, Buchan, J Ross, Buckingham, Erin, Budak, Hikmet, Budini, Mauricio, Bultynck, Geert, Burada, Florin, Burgoyne, Joseph, Burón, M Isabel, Bustos, Victor, Büttner, Sabrina, Butturini, Elena, Byrd, Aaron, Cabas, Isabel, Cabrera-Benitez, Sandra, Cadwell, Ken, Cai, Jingjing, Cai, Lu, Cai, Qian, Cairó, Montserrat, Calbet, Jose, Caldwell, Guy, Caldwell, Kim, Call, Jarrod, Calvani, Riccardo, Calvo, Ana, Calvo-Rubio Barrera, Miguel, Camara, Niels OS, Camonis, Jacques, Camougrand, Nadine, Campanella, Michelangelo, Campbell, Edward, Campbell-Valois, François-Xavier, Campello, Silvia, Campesi, Ilaria, Campos, Juliane, Camuzard, Olivier, Cancino, Jorge, Candido de Almeida, Danilo, Canesi, Laura, Caniggia, Isabella, Canonico, Barbara, Cantí, Carles, Cao, Bin, Caraglia, Michele, Caramés, Beatriz, Carchman, Evie, Cardenal-Muñoz, Elena, Cardenas, Cesar, Cardenas, Luis, Cardoso, Sandra, Carew, Jennifer, Carle, Georges, Carleton, Gillian, Carloni, Silvia, Carmona-Gutierrez, Didac, Carneiro, Leticia, Carnevali, Oliana, Carosi, Julian, Carra, Serena, Carrier, Alice, Carrier, Lucie, Carroll, Bernadette, Carter, A Brent, Carvalho, Andreia Neves, Casanova, Magali, Casas, Caty, Casas, Josefina, Cassioli, Chiara, Castillo, Eliseo, Castillo, Karen, Castillo-Lluva, Sonia, Castoldi, Francesca, Castori, Marco, Castro, Ariel, Castro-Caldas, Margarida, Castro-Hernandez, Javier, Castro-Obregon, Susana, Catz, Sergio, Cavadas, Claudia, Cavaliere, Federica, Cavallini, Gabriella, Cavinato, Maria, Cayuela, Maria, Cebollada Rica, Paula, Cecarini, Valentina, Cecconi, Francesco, Cechowska-Pasko, Marzanna, Cenci, Simone, Ceperuelo-Mallafré, Victòria, Cerqueira, João, Cerutti, Janete, Cervia, Davide, Cetintas, Vildan Bozok, Cetrullo, Silvia, Chae, Han-Jung, Chagin, Andrei, Chai, Chee-Yin, Chakrabarti, Gopal, Chakrabarti, Oishee, Chakraborty, Tapas, Chakraborty, Trinad, Chami, mounia, Chamilos, Georgios, Chan, David, Chan, Edmond, Chan, Edward, Chan, H.Y. Edwin, Chan, Helen, Chan, Hung, Chan, Matthew, Chan, Yau Sang, Chandra, Partha, Chang, Chih-Peng, Chang, Chunmei, Chang, Hao-Chun, Chang, Kai, Chao, Jie, Chapman, Tracey, Charlet-Berguerand, Nicolas, Chatterjee, Samrat, Chaube, Shail, Chaudhary, Anu, Chauhan, Santosh, Chaum, Edward, Checler, Frédéric, Cheetham, Michael, Chen, Chang-Shi, Chen, Guang-Chao, Chen, Jian-Fu, Chen, Liam, Chen, Leilei, Chen, Lin, Chen, Mingliang, Chen, Mu-Kuan, Chen, Ning, Chen, Quan, Chen, Ruey-Hwa, Chen, Shi, Chen, Wei, Chen, Weiqiang, Chen, Xin-Ming, Chen, Xiong-Wen, Chen, Xu, Chen, Yan, Chen, Ye-Guang, Chen, Yingyu, Chen, Yongqiang, Chen, Yu-Jen, Chen, Yue-Qin, Chen, Zhefan Stephen, Chen, Zhi, Chen, Zhi-Hua, Chen, Zhijian, Chen, Zhixiang, Cheng, Hanhua, Cheng, Jun, Cheng, Shi-Yuan, Cheng, Wei, Cheng, Xiaodong, Cheng, Xiu-Tang, Cheng, Yiyun, Cheng, Zhiyong, Chen, Zhong, Cheong, Heesun, Cheong, Jit Kong, Chernyak, Boris, Cherry, Sara, Cheung, Chi Fai Randy, Cheung, Chun Hei Antonio, Cheung, King-Ho, Chevet, Eric, Chi, Richard, Chiang, Alan Kwok Shing, Chiaradonna, Ferdinando, Chiarelli, Roberto, Chiariello, Mario, Chica, Nathalia, Chiocca, Susanna, Chiong, Mario, Chiou, Shih-Hwa, Chiramel, Abhilash, Chiurchiù, Valerio, Cho, Dong-Hyung, Choe, Seong-Kyu, Choi, Augustine, Choi, Mary, Choudhury, Kamalika Roy, Chow, Norman, Chu, Charleen, Chua, Jason, Chua, John Jia En, Chung, Hyewon, Chung, Kin Pan, Chung, Seockhoon, Chung, So-Hyang, Chung, Yuen-Li, Cianfanelli, Valentina, Ciechomska, Iwona, Cifuentes, Mariana, Cinque, Laura, Cirak, Sebahattin, Cirone, Mara, Clague, Michael, Clarke, Robert, Clementi, Emilio, Coccia, Eliana, Codogno, Patrice, Cohen, Ehud, Cohen, Mickael, Colasanti, Tania, Colasuonno, Fiorella, Colbert, Robert, Colell, Anna, Čolić, Miodrag, Coll, Nuria, Collins, Mark, Colombo, María, Colón-Ramos, Daniel, Combaret, Lydie, Comincini, Sergio, Cominetti, Márcia, Consiglio, Antonella, Conte, Andrea, Conti, Fabrizio, Contu, Viorica Raluca, Cookson, Mark, Coombs, Kevin, Coppens, Isabelle, Corasaniti, Maria Tiziana, Corkery, Dale, Cordes, Nils, Cortese, Katia, Costa, Maria do Carmo, Costantino, Sarah, Costelli, Paola, Coto-Montes, Ana, Crack, Peter, Crespo, Jose, Criollo, Alfredo, Crippa, Valeria, Cristofani, Riccardo, Csizmadia, Tamas, Cuadrado, Antonio, Cui, Bing, Cui, Jun, Cui, Yixian, Cui, Yong, Culetto, Emmanuel, Cumino, Andrea, Cybulsky, Andrey, Czaja, Mark, Czuczwar, Stanislaw, D'Adamo, Stefania, D'Amelio, Marcello, D'Arcangelo, Daniela, D'Lugos, Andrew, D'Orazi, Gabriella, da Silva, James, Dafsari, Hormos Salimi, Dagda, Ruben, Dagdas, Yasin, Daglia, Maria, Dai, Xiaoxia, Dai, Yun, Dai, Yuyuan, Dal Col, Jessica, Dalhaimer, Paul, Dalla Valle, Luisa, Dallenga, Tobias, Dalmasso, Guillaume, Damme, Markus, Dando, Ilaria, Dantuma, Nico, Darling, April, Das, Hiranmoy, Dasarathy, Srinivasan, Dasari, Santosh, Dash, Srikanta, Daumke, Oliver, Dauphinee, Adrian, Davies, Jeffrey, Dávila, Valeria, Davis, Roger, Davis, Tanja, Dayalan Naidu, Sharadha, De Amicis, Francesca, De Bosscher, Karolien, De Felice, Francesca, De Franceschi, Lucia, De Leonibus, Chiara, de Mattos Barbosa, Mayara, De Meyer, Guido, De Milito, Angelo, De Nunzio, Cosimo, De Palma, Clara, De Santi, Mauro, De Virgilio, Claudio, De Zio, Daniela, Debnath, Jayanta, DeBosch, Brian, Decuypere, Jean-Paul, Deehan, Mark, Deflorian, Gianluca, DeGregori, James, Dehay, Benjamin, Del Rio, Gabriel, Delaney, Joe, Delbridge, Lea, Delorme-Axford, Elizabeth, Delpino, M Victoria, Demarchi, Francesca, Dembitz, Vilma, Demers, Nicholas, Deng, Hongbin, Deng, Zhiqiang, Dengjel, Joern, Dent, Paul, Denton, Donna, DePamphilis, Melvin, Der, Channing, Deretic, Vojo, Descoteaux, Albert, Devis, Laura, Devkota, Sushil, Devuyst, Olivier, Dewson, Grant, Dharmasivam, Mahendiran, Dhiman, Rohan, di Bernardo, Diego, Di Cristina, Manlio, Di Domenico, Fabio, Di Fazio, Pietro, Di Fonzo, Alessio, Di Guardo, Giovanni, Di Guglielmo, Gianni, Di Leo, Luca, Di Malta, Chiara, Di Nardo, Alessia, Di Rienzo, Martina, Di Sano, Federica, Diallinas, George, Diao, Jiajie, Diaz-Araya, Guillermo, Díaz-Laviada, Inés, Dickinson, Jared, Diederich, Marc, Dieudé, Mélanie, Dikic, Ivan, Ding, Shiping, Ding, Wen-Xing, Dini, Luciana, Dinić, Jelena, Dinic, Miroslav, Dinkova-Kostova, Albena, Dionne, Marc, Distler, Jörg, Diwan, Abhinav, Dixon, Ian, Djavaheri-Mergny, Mojgan, Dobrinski, Ina, Dobrovinskaya, Oxana, Dobrowolski, Radek, Dobson, Renwick, Đokić, Jelena, Dokmeci Emre, Serap, Donadelli, Massimo, Dong, Bo, Dong, Xiaonan, Dong, Zhiwu, Dorn Ii, Gerald, Dotsch, Volker, Dou, Huan, Dou, Juan, Dowaidar, Moataz, Dridi, Sami, Drucker, Liat, Du, Ailian, Du, Caigan, Du, Guangwei, Du, Hai-Ning, Du, Li-Lin, du Toit, André, Duan, Shao-Bin, Duan, Xiaoqiong, Duarte, Sónia, Dubrovska, Anna, Dunlop, Elaine, Dupont, Nicolas, Durán, Raúl, Dwarakanath, Bilikere, Dyshlovoy, Sergey, Ebrahimi-Fakhari, Darius, Eckhart, Leopold, Edelstein, Charles, Efferth, Thomas, Eftekharpour, Eftekhar, Eichinger, Ludwig, Eid, Nabil, Eisenberg, Tobias, Eissa, N Tony, Eissa, Sanaa, Ejarque, Miriam, El Andaloussi, Abdeljabar, El-Hage, Nazira, El-Naggar, Shahenda, Eleuteri, Anna Maria, El-Shafey, Eman, Elgendy, Mohamed, Eliopoulos, Aristides, Elizalde, María, Elks, Philip, Elsasser, Hans-Peter, Elsherbiny, Eslam, Emerling, Brooke, Emre, N., Eng, Christina, Engedal, Nikolai, Engelbrecht, Anna-Mart, Engelsen, Agnete, Enserink, Jorrit, Escalante, Ricardo, Esclatine, Audrey, Escobar-Henriques, Mafalda, Eskelinen, Eeva-Liisa, Espert, Lucile, Eusebio, Makandjou-Ola, Fabrias, Gemma, Fabrizi, Cinzia, Facchiano, Antonio, Facchiano, Francesco, Fadeel, Bengt, Fader, Claudio, Faesen, Alex, Fairlie, W Douglas, Falcó, Alberto, Falkenburger, Bjorn, Fan, Daping, Fan, Jie, Fan, Yanbo, Fang, Evandro, Fang, Yanshan, Fang, Yognqi, Fanto, Manolis, Farfel-Becker, Tamar, Faure, Mathias, Fazeli, Gholamreza, Fedele, Anthony, Feldman, Arthur, Feng, Du, Feng, Jiachun, Feng, Lifeng, Feng, Yibin, Feng, Yuchen, Feng, Wei, Fenz Araujo, Thais, Ferguson, Thomas, Fernández, Álvaro, Fernandez-Checa, Jose, Fernández-Veledo, Sonia, Fernie, Alisdair, Ferrante, Anthony, Ferraresi, Alessandra, Ferrari, Merari, Ferreira, Julio, Ferro-Novick, Susan, Figueras, Antonio, Filadi, Riccardo, Filigheddu, Nicoletta, Filippi-Chiela, Eduardo, Filomeni, Giuseppe, Fimia, Gian Maria, Fineschi, Vittorio, Finetti, Francesca, Finkbeiner, Steven, Fisher, Edward, Fisher, Paul, Flamigni, Flavio, Fliesler, Steven, Flo, Trude, Florance, Ida, Florey, Oliver, Florio, Tullio, Fodor, Erika, Follo, Carlo, Fon, Edward, Forlino, Antonella, Fornai, Francesco, Fortini, Paola, Fracassi, Anna, Fraldi, Alessandro, Franco, Brunella, Franco, Rodrigo, Franconi, Flavia, Frankel, Lisa, Friedman, Scott, Fröhlich, Leopold, Frühbeck, Gema, Fuentes, Jose, Fujiki, Yukio, Fujita, Naonobu, Fujiwara, Yuuki, Fukuda, Mitsunori, Fulda, Simone, Furic, Luc, Furuya, Norihiko, Fusco, Carmela, Gack, Michaela, Gaffke, Lidia, Galadari, Sehamuddin, Galasso, Alessia, Galindo, Maria, Gallolu Kankanamalage, Sachith, Galluzzi, Lorenzo, Galy, Vincent, Gammoh, Noor, Gan, Boyi, Ganley, Ian, Gao, Feng, Gao, Hui, Gao, Minghui, Gao, Ping, Gao, Shou-Jiang, Gao, Wentao, Gao, Xiaobo, Garcera, Ana, Garcia, Maria Noé, Garcia, Verónica, García-del Portillo, Francisco, Garcia-Escudero, Vega, Garcia-Garcia, Aracely, Garcia-Macia, Marina, García-Moreno, Diana, Garcia-Ruiz, Carmen, García-Sanz, Patricia, Garg, Abhishek, Gargini, Ricardo, Garofalo, Tina, Garry, Robert, Gassen, Nils, Gatica, Damian, Ge, Liang, Ge, Wanzhong, Geiss-Friedlander, Ruth, Gelfi, Cecilia, Genschik, Pascal, Gentle, Ian, Gerbino, Valeria, Gerhardt, Christoph, Germain, Kyla, Germain, Marc, Gewirtz, David, Ghasemipour Afshar, Elham, Ghavami, Saeid, Ghigo, Alessandra, Ghosh, Manosij, Giamas, Georgios, Giampietri, Claudia, Giatromanolaki, Alexandra, Gibson, Gary, Gibson, Spencer, Ginet, Vanessa, Giniger, Edward, Giorgi, Carlotta, Girao, Henrique, Girardin, Stephen, Giridharan, Mridhula, Giuliano, Sandy, Giulivi, Cecilia, Giuriato, Sylvie, Giustiniani, Julien, Gluschko, Alexander, Goder, Veit, Goginashvili, Alexander, Golab, Jakub, Goldstone, David, Golebiewska, Anna, Gomes, Luciana, Gomez, Rodrigo, Gómez-Sánchez, Rubén, Gomez-Puerto, Maria Catalina, Gomez-Sintes, Raquel, Gong, Qingqiu, Goni, Felix, González-Gallego, Javier, Gonzalez-Hernandez, Tomas, Gonzalez-Polo, Rosa, Gonzalez-Reyes, Jose, González-Rodríguez, Patricia, Goping, Ing Swie, Gorbatyuk, Marina, Gorbunov, Nikolai, Görgülü, Kıvanç, Gorojod, Roxana, Gorski, Sharon, Goruppi, Sandro, Gotor, Cecilia, Gottlieb, Roberta, Gozes, Illana, Gozuacik, Devrim, Graef, Martin, Gräler, Markus, Granatiero, Veronica, Grasso, Daniel, Gray, Joshua, Green, Douglas, Greenhough, Alexander, Gregory, Stephen, Griffin, Edward, Grinstaff, Mark, Gros, Frederic, Grose, Charles, Gross, Angelina, Gruber, Florian, Grumati, Paolo, Grune, Tilman, Gu, Xueyan, Guan, Jun-Lin, Guardia, Carlos, Guda, Kishore, Guerra, Flora, Guerri, Consuelo, Guha, Prasun, Guillén, Carlos, Gujar, Shashi, Gukovskaya, Anna, Gukovsky, Ilya, Gunst, Jan, Günther, Andreas, Guntur, Anyonya, Guo, Chuanyong, Guo, Chun, Guo, Hongqing, Guo, Lian-Wang, Guo, Ming, Gupta, Pawan, Gupta, Shashi Kumar, Gupta, Swapnil, Gupta, Veer Bala, Gupta, Vivek, Gustafsson, Asa, Gutterman, David, H B, Ranjitha, Haapasalo, Annakaisa, Haber, James, Hać, Aleksandra, Hadano, Shinji, Hafrén, Anders, Haidar, Mansour, Hall, Belinda, Halldén, Gunnel, Hamacher-Brady, Anne, Hamann, Andrea, Hamasaki, Maho, Han, Weidong, Hansen, Malene, Hanson, Phyllis, Hao, Zijian, Harada, Masaru, Harhaji-Trajkovic, Ljubica, Hariharan, Nirmala, Haroon, Nigil, Harris, James, Hasegawa, Takafumi, Hasima Nagoor, Noor, Haspel, Jeffrey, Haucke, Volker, Hawkins, Wayne, Hay, Bruce, Haynes, Cole, Hayrabedyan, Soren, Hays, Thomas, He, Congcong, He, Qin, He, Rong-Rong, He, You-Wen, He, Yu-Ying, Heakal, Yasser, Heberle, Alexander, Hejtmancik, J Fielding, Helgason, Gudmundur Vignir, Henkel, Vanessa, Herb, Marc, Hergovich, Alexander, Herman-Antosiewicz, Anna, Hernández, Agustín, Hernandez, Carlos, Hernandez-Diaz, Sergio, Hernandez-Gea, Virginia, Herpin, Amaury, Herreros, Judit, Hervás, Javier, Hesselson, Daniel, Hetz, Claudio, Heussler, Volker, Higuchi, Yujiro, Hilfiker, Sabine, Hill, Joseph, Hlavacek, William, Ho, Emmanuel, Ho, Idy, Ho, Philip Wing-Lok, Ho, Shu-Leong, Ho, Wan Yun, Hobbs, G Aaron, Hochstrasser, Mark, Hoet, Peter, Hofius, Daniel, Hofman, Paul, Höhn, Annika, Holmberg, Carina, Hombrebueno, Jose, Yi-Ren Hong, Chang-Won Hong, Hooper, Lora, Hoppe, Thorsten, Horos, Rastislav, Hoshida, Yujin, Hsin, I-Lun, Hsu, Hsin-Yun, Hu, Bing, Hu, Dong, Hu, Li-Fang, Hu, Ming Chang, Hu, Ronggui, Hu, Wei, Hu, Yu-Chen, Hu, Zhuo-Wei, Hua, Fang, Hua, Jinlian, Hua, Yingqi, Huan, Chongmin, Huang, Canhua, Huang, Chuanshu, Huang, Chuanxin, Huang, Chunling, Huang, Haishan, Huang, Kun, Huang, Michael, Huang, Rui, Huang, Shan, Huang, Tianzhi, Huang, Xing, Huang, Yuxiang Jack, Huber, Tobias, Hubert, Virginie, Hubner, Christian, Hughes, Stephanie, Hughes, William, Humbert, Magali, Hummer, Gerhard, Hurley, James, Hussain, Sabah, Hussain, Salik, Hussey, Patrick, Hutabarat, Martina, Hwang, Hui-Yun, Hwang, Seungmin, Ieni, Antonio, Ikeda, Fumiyo, Imagawa, Yusuke, Imai, Yuzuru, Imbriano, Carol, Imoto, Masaya, Inman, Denise, Inoki, Ken, Iovanna, Juan, Iozzo, Renato, Ippolito, Giuseppe, Irazoqui, Javier, Iribarren, Pablo, Ishaq, Mohd, ISHIKAWA, Makoto, Ishimwe, Nestor, Isidoro, Ciro, Ismail, Nahed, Issazadeh-Navikas, Shohreh, Itakura, Eisuke, Ito, Daisuke, Ivankovic, Davor, Ivanova, Saška, Iyer, Anand Krishnan V, Izquierdo, José, Izumi, Masanori, Jäättelä, Marja, Jabir, Majid Sakhi, Jackson, William, Jacobo-Herrera, Nadia, Jacomin, Anne-Claire, Jacquin, Elise, Jadiya, Pooja, Jaeschke, Hartmut, Jagannath, Chinnaswamy, Jakobi, Arjen, Jakobsson, Johan, Janji, Bassam, Jansen-Dürr, Pidder, Jansson, Patric, Jantsch, Jonathan, Januszewski, Sławomir, Jassey, Alagie, Jean, Steve, Jeltsch-David, Hélène, Jendelova, Pavla, Jenny, Andreas, Jensen, Thomas, Jessen, Niels, Jewell, Jenna, Ji, Jing, Jia, Lijun, Jia, Rui, Jiang, Liwen, Jiang, Qing, Jiang, Richeng, Jiang, Teng, Jiang, Xuejun, Jiang, Yu, Jimenez-Sanchez, Maria, Jin, Eun-Jung, Jin, Fengyan, Jin, Hongchuan, Jin, Li, Jin, Luqi, Jin, Meiyan, Jin, Si, Jo, Eun-Kyeong, Joffre, Carine, Johansen, Terje, Johnson, Gail, Johnston, Simon, Jokitalo, Eija, Jolly, Mohit Kumar, Joosten, Leo, Jordan, Joaquin, Joseph, Bertrand, Ju, Dianwen, Ju, Jeong-Sun, Ju, Jingfang, Juárez, Esmeralda, Judith, Delphine, Juhász, Gábor, Jun, Youngsoo, Jung, Chang Hwa, Jung, Sung-Chul, Jung, Yong Keun, Jungbluth, Heinz, Jungverdorben, Johannes, Just, Steffen, Kaarniranta, Kai, Kaasik, Allen, Kabuta, Tomohiro, Kaganovich, Daniel, Kahana, Alon, Kain, Renate, Kajimura, Shinjo, Kalamvoki, Maria, Kalia, Manjula, Kalinowski, Danuta, Kaludercic, Nina, Kalvari, Ioanna, Kaminska, Joanna, Kaminskyy, Vitaliy, Kanamori, Hiromitsu, Kanasaki, Keizo, Kang, Chanhee, Kang, Rui, Kang, Sang Sun, Kaniyappan, Senthilvelrajan, Kanki, Tomotake, Kanneganti, Thirumala-Devi, Kanthasamy, Anumantha, Kanthasamy, Arthi, Kantorow, Marc, Kapuy, Orsolya, Karamouzis, Michalis, Karim, Md Razaul, Karmakar, Parimal, Katare, Rajesh, Kato, Masaru, Kaufmann, Stefan, Kauppinen, Anu, Kaushal, Gur, Kaushik, Susmita, Kawasaki, Kiyoshi, Kazan, Kemal, Ke, Po-Yuan, Keating, Damien, Keber, Ursula, Kehrl, John, Keller, Kate, Keller, Christian, Kemper, Jongsook Kim, Kenific, Candia, Kepp, Oliver, Kermorgant, Stephanie, Kern, Andreas, Ketteler, Robin, Keulers, Tom, Khalfin, Boris, Khalil, Hany, Khambu, Bilon, Khan, Shahid, Khandelwal, Vinoth Kumar Megraj, Khandia, Rekha, Kho, Widuri, Khobrekar, Noopur, Khuansuwan, Sataree, Khundadze, Mukhran, Killackey, Samuel, Kim, Dasol, Kim, Deok Ryong, Kim, Do-Hyung, Kim, Dong-Eun, Kim, Eun Young, Kim, Eun-Kyoung, Kim, Hak-Rim, Kim, Hee-Sik, Kim, Hyung Ryong, Kim, Jeong Hun, Kim, Jin Kyung, Kim, Jin-Hoi, Kim, Joungmok, Kim, Ju Hwan, Kim, Keun Il, Kim, Peter, Kim, Seong-Jun, Kimball, Scot, Kimchi, Adi, Kimmelman, Alec, Kimura, Tomonori, King, Matthew, Kinghorn, Kerri, Kinsey, Conan, Kirkin, Vladimir, Kirshenbaum, Lorrie, Kiselev, Sergey, Kishi, Shuji, Kitamoto, Katsuhiko, Kitaoka, Yasushi, Kitazato, Kaio, Kitsis, Richard, Kittler, Josef, Kjaerulff, Ole, Klein, Peter, Klopstock, Thomas, Klucken, Jochen, Knævelsrud, Helene, Knorr, Roland, Ko, Ben, Ko, Fred, Ko, Jiunn-Liang, Kobayashi, Hotaka, Kobayashi, Satoru, Koch, Ina, Koch, Jan, Koenig, Ulrich, Kögel, Donat, Koh, Young Ho, Koike, Masato, Kohlwein, Sepp, Kocaturk, Nur, Komatsu, Masaaki, König, Jeannette, Kono, Toru, Kopp, Benjamin, Korcsmaros, Tamas, Korkmaz, Gözde, Korolchuk, Viktor, Korsnes, Mónica Suárez, Koskela, Ali, Kota, Janaiah, Kotake, Yaichiro, Kotler, Monica, Kou, Yanjun, Koukourakis, Michael, Koustas, Evangelos, Kovacs, Attila, Kovács, Tibor, Koya, Daisuke, Kozako, Tomohiro, Kraft, Claudine, Krainc, Dimitri, Krämer, Helmut, Krasnodembskaya, Anna, Kretz-Remy, Carole, Kroemer, Guido, Ktistakis, Nicholas, Kuchitsu, Kazuyuki, Kuenen, Sabine, Kuerschner, Lars, Kukar, Thomas, Kumar, Ajay, Kumar, Ashok, Kumar, Deepak, Kumar, Dhiraj, Kumar, Sharad, Kume, Shinji, Kumsta, Caroline, Kundu, Chanakya, Kundu, Mondira, Kunnumakkara, Ajaikumar, Kurgan, Lukasz, Kutateladze, Tatiana, Kutlu, Ozlem, Kwak, SeongAe, Kwon, Ho Jeong, Kwon, Taeg Kyu, Kwon, Yong Tae, Kyrmizi, Irene, La Spada, Albert, Labonté, Patrick, Ladoire, Sylvain, Laface, Ilaria, Lafont, Frank, Lagace, Diane, Lahiri, Vikramjit, Lai, Zhibing, Laird, Angela, Lakkaraju, Aparna, Lamark, Trond, Lan, Sheng-Hui, Landajuela, Ane, Lane, Darius, Lane, Jon, Lang, Charles, Lange, Carsten, Langel, Ülo, Langer, Rupert, Lapaquette, Pierre, Laporte, Jocelyn, LaRusso, Nicholas, Lastres-Becker, Isabel, Lau, Wilson Chun Yu, Laurie, Gordon, Lavandero, Sergio, Law, Betty Yuen Kwan, Law, Helen Ka-wai, Layfield, Rob, Le, Weidong, Le Stunff, Herve, Leary, Alexandre, Lebrun, Jean-Jacques, Leck, Lionel, Leduc-Gaudet, Jean-Philippe, Lee, Changwook, Lee, Chung-Pei, Lee, Da-Hye, Lee, Edward, Lee, Erinna, Lee, Gyun Min, Lee, He-Jin, Lee, Heung Kyu, Lee, Jae Man, Lee, Jason, Lee, Jin-A, Lee, Joo-Yong, Lee, Jun Hee, Lee, Michael, Lee, Min Goo, Lee, Min Jae, Lee, Myung-Shik, Lee, Sang Yoon, Lee, Seung-Jae, Lee, Stella, Lee, Sung Bae, Lee, Won Hee, Lee, Ying-Ray, Lee, Yong-ho, Lee, Youngil, Lefebvre, Christophe, Legouis, Renaud, Lei, Yu, Lei, Yuchen, Leikin, Sergey, Leitinger, Gerd, Lemus, Leticia, Leng, Shuilong, Lenoir, Olivia, Lenz, Guido, Lenz, Heinz Josef, Lenzi, Paola, León, Yolanda, Leopoldino, Andréia, Leschczyk, Christoph, Leskelä, Stina, Letellier, Elisabeth, Leung, Chi-Ting, Leung, Po Sing, Leventhal, Jeremy, Levine, Beth, Lewis, Patrick, Ley, Klaus, Li, Bin, Li, Da-Qiang, Li, Jianming, Li, Jing, Li, Jiong, Li, Ke, Li, Liwu, Li, Mei, Li, Min, Li, Ming, Li, Mingchuan, Li, Pin-Lan, Li, Ming-Qing, Li, Qing, Li, Sheng, Li, Tiangang, Li, Wei, Li, Wenming, Li, Xue, Li, Yi-Ping, Li, Yuan, Li, Zhiqiang, Li, Zhiyong, Li, Zhiyuan, Lian, Jiqin, Liang, Chengyu, Liang, Qiangrong, Liang, Weicheng, Liang, Yongheng, Liang, YongTian, Liao, Guanghong, Liao, Lujian, Liao, Mingzhi, Liao, Yung-Feng, Librizzi, Mariangela, Lie, Pearl, Lilly, Mary, Lim, Hyunjung, Lima, Thania, Limana, Federica, Lin, Chao, Lin, Chih-Wen, Lin, Dar-Shong, Lin, Fu-Cheng, Lin, Jiandie, Lin, Kurt, Lin, Kwang-Huei, Lin, Liang-Tzung, LIN, Pei-Hui, Lin, Qiong, Lin, Shaofeng, Lin, Su-Ju, Lin, Wenyu, Lin, Xueying, Lin, Yao-Xin, Lin, Yee-Shin, Linden, Rafael, Lindner, Paula, Ling, Shuo-Chien, Lingor, Paul, Linnemann, Amelia, Liou, Yih-Cherng, Lipinski, Marta, Lipovšek, Saška, Lira, Vitor, Lisiak, Natalia, Liton, Paloma, Liu, Chao, Liu, Ching-Hsuan, Liu, Chun-Feng, Liu, Cui Hua, Liu, Fang, Liu, Hao, Liu, Hsiao-Sheng, Liu, Hua-feng, Liu, Huifang, Liu, Jia, Liu, Jing, Liu, Julia, Liu, Leyuan, Liu, Longhua, Liu, Meilian, Liu, Qin, Liu, Wei, Liu, Wende, Liu, Xiao-Hong, Liu, Xiaodong, Liu, Xingguo, Liu, Xu, Liu, Xuedong, Liu, Yanfen, Liu, Yang, Liu, Yueyang, Liu, Yule, Livingston, J Andrew, Lizard, Gerard, Lizcano, Jose, Ljubojevic-Holzer, Senka, LLeonart, Matilde, Llobet-Navàs, David, Llorente, Alicia, Lo, Chih Hung, Lobato-Márquez, Damián, Long, Qi, Long, Yun Chau, Loos, Ben, Loos, Julia, López, Manuela, López-Doménech, Guillermo, López-Guerrero, José Antonio, López-Jiménez, Ana, López-Pérez, Óscar, López-Valero, Israel, Lorenowicz, Magdalena, Lorente, Mar, Lorincz, Peter, Lossi, Laura, Lotersztajn, Sophie, Lovat, Penny, Lovell, Jonathan, Lovy, Alenka, Lőw, Péter, Lu, Guang, Lu, Haocheng, Lu, Jia-Hong, Lu, Jin-Jian, Lu, Mengji, Lu, Shuyan, Luciani, Alessandro, Lucocq, John, Ludovico, Paula, Luftig, Micah, Luhr, Morten, Luis-Ravelo, Diego, Lum, Julian, Luna-Dulcey, Liany, Lund, Anders, Lund, Viktor, Lünemann, Jan, Lüningschrör, Patrick, Luo, Honglin, Luo, Rongcan, Luo, Shouqing, Luo, Zhi, Luparello, Claudio, Lüscher, Bernhard, Luu, Luan, Lyakhovich, Alex, Lyamzaev, Konstantin, Lystad, Alf Håkon, Lytvynchuk, Lyubomyr, Ma, Alvin, Ma, Changle, Ma, Mengxiao, Ma, Ning-Fang, Ma, Quan-Hong, Ma, Xinliang, Ma, Yueyun, Ma, Zhenyi, MacDougald, Ormond, Macian, Fernando, MacIntosh, Gustavo, MacKeigan, Jeffrey, Macleod, Kay, Maday, Sandra, Madeo, Frank, Madesh, Muniswamy, Madl, Tobias, Madrigal-Matute, Julio, Maeda, Akiko, Maejima, Yasuhiro, Magarinos, Marta, Mahavadi, Poornima, Maiani, Emiliano, Maiese, Kenneth, Maiti, Panchanan, Maiuri, Maria Chiara, Majello, Barbara, Major, Michael, Makareeva, Elena, Malik, Fayaz, Mallilankaraman, Karthik, Malorni, Walter, Maloyan, Alina, Mammadova, Najiba, Man, Gene Chi Wai, Manai, Federico, Mancias, Joseph, Mandelkow, Eva-Maria, Mandell, Michael, Manfredi, Angelo, Manjili, Masoud, Manjithaya, Ravi, Manque, Patricio, Manshian, Bella, Manzano, Raquel, Manzoni, Claudia, Mao, Kai, Marchese, Cinzia, Marchetti, Sandrine, Marconi, Anna Maria, Marcucci, Fabrizio, Mardente, Stefania, Mareninova, Olga, Margeta, Marta, Mari, Muriel, Marinelli, Sara, Marinelli, Oliviero, Mariño, Guillermo, Mariotto, Sofia, Marshall, Richard, Marten, Mark, Martens, Sascha, Martin, Alexandre, Martin, Katie, Martin, Sara, Martin, Shaun, Martín-Segura, Adrián, Martín-Acebes, Miguel, Martin-Burriel, Inmaculada, Martin-Rincon, Marcos, Martin-Sanz, Paloma, Martina, José, Martinet, Wim, Martinez, Aitor, Martinez, Ana, Martinez, Jennifer, Martinez Velazquez, Moises, Martinez-Lopez, Nuria, Martinez-Vicente, Marta, Martins, Daniel, Martins, Joilson, Martins, Waleska, Martins-Marques, Tania, Marzetti, Emanuele, Masaldan, Shashank, Masclaux-Daubresse, Celine, Mashek, Douglas, Massa, Valentina, Massieu, Lourdes, Masson, Glenn, Masuelli, Laura, Masyuk, Anatoliy, Masyuk, Tetyana, Matarrese, Paola, Matheu, Ander, Matoba, Satoaki, Matsuzaki, Sachiko, Mattar, Pamela, Matte, Alessandro, Mattoscio, Domenico, Mauriz, José, Mauthe, Mario, Mauvezin, Caroline, Maverakis, Emanual, Maycotte, Paola, Mayer, Johanna, Mazzoccoli, Gianluigi, Mazzoni, Cristina, Mazzulli, Joseph, McCarty, Nami, Mcdonald, Christine, McGill, Mitchell, McKenna, Sharon, Mclaughlin, Bethann, McLoughlin, Fionn, McNiven, Mark, McWilliams, Thomas, Mechta-Grigoriou, Fatima, Medeiros, Tania Catarina, Medina, Diego, Megeney, Lynn, Megyeri, Klara, Mehrpour, Maryam, Mehta, Jawahar, Meijer, Alfred, Meijer, Annemarie, Mejlvang, Jakob, Meléndez, Alicia, Melk, Annette, Memisoglu, Gonen, Mendes, Alexandrina, Meng, Delong, Meng, Fei, Meng, Tian, Menna-Barreto, Rubem, Menon, Manoj, Mercer, Carol, Mercier, Anne, MERGNY, Jean-Louis, Merighi, Adalberto, Merkley, Seth, Merla, Giuseppe, Meske, Volker, Mestre, Ana Cecilia, Metur, Shree Padma, Meyer, Christian, Meyer, Hemmo, Mi, Wenyi, Mialet-Perez, Jeanne, Miao, Junying, Micale, Lucia, Miki, Yasuo, Milan, Enrico, Milczarek, Małgorzata, Miller, Dana, Miller, Samuel, Miller, Silke, Millward, Steven, Milosevic, Ira, Minina, Elena, Mirzaei, Hamed, Mirzaei, Hamid Reza, Mirzaei, Mehdi, Mishra, Amit, Mishra, Nandita, Mishra, Paras Kumar, Misirkic Marjanovic, Maja, Misasi, Roberta, Misra, Amit, Misso, Gabriella, Mitchell, Claire, Mitou, Geraldine, Miura, Tetsuji, Miyamoto, Shigeki, MIYAZAKI, Makoto, Miyazaki, Mitsunori, Miyazaki, Taiga, Miyazawa, Keisuke, Mizushima, Noboru, Mogensen, Trine, Mograbi, Baharia, Mohammadinejad, Reza, Mohamud, Yasir, Mohanty, Abhishek, Mohapatra, Sipra, Möhlmann, Torsten, Mohmmed, Asif, Moles, Anna, Moley, Kelle, Molinari, Maurizio, Mollace, Vincenzo, Møller, Andreas Buch, Mollereau, Bertrand, Mollinedo, Faustino, Montagna, Costanza, Monteiro, Mervyn, Montella, Andrea, Montes, L Ruth, Montico, Barbara, Mony, Vinod, Monzio Compagnoni, Giacomo, Moore, Michael, Moosavi, Mohammad, Mora, Ana, Mora, Marina, Morales-Alamo, David, Moratalla, Rosario, Moreira, Paula, Morelli, Elena, Moreno, Sandra, Moreno-Blas, Daniel, Moresi, Viviana, Morga, Benjamin, Morgan, Alwena, Morin, Fabrice, Morishita, Hideaki, Moritz, Orson, Moriyama, Mariko, Moriyasu, Yuji, Morleo, Manuela, Morselli, Eugenia, Moruno-Manchon, Jose, Moscat, Jorge, Mostowy, Serge, Motori, Elisa, Moura, Andrea Felinto, Moustaid-Moussa, Naima, Mrakovcic, Maria, Muciño-Hernández, Gabriel, Mukherjee, Anupam, Mukhopadhyay, Subhadip, Mulcahy Levy, Jean, Mulero, Victoriano, Muller, Sylviane, Münch, Christian, Munjal, Ashok, Munoz-Canoves, Pura, Muñoz-Galdeano, Teresa, Münz, Christian, Murakawa, Tomokazu, Muratori, Claudia, Murphy, Brona, Murphy, J Patrick, Murthy, Aditya, Myöhänen, Timo, Mysorekar, Indira, Mytych, Jennifer, Nabavi, Seyed Mohammad, Nabissi, Massimo, Nagy, Péter, Nah, Jihoon, Nahimana, Aimable, Nakagawa, Ichiro, Nakamura, Ken, Nakatogawa, Hitoshi, Nandi, Shyam, Nanjundan, Meera, Nanni, Monica, Napolitano, Gennaro, Nardacci, Roberta, Narita, Masashi, Nassif, Melissa, Nathan, Ilana, Natsumeda, Manabu, Naude, Ryno, Naumann, Christin, Naveiras, Olaia, Navid, Fatemeh, Nawrocki, Steffan, Nazarko, Taras, Nazio, Francesca, Negoita, Florentina, Neill, Thomas, Neisch, Amanda, Neri, Luca, Netea, Mihai, Neubert, Patrick, Neufeld, Thomas, Neumann, Dietbert, Neutzner, Albert, Newton, Phillip, Ney, Paul, Nezis, Ioannis, Ng, Charlene, Ng, Tzi Bun, Nguyen, Hang, Nguyen, Long, Ni, Hong-Min, Ní Cheallaigh, Clíona, Ni, Zhenhong, Nicolao, M Celeste, Nicoli, Francesco, Nieto-Diaz, Manuel, Nilsson, Per, Ning, Shunbin, Niranjan, Rituraj, Nishimune, Hiroshi, Niso-Santano, Mireia, Nixon, Ralph, Nobili, Annalisa, Nobrega, Clevio, Noda, Takeshi, Nogueira-Recalde, Uxía, Nolan, Trevor, Nombela, Ivan, Novak, Ivana, Novoa, Beatriz, Nozawa, Takashi, Nukina, Nobuyuki, Nussbaum-Krammer, Carmen, Nylandsted, Jesper, O'Donovan, Tracey, O'Leary, Seónadh, O'Rourke, Eyleen, O'Sullivan, Mary, O'Sullivan, Timothy, Oddo, Salvatore, Oehme, Ina, Ogawa, Michinaga, Ogier-Denis, Eric, Ogmundsdottir, Margret, Ogretmen, Besim, Oh, Goo Taeg, Oh, Seon-Hee, Oh, Young, Ohama, Takashi, Ohashi, Yohei, Ohmuraya, Masaki, Oikonomou, Vasileios, Ojha, Rani, Okamoto, Koji, Okazawa, Hitoshi, Oku, Masahide, Oliván, Sara, Oliveira, Jorge, Ollmann, Michael, Olzmann, James, Omari, Shakib, Omary, M Bishr, Önal, Gizem, Ondrej, Martin, Ong, Sang-Bing, Ong, Sang-Ging, Onnis, Anna, Orellana, Juan, Orellana-Muñoz, Sara, Ortega-Villaizan, Maria Del Mar, Ortiz-Gonzalez, Xilma, Ortona, Elena, Osiewacz, Heinz, Osman, Abdel-Hamid, Osta, Rosario, Otegui, Marisa, Otsu, Kinya, Ott, Christiane, Ottobrini, Luisa, Ou, Jing-Hsiung James, Outeiro, Tiago, Oynebraten, Inger, Ozturk, Melek, Pagès, Gilles, Pahari, Susanta, Pajares, Marta, Pajvani, Utpal, Pal, Rituraj, Paladino, Simona, Pallet, Nicolas, Palmieri, Michela, Palmisano, Giuseppe, Palumbo, Camilla, Pampaloni, Francesco, Pan, Lifeng, Pan, Qingjun, Pan, Wenliang, Pan, Xin, Panasyuk, Ganna, Pandey, Rahul, Pandey, Udai, Pandya, Vrajesh, Paneni, Francesco, Pang, Shirley, Panzarini, Elisa, Papademetrio, Daniela, Papaleo, Elena, Papinski, Daniel, Papp, Diana, Park, Eun Chan, Park, Hwan Tae, Park, Ji-Man, Park, Jong-In, Park, Joon Tae, Park, Junsoo, Park, Sang Chul, Park, Sang-Youel, Parola, Abraham, Parys, Jan, Pasquier, Adrien, Pasquier, Benoit, Passos, João, Pastore, Nunzia, Patel, Hemal, Patschan, Daniel, Pattingre, Sophie, Pedraza-Alva, Gustavo, Pedraza-Chaverri, Jose, Pedrozo, Zully, Pei, Gang, Pei, Jianming, Peled-Zehavi, Hadas, Pellegrini, Joaquín, Pelletier, Joffrey, Peñalva, Miguel, Peng, Di, Peng, Ying, Penna, Fabio, Pennuto, Maria, Pentimalli, Francesca, Pereira, Cláudia MF, Pereira, Gustavo, Pereira, Lilian, Pereira de Almeida, Luis, Perera, Nirma, Pérez-Lara, Ángel, Perez-Oliva, Ana, Pérez-Pérez, María Esther, Periyasamy, Palsamy, Perl, Andras, Perrotta, Cristiana, Perrotta, Ida, Pestell, Richard, Petersen, Morten, Petrache, Irina, Petrovski, Goran, Pfirrmann, Thorsten, Pfister, Astrid, Philips, Jennifer, Pi, Huifeng, Picca, Anna, Pickrell, Alicia, Picot, Sandy, Pierantoni, Giovanna, Pierdominici, Marina, Pierre, Philippe, Pierrefite-Carle, Valérie, Pierzynowska, Karolina, Pietrocola, Federico, Pietruczuk, Miroslawa, Pignata, Claudio, Pimentel-Muiños, Felipe, Pinar, Mario, Pinheiro, Roberta, Pinkas-Kramarski, Ronit, Pinton, Paolo, Pircs, Karolina, Piya, Sujan, Pizzo, Paola, Plantinga, Theo, Platta, Harald, Plaza-Zabala, Ainhoa, Plomann, Markus, Plotnikov, Egor, Plun-Favreau, Helene, Pluta, Ryszard, Pocock, Roger, Pöggeler, Stefanie, Pohl, Christian, Poirot, Marc, Poletti, Angelo, Ponpuak, Marisa, Popelka, Hana, Popova, Blagovesta, Porta, Helena, Porte Alcon, Soledad, Portilla-Fernandez, Eliana, Post, Martin, Potts, Malia, Poulton, Joanna, Powers, Ted, Prahlad, Veena, Prajsnar, Tomasz, Praticò, Domenico, Prencipe, Rosaria, Priault, Muriel, Proikas-Cezanne, Tassula, Promponas, Vasilis, Proud, Christopher, Puertollano, Rosa, Puglielli, Luigi, Pulinilkunnil, Thomas, Puri, Deepika, Puri, Rajat, Puyal, Julien, Qi, Xiaopeng, Qi, Yongmei, Qian, Wenbin, Qiang, Lei, Qiu, Yu, Quadrilatero, Joe, Quarleri, Jorge, Raben, Nina, Rabinowich, Hannah, Ragona, Debora, Ragusa, Michael, Rahimi, Nader, Rahmati, Marveh, Raia, Valeria, Raimundo, Nuno, Rajasekaran, Namakkal-Soorappan, Ramachandra Rao, Sriganesh, Rami, Abdelhaq, Ramírez-Pardo, Ignacio, Ramsden, David, Randow, Felix, Rangarajan, Pundi, Ranieri, Danilo, Rao, Hai, Rao, Lang, Rao, Rekha, Rathore, Sumit, Ratnayaka, J Arjuna, Ratovitski, Edward, Ravanan, Palaniyandi, Ravegnini, Gloria, Ray, Swapan, Razani, Babak, Rebecca, Vito, Reggiori, Fulvio, Régnier-Vigouroux, Anne, Reichert, Andreas, Reigada, David, Reiling, Jan, Rein, Theo, Reipert, Siegfried, Rekha, Rokeya Sultana, Ren, Hongmei, Ren, Jun, Ren, Weichao, Renault, Tristan, Renga, Giorgia, Reue, Karen, Rewitz, Kim, Ribeiro de Andrade Ramos, Bruna, Riazuddin, S Amer, Ribeiro-Rodrigues, Teresa, Ricci, Jean-Ehrland, Ricci, Romeo, Riccio, Victoria, Richardson, Des, Rikihisa, Yasuko, Risbud, Makarand, Risueño, Ruth, Ritis, Konstantinos, Rizza, Salvatore, Rizzuto, Rosario, Roberts, Helen, Roberts, Luke, Robinson, Katherine, Roccheri, Maria Carmela, Rocchi, Stephane, Rodney, George, Rodrigues, Tiago, Rodrigues Silva, Vagner Ramon, Rodriguez, Amaia, Rodriguez-Barrueco, Ruth, Rodriguez-Henche, Nieves, Rodriguez-Rocha, Humberto, Roelofs, Jeroen, Rogers, Robert, Rogov, Vladimir, ROJO, Ana, Rolka, Krzysztof, Romanello, Vanina, Romani, Luigina, Romano, Alessandra, Romano, Patricia, Romeo-Guitart, David, Romero, Luis, Romero, Montserrat, Roney, Joseph, Rongo, Christopher, Roperto, Sante, Rosenfeldt, Mathias, Rosenstiel, Philip, Rosenwald, Anne, Roth, Kevin, Roth, Lynn, Roth, Steven, Rouschop, Kasper, Roussel, Benoit, Roux, Sophie, Rovere-Querini, Patrizia, Roy, Ajit, Rozieres, Aurore, Ruano, Diego, Rubinsztein, David, Rubtsova, Maria, Ruckdeschel, Klaus, Ruckenstuhl, Christoph, Rudolf, Emil, Rudolf, Rüdiger, Ruggieri, Alessandra, Ruparelia, Avnika Ashok, Rusmini, Paola, Russell, Ryan, Russo, Gian Luigi, Russo, Maria, Russo, Rossella, Ryabaya, Oxana, Ryan, Kevin, Ryu, Kwon-Yul, Sabater-Arcis, Maria, Sachdev, Ulka, Sacher, Michael, Sachse, Carsten, Sadhu, Abhishek, Sadoshima, Junichi, Safren, Nathaniel, Saftig, Paul, Sagona, Antonia, Sahay, Gaurav, Sahebkar, Amirhossein, Sahin, Mustafa, Sahin, Ozgur, Sahni, Sumit, Saito, Nayuta, Saito, Shigeru, Saito, Tsunenori, Sakai, Ryohei, Sakai, Yasuyoshi, Sakamaki, Jun-Ichi, Saksela, Kalle, Salazar, Gloria, Salazar-Degracia, Anna, Salekdeh, Ghasem, Saluja, Ashok, Sampaio-Marques, Belém, Sanchez, Maria Cecilia, Sanchez-Alcazar, Jose, Sanchez-Vera, Victoria, Sancho-Shimizu, Vanessa, Sanderson, J Thomas, Sandri, Marco, Santaguida, Stefano, Santambrogio, Laura, Santana, Magda, Santoni, Giorgio, Sanz, Alberto, Sanz, Pascual, Saran, Shweta, Sardiello, Marco, Sargeant, Timothy, Sarin, Apurva, Sarkar, Chinmoy, Sarkar, Sovan, Sarrias, Maria-Rosa, Sarkar, Surajit, Sarmah, Dipanka Tanu, Sarparanta, Jaakko, Sathyanarayan, Aishwarya, Sathyanarayanan, Ranganayaki, Scaglione, K Matthew, Scatozza, Francesca, Schaefer, Liliana, Schafer, Zachary, Schaible, Ulrich, Schapira, Anthony, Scharl, Michael, Schatzl, Hermann, Schein, Catherine, Scheper, Wiep, Scheuring, David, Schiaffino, Maria Vittoria, Schiappacassi, Monica, Schindl, Rainer, Schlattner, Uwe, Schmidt, Oliver, Schmitt, Roland, Schmidt, Stephen, Schmitz, Ingo, Schmukler, Eran, Schneider, Anja, Schneider, Bianca, Schober, Romana, Schoijet, Alejandra, Schott, Micah, Schramm, Michael, Schröder, Bernd, Schuh, Kai, Schüller, Christoph, Schulze, Ryan, Schürmanns, Lea, Schwamborn, Jens, Schwarten, Melanie, Scialo, Filippo, Sciarretta, Sebastiano, Scott, Melanie, Scotto, Kathleen, Scovassi, A Ivana, Scrima, Andrea, Scrivo, Aurora, Sebastian, David, Sebti, Salwa, Sedej, Simon, Segatori, Laura, Segev, Nava, Seglen, Per, Seiliez, Iban, Seki, Ekihiro, Selleck, Scott, Sellke, Frank, Selsby, Joshua, Sendtner, Michael, Senturk, Serif, Seranova, Elena, Sergi, Consolato, Serra-Moreno, Ruth, Sesaki, Hiromi, Settembre, Carmine, Setty, Subba Rao Gangi, Sgarbi, Gianluca, Sha, Ou, Shacka, John, Shah, Javeed, Shang, Dantong, Shao, Changshun, Shao, Feng, Sharbati, Soroush, Sharkey, Lisa, Sharma, Dipali, Sharma, Gaurav, Sharma, Kulbhushan, Sharma, Pawan, Sharma, Surendra, Shen, Han-Ming, Shen, Hongtao, Shen, Jiangang, Shen, Ming, Shen, Weili, Shen, Zheni, Sheng, Rui, Sheng, Zhi, Sheng, Zu-Hang, Shi, Jianjian, Shi, Xiaobing, Shi, Ying-Hong, Shiba-Fukushima, Kahori, Shieh, Jeng-Jer, Shimada, Yohta, Shimizu, Shigeomi, Shimozawa, Makoto, Shintani, Takahiro, Shoemaker, Christopher, Shojaei, Shahla, Shoji, Ikuo, Shravage, Bhupendra, Shridhar, Viji, Shu, Chih-Wen, Shu, Hong-Bing, Shui, Ke, Shukla, Arvind, Shutt, Timothy, Sica, Valentina, Siddiqui, Aleem, Sierra, Amanda, Sierra-Torre, Virginia, Signorelli, Santiago, Sil, Payel, Silva, Bruno, Silva, Johnatas, Silva-Pavez, Eduardo, Silvente-Poirot, Sandrine, Simmonds, Rachel, Simon, Anna Katharina, Simon, Hans-Uwe, Simons, Matias, Singh, Anurag, Singh, Lalit, Singh, Rajat, Singh, Shivendra, Singh, Shrawan, Singh, Sudha, Singh, Sunaina, Singh, Surinder Pal, Sinha, Debasish, Sinha, Rohit Anthony, Sinha, Sangita, Sirko, Agnieszka, Sirohi, Kapil, Sivridis, Efthimios, Skendros, Panagiotis, Skirycz, Aleksandra, Slaninová, Iva, Smaili, Soraya, Smertenko, Andrei, Smith, Matthew, Soenen, Stefaan, Sohn, Eun Jung, Sok, Sophia, Solaini, Giancarlo, Soldati, Thierry, Soleimanpour, Scott, Soler, Rosa, Solovchenko, Alexei, Somarelli, Jason, Sonawane, Avinash, Song, Fuyong, Song, Hyun Kyu, Song, Ju-Xian, Song, Kunhua, Song, Zhiyin, Soria, Leandro, Sorice, Maurizio, Soukas, Alexander, Soukup, Sandra-Fausia, Sousa, Diana, Sousa, Nadia, Spagnuolo, Paul, Spector, Stephen, Srinivas Bharath, M., St Clair, Daret, Stagni, Venturina, Staiano, Leopoldo, Stalnecker, Clint, Stankov, Metodi, Stathopulos, Peter, Stefan, Katja, Stefan, Sven Marcel, Stefanis, Leonidas, Steffan, Joan, Steinkasserer, Alexander, Stenmark, Harald, Sterneckert, Jared, Stevens, Craig, Stoka, Veronika, Storch, Stephan, Stork, Björn, Strappazzon, Flavie, Strohecker, Anne Marie, Stupack, Dwayne, Su, Huanxing, Su, Ling-Yan, Su, Longxiang, Suarez-Fontes, Ana, Subauste, Carlos, Subbian, Selvakumar, Subirada, Paula, Sudhandiran, Ganapasam, Sue, Carolyn, Sui, Xinbing, Summers, Corey, Sun, Guangchao, Sun, Jun, SUN, Kang, Sun, Meng-xiang, Sun, Qiming, Sun, Yi, Sun, Zhongjie, Sunahara, Karen, Sundberg, Eva, Susztak, Katalin, Sutovsky, Peter, Suzuki, Hidekazu, Sweeney, Gary, Symons, J David, Sze, Stephen Cho Wing, Szewczyk, Nathaniel, Tabęcka-Łonczynska, Anna, Tabolacci, Claudio, Tacke, Frank, Taegtmeyer, Heinrich, Tafani, Marco, Tagaya, Mitsuo, Tai, Haoran, Tait, Stephen, Takahashi, Yoshinori, Takats, Szabolcs, Talwar, Priti, Tam, Chit, Tam, Shing Yau, Tampellini, Davide, Tamura, Atsushi, Tan, Chong Teik, Tan, Eng-King, Tan, Ya-Qin, Tanaka, Masaki, Tanaka, Motomasa, Tang, Daolin, Tang, Jingfeng, Tang, Tie-Shan, Tanida, Isei, Tao, Zhipeng, Taouis, Mohammed, Tatenhorst, Lars, Tavernarakis, Nektarios, Taylor, Allen, Taylor, Gregory, Taylor, Joan, Tchetina, Elena, Tee, Andrew, Tegeder, Irmgard, Teis, David, Teixeira, Natercia, Teixeira-Clerc, Fatima, Tekirdag, Kumsal, Tencomnao, Tewin, Tenreiro, Sandra, Tepikin, Alexei, Testillano, Pilar, Tettamanti, Gianluca, Tharaux, Pierre-Louis, Thedieck, Kathrin, Thekkinghat, Arvind, Thellung, Stefano, Thinwa, Josephine, Thirumalaikumar, V.P., Thomas, Sufi Mary, Thomes, Paul, Thorburn, Andrew, Thukral, Lipi, Thum, Thomas, Thumm, Michael, Tian, Ling, Tichy, Ales, Till, Andreas, Timmerman, Vincent, Titorenko, Vladimir, Todi, Sokol, Todorova, Krassimira, Toivonen, Janne, Tomaipitinca, Luana, Tomar, Dhanendra, Tomas-Zapico, Cristina, Tomić, Sergej, Tong, Benjamin Chun-Kit, Tong, Chao, Tong, Xin, Tooze, Sharon, Torgersen, Maria, Torii, Satoru, Torres-López, Liliana, Torriglia, Alicia, Towers, Christina, Towns, Roberto, Toyokuni, Shinya, Trajkovic, Vladimir, Tramontano, Donatella, Tran, Quynh-Giao, Travassos, Leonardo, Trelford, Charles, Tremel, Shirley, Trougakos, Ioannis, Tsao, Betty, Tschan, Mario, Tse, Hung-Fat, Tse, Tak Fu, Tsugawa, Hitoshi, Tsvetkov, Andrey, Tumbarello, David, Tumtas, Yasin, Tuñón, María, Turcotte, Sandra, Turk, Boris, Turk, Vito, Turner, Bradley, Tuxworth, Richard, Tyler, Jessica, Tyutereva, Elena, Uchiyama, Yasuo, Ugun-Klusek, Aslihan, Uhlig, Holm, Ułamek-Kozioł, Marzena, Ulasov, Ilya, Umekawa, Midori, Ungermann, Christian, Unno, Rei, Urbe, Sylvie, Uribe-Carretero, Elisabet, Üstün, Suayib, Uversky, Vladimir, Vaccari, Thomas, Vaccaro, Maria, Vahsen, Björn, Vakifahmetoglu-Norberg, Helin, Valdor, Rut, Valente, Maria, Valko, Ayelén, Vallee, Richard, Valverde, Angela, Van Den Berghe, Greet, van der Veen, Stijn, Van Kaer, Luc, van Loosdregt, Jorg, van Wijk, Sjoerd, Vandenberghe, Wim, Vanhorebeek, Ilse, Vannier-Santos, Marcos, Vannini, Nicola, Vanrell, M Cristina, Vantaggiato, Chiara, Varano, Gabriele, Varela-Nieto, Isabel, Varga, Máté, Vasconcelos, M Helena, Vats, Somya, Vavvas, Demetrios, Vega-Naredo, Ignacio, Vega-Rubin-de-Celis, Silvia, Velasco, Guillermo, Velázquez, Ariadna, Vellai, Tibor, Vellenga, Edo, Velotti, Francesca, Verdier, Mireille, Verginis, Panayotis, Vergne, Isabelle, Verkade, Paul, Verma, Manish, Verstreken, Patrik, Vervliet, Tim, Vervoorts, Jörg, Vessoni, Alexandre, Victor, Victor, Vidal, Michel, Vidoni, Chiara, Vieira, Otilia, Vierstra, Richard, Viganó, Sonia, Vihinen, Helena, Vijayan, Vinoy, Vila, Miquel, Vilar, Marçal, Villalba, José, Villalobo, Antonio, Villarejo-Zori, Beatriz, Villarroya, Francesc, Villarroya, Joan, Vincent, Olivier, Vindis, Cecile, Viret, Christophe, Viscomi, Maria Teresa, Visnjic, Dora, Vitale, Ilio, Vocadlo, David, Voitsekhovskaja, Olga, Volonté, Cinzia, Volta, Mattia, Vomero, Marta, Von Haefen, Clarissa, Vooijs, Marc, Voos, Wolfgang, Vucicevic, Ljubica, Wade-Martins, Richard, Waguri, Satoshi, Waite, Kenrick, Wakatsuki, Shuji, Walker, David, Walker, Mark, Walker, Simon, Walter, Jochen, Wandosell, Francisco, Wang, Bo, Wang, Chao-Yung, Wang, Chen, Wang, Chenran, Wang, Chenwei, Wang, Cun-Yu, Wang, Dong, Wang, Fangyang, Wang, Feng, Wang, Fengming, Wang, Guansong, Wang, Han, Wang, Hao, Wang, Hexiang, Wang, Hong-Gang, Wang, Jianrong, Wang, Jigang, Wang, Jiou, Wang, Jundong, Wang, Kui, Wang, Lianrong, Wang, Liming, Wang, Maggie Haitian, Wang, Meiqing, Wang, Nanbu, Wang, PengWei, Wang, PeiPei, Wang, Ping, Wang, Qing Jun, Wang, Qing, Wang, Qing Kenneth, Wang, Qiong, Wang, Wen-Tao, Wang, Wuyang, Wang, Xinnan, Wang, Xuejun, Wang, Yan, Wang, Yanchang, Wang, Yanzhuang, Wang, Yen-Yun, Wang, Yihua, Wang, Yipeng, Wang, Yu, wang, yuqi, Wang, Zhe, Wang, Zhenyu, Wang, Zhouguang, Warnes, Gary, Warnsmann, Verena, Watada, Hirotaka, Watanabe, Eizo, Watchon, Maxinne, Wawrzyńska, Anna, Weaver, Timothy, Wegrzyn, Grzegorz, Wehman, Ann, Wei, Huafeng, Wei, Lei, Wei, Taotao, Wei, Yongjie, Weiergräber, Oliver, Weihl, Conrad, Weindl, Günther, Weiskirchen, Ralf, Wells, Alan, Wen, Runxia, Wen, Xin, Werner, Antonia, Weykopf, Beatrice, Wheatley, Sally, Whitton, J Lindsay, Whitworth, Alexander, Wiktorska, Katarzyna, Wildenberg, Manon, Wileman, Tom, Wilkinson, Simon, Willbold, Dieter, Williams, Brett, Williams, Robin, Williams, Roger, Williamson, Peter, Wilson, Richard, Winner, Beate, Winsor, Nathaniel, Witkin, Steven, Wodrich, Harald, Woehlbier, Ute, Wollert, Thomas, Wong, Esther, Wong, Jack Ho, Wong, Richard, Wong, Vincent Kam Wai, Wong, W Wei-Lynn, Wu, An-Guo, Wu, Chengbiao, Wu, Jian, Wu, Junfang, Wu, Kenneth, Wu, Min, Wu, Shan-Ying, Wu, Shengzhou, Wu, Shu-Yan, Wu, Shufang, Wu, William, Wu, Xiaohong, Wu, Xiaoqing, Wu, Yao-Wen, Wu, Yihua, Xavier, Ramnik, Xia, Hongguang, Xia, Lixin, Xia, Zhengyuan, Xiang, Ge, Xiang, Jin, Xiang, Mingliang, Xiang, Wei, Xiao, Bin, Xiao, Guozhi, Xiao, Hengyi, Xiao, Hong-tao, Xiao, Jian, Xiao, Lan, Xiao, Shi, Xiao, Yin, Xie, Baoming, Xie, Chuan-Ming, Xie, Min, Xie, Yuxiang, Xie, Zhiping, Xie, Zhonglin, Xilouri, Maria, Xu, Congfeng, Xu, En, Xu, Haoxing, Xu, Jing, Xu, Jinrong, Xu, Liang, Xu, Wen Wen, Xu, Xiulong, Xue, Yu, Yakhine-Diop, Sokhna, Yamaguchi, Masamitsu, Yamaguchi, Osamu, Yamamoto, Ai, Yamashina, Shunhei, Yan, Shengmin, Yan, Shian-Jang, Yan, Zhen, Yanagi, Yasuo, Yang, Chuanbin, Yang, Dun-Sheng, Yang, Huan, Yang, Huang-Tian, Yang, Hui, Yang, Jin-Ming, Yang, Jing, Yang, Jingyu, Yang, Ling, Yang, Liu, Yang, Ming, Yang, Pei-Ming, Yang, Qian, Yang, Seungwon, Yang, Shu, Yang, Shun-Fa, Yang, Wannian, Yang, Wei Yuan, Yang, Xiaoyong, Yang, Xuesong, Yang, Yi, Yang, Ying, Yao, Honghong, Yao, Shenggen, Yao, Xiaoqiang, Yao, Yong-Gang, Yao, Yong-Ming, Yasui, Takahiro, Yazdankhah, Meysam, Yen, Paul, Yi, Cong, Yin, Xiao-Ming, Yin, Yanhai, Yin, Zhangyuan, Yin, Ziyi, Ying, Meidan, Ying, Zheng, Yip, Calvin, Yiu, Stephanie Pei Tung, Yoo, Young, Yoshida, Kiyotsugu, Yoshii, Saori, Yoshimori, Tamotsu, Yousefi, Bahman, Yu, Boxuan, Yu, Haiyang, Yu, Jun, Yu, Li, Yu, Ming-Lung, Yu, Seong-Woon, Yu, Victor, Yu, W Haung, Yu, Zhengping, Yu, Zhou, Yuan, Junying, Yuan, Ling-Qing, Yuan, Shilin, Yuan, Shyng-Shiou, Yuan, Yanggang, Yuan, Zengqiang, Yue, Jianbo, Yue, Zhenyu, Yun, Jeanho, Yung, Raymond, Zacks, David, Zaffagnini, Gabriele, Zambelli, Vanessa, Zanella, Isabella, Zang, Qun, Zanivan, Sara, Zappavigna, Silvia, Zaragoza, Pilar, Zarbalis, Konstantinos, Zarebkohan, Amir, Zarrouk, Amira, Zeitlin, Scott, Zeng, Jialiu, Zeng, Ju-deng, Žerovnik, Eva, Zhan, Lixuan, Zhang, Bin, Zhang, Donna, Zhang, Hanlin, Zhang, Hong, Zhang, Honghe, Zhang, Huafeng, Zhang, Huaye, Zhang, Hui, Zhang, Hui-Ling, Zhang, Jianbin, Zhang, Jianhua, Zhang, Jing-Pu, Zhang, Kalin, Zhang, Leshuai, Zhang, Lin, Zhang, Lisheng, Zhang, Lu, Zhang, Luoying, Zhang, Menghuan, Zhang, Peng, Zhang, Sheng, Zhang, Wei, Zhang, Xiangnan, Zhang, Xiao-Wei, Zhang, Xiaolei, Zhang, Xiaoyan, Zhang, Xin, Zhang, Xinxin, Zhang, Xu Dong, Zhang, Yang, Zhang, Yanjin, Zhang, Yi, Zhang, Ying-Dong, Zhang, Yingmei, Zhang, Yuan-Yuan, Zhang, Yuchen, Zhang, Zhe, Zhang, Zhengguang, Zhang, Zhibing, Zhang, Zhihai, Zhang, Zhiyong, Zhang, Zili, Zhao, Haobin, Zhao, Lei, Zhao, Shuang, Zhao, Tongbiao, Zhao, Xiao-Fan, Zhao, Ying, Zhao, Yongchao, Zhao, Yongliang, Zhao, Yuting, Zheng, Guoping, Zheng, Kai, Zheng, Ling, Zheng, Shizhong, Zheng, Xi-Long, Zheng, Yi, Zheng, Zu-Guo, Zhivotovsky, Boris, Zhong, Qing, Zhou, Ao, Zhou, Ben, Zhou, Cefan, ZHOU, Gang, Zhou, Hao, Zhou, Hong, Zhou, Hongbo, Zhou, Jie, Zhou, Jing, Zhou, Jiyong, Zhou, Kailiang, Zhou, Rongjia, Zhou, Xu-jie, Zhou, Yanshuang, Zhou, Yinghong, Zhou, Yubin, Zhou, Zheng-Yu, Zhou, Zhou, Zhu, Binglin, Zhu, Changlian, Zhu, Guo-Qing, Zhu, Haining, Zhu, Hongxin, Zhu, Hua, Zhu, Wei-Guo, Zhu, Yanping, Zhu, Yushan, Zhuang, Haixia, Zhuang, Xiaohong, Zientara-Rytter, Katarzyna, Zimmermann, Christine, Ziviani, Elena, Zoladek, Teresa, Zong, Wei-Xing, Zorov, Dmitry, Zorzano, Antonio, Zou, Weiping, Zou, Zhen, Zou, Zhengzhi, Zuryn, Steven, Zwerschke, Werner, Brand-Saberi, Beate, Dong, X Charlie, Kenchappa, Chandra Shekar, Li, Zuguo, Lin, Yong, Oshima, Shigeru, Rong, Yueguang, Sluimer, Judith, Stallings, Christina, Tong, Chun-Kit, Ahmad, S. Tariq, Alim Al-Bari, M. Abdul, Bechara, Luiz R.G., Behrens, Georg M.N., Bhuiyan, Md. Shenuarin, Broaddus, V. Courtney, Buchan, J. Ross, Burón, M. Isabel, Carter, A. Brent, Chan, Matthew T.V., Choi, Augustine M.K., D’Adamo, Stefania, D’Amelio, Marcello, D’Arcangelo, Daniela, D’Lugos, Andrew, D’Orazi, Gabriella, De Meyer, Guido R.Y., Delpino, M. Victoria, Distler, Jörg H.W., Dixon, Ian M.C., Dobson, Renwick C.J., 2nd Dorn, Gerald, Eissa, N. Tony, Engelsen, Agnete S.T., Fairlie, W. Douglas, Ferreira, Julio C.B., H.B., Ranjitha, Hanson, Phyllis I., Hejtmancik, J. Fielding, Ho, Idy H.T., Hobbs, G. Aaron, Hoet, Peter H.M., Huang, Michael L.H., Iyer, Anand Krishnan V., Johnson, Gail V.W., Joosten, Leo A.B., Karim, Md. Razaul, Kaufmann, Stefan H.E., Ko, Ben C.B., Leck, Lionel Y.W., Lima, Thania R.R., Livingston, J. Andrew, Martin, Alexandre P.J., Montes, L. Ruth, Murphy, J. Patrick, Ng, Charlene C.W., Nicolao, M. Celeste, O’Donovan, Tracey, O’Leary, Seónadh, O’Rourke, Eyleen, O’Sullivan, Mary, O’Sullivan, Timothy, Omary, M. Bishr, Pereira, Gustavo J.S., Ratnayaka, J. Arjuna, Riazuddin, S. Amer, Rouschop, Kasper M.A., Sanderson, J. Thomas, Scaglione, K. Matthew, Schapira, Anthony H.V., Scovassi, A. Ivana, St. Clair, Daret, Sunahara, Karen K.S., Symons, J. David, Triola, Gemma, van Wijk, Sjoerd J.L., Vanrell, M. Cristina, Vasconcelos, M. Helena, Whitton, J. Lindsay, Williams, Robin S.B., Wong, W. Wei-Lynn, Wu, William K.K., Yakhine-Diop, Sokhna M.S., Yu, W. Haung, Zhang, Kalin Y.B., Dong, X. Charlie, Ain Shams University [ASU], Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University [JGU], Medical University Graz, Centre de Recherche des Cordeliers [CRC (UMR_S_1138 / U1138)], Institut Pasteur d'Iran, Leibniz Institute of Plant Biochemistry [IPB], The University of Texas M.D. Anderson Cancer Center [Houston], Institut de pharmacologie moléculaire et cellulaire [IPMC], Lipides - Nutrition - Cancer [Dijon - U1231] [LNC], Centre méditerranéen de médecine moléculaire [C3M], Institut de Biologie Valrose [IBV], Petites Molécules de neuroprotection, neurorégénération et remyélinisation, Signalisation Hormonale, Physiopathologie Endocrinienne et Métabolique, Institut Cochin [IC UM3 (UMR 8104 / U1016)], Institut NeuroMyoGène [INMG], Paris-Centre de Recherche Cardiovasculaire [PARCC (UMR_S 970/ U970)], Marqueurs cardiovasculaires en situation de stress [MASCOT (UMR_S_942 / U942)], Institut de Recherche sur le Cancer et le Vieillissement [IRCAN], Centre de Recherche en Cancérologie de Marseille [CRCM], Centre for Integrative Biology - CBI [Inserm U964 - CNRS UMR7104 - IGBMC], Oncogenesis, Stress, Signaling [OSS], Institut Necker Enfants-Malades [INEM - UM 111 (UMR 8253 / U1151)], Institut de Biologie Intégrative de la Cellule [I2BC], Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH], Centre de Recherches en Cancérologie de Toulouse [CRCT], Physiopathologie et traitement des maladies du foie, Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL], Institut de Génétique et de Biologie Moléculaire et Cellulaire [IGBMC], Laboratoire Bio-PeroxIL. Biochimie du peroxysome, inflammation et métabolisme lipidique [Dijon] [BIO-PEROXIL], Centre de recherche sur l'Inflammation [CRI (UMR_S_1149 / ERL_8252 / U1149)], Unité de génétique et biologie des cancers [U830], Laboratoire d'Optique et Biosciences [LOB], Institut des Maladies Métaboliques et Casdiovasculaires [UPS/Inserm U1297 - I2MC], Différenciation et communication neuronale et neuroendocrine [DC2N], Institut de Recherche en Cancérologie de Montpellier [IRCM - U1194 Inserm - UM], Centre d'Immunologie de Marseille - Luminy [CIML], Physiopathologie et imagerie des troubles neurologiques [PhIND], Laboratory of Fundamental and Applied Bioenergetics = Laboratoire de bioénergétique fondamentale et appliquée [LBFA], Imagine - Institut des maladies génétiques (IHU) [Imagine - U1163], Institut Mondor de Recherche Biomédicale [IMRB], Franco-czech Laboratory for clinical research on obesity, University of Michigan [Ann Arbor], University of Michigan System, Institut de pharmacologie moléculaire et cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Université Côte d'Azur (UCA), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Institut de Biologie Valrose (IBV), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Nutrition, Métabolisme, Aquaculture (NuMéA), Université de Pau et des Pays de l'Adour (UPPA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Institut NeuroMyoGène (INMG), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Centre for Integrative Biology - CBI (Inserm U964 - CNRS UMR7104 - IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institute of genetics and molecular and cellular biology-Centre National de la Recherche Scientifique (CNRS), Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Institut de Biologie Intégrative de la Cellule (I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Institut des Maladies Neurodégénératives [Bordeaux] (IMN), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physiologie et Génomique des Poissons (LPGP), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Laboratoire Bio-PeroxIL. Biochimie du peroxysome, inflammation et métabolisme lipidique [Dijon] (BIO-PEROXIL), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut Jean-Pierre Bourgin (IJPB), AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Unité de génétique et biologie des cancers (U830), Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Optique et Biosciences (LOB), École polytechnique (X)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie et imagerie des troubles neurologiques (PhIND), Université de Caen Normandie (UNICAEN), Laboratory of Fundamental and Applied Bioenergetics = Laboratoire de bioénergétique fondamentale et appliquée (LBFA), Université Grenoble Alpes (UGA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epithelial biology and disease - Liliane Bettencourt Chair of Developmental Biology (Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Biomécanique cellulaire et respiratoire (BCR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), Charles University [Prague]-Institut National de la Santé et de la Recherche Médicale (INSERM), This work was supported by the National Institute of General Medical Sciences [GM131919]., Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Université Sorbonne Paris Nord, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes (UN)-Institut National de la Recherche Agronomique (INRA), Département Plateforme (PF I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Institut Gustave Roussy (IGR), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Chinese Academy of Medical Sciences [Suzhou, Chine] (CAMS), Karolinska Institutet [Stockholm], Karolinska University Hospital [Stockholm], Department of Women's and Children's Health [Stockholm, Sweden], Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École polytechnique (X), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, FHU OncoAge - Pathologies liées à l’âge [CHU Nice] (OncoAge), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Institut de Pharmacologie Moléculaire et Cellulaire [UNIV Côte d'Azur] (UPMC), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Life Sciences Institute [Ann Arbor, MI, USA], University of Michigan System-University of Michigan System, European Institute of Oncology IRCCS [Milan, Italy] (EIO), Ain Shams University (ASU), Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Réseau International des Instituts Pasteur (RIIP), Leibniz Institute of Plant Biochemistry (IPB), Hebrew University of Jerusalem, Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Oncogenesis, Stress, Signaling (OSS), Institut des Maladies Métaboliques et Casdiovasculaires (UPS/Inserm U1297 - I2MC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Charles University [Prague] (CU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., Adamopoulos, I. E., Adeli, K., Adolph, T. E., Adornetto, A., Aflaki, E., Agam, G., Agarwal, A., Aggarwal, B. B., Agnello, M., Agostinis, P., Agrewala, J. N., Agrotis, A., Aguilar, P. V., Ahmad, S. T., Ahmed, Z. M., Ahumada-Castro, U., Aits, S., Aizawa, S., Akkoc, Y., Akoumianaki, T., Akpinar, H. A., Al-Abd, A. M., Al-Akra, L., Al-Gharaibeh, A., Alaoui-Jamali, M. A., Alberti, S., Alcocer-Gomez, E., Alessandri, C., Ali, M., Alim Al-Bari, M. A., Aliwaini, S., Alizadeh, J., Almacellas, E., Almasan, A., Alonso, A., Alonso, G. D., Altan-Bonnet, N., Altieri, D. C., Alvarez, E. M. C., Alves, S., Alves da Costa, C., Alzaharna, M. M., Amadio, M., Amantini, C., Amaral, C., Ambrosio, S., Amer, A. O., Ammanathan, V., An, Z., Andersen, S. U., Andrabi, S. A., Andrade-Silva, M., Andres, A. M., Angelini, S., Ann, D., Anozie, U. C., Ansari, M. Y., Antas, P., Antebi, A., Anton, Z., Anwar, T., Apetoh, L., Apostolova, N., Araki, T., Araki, Y., Arasaki, K., Araujo, W. L., Araya, J., Arden, C., Arevalo, M. -A., Arguelles, S., Arias, E., Arikkath, J., Arimoto, H., Ariosa, A. R., Armstrong-James, D., Arnaune-Pelloquin, L., Aroca, A., Arroyo, D. S., Arsov, I., Artero, R., Asaro, D. M. L., Aschner, M., Ashrafizadeh, M., Ashur-Fabian, O., Atanasov, A. G., Au, A. K., Auberger, P., Auner, H. W., Aurelian, L., Autelli, R., Avagliano, L., Avalos, Y., Aveic, S., Aveleira, C. A., Avin-Wittenberg, T., Aydin, Y., Ayton, S., Ayyadevara, S., Azzopardi, M., Baba, M., Backer, J. M., Backues, S. K., Bae, D. -H., Bae, O. -N., Bae, S. H., Baehrecke, E. H., Baek, A., Baek, S. -H., Baek, S. H., Bagetta, G., Bagniewska-Zadworna, A., Bai, H., Bai, J., Bai, X., Bai, Y., Bairagi, N., Baksi, S., Balbi, T., Baldari, C. T., Balduini, W., Ballabio, A., Ballester, M., Balazadeh, S., Balzan, R., Bandopadhyay, R., Banerjee, S., Banreti, A., Bao, Y., Baptista, M. S., Baracca, A., Barbati, C., Bargiela, A., Barila, D., Barlow, P. G., Barmada, S. J., Barreiro, E., Barreto, G. E., Bartek, J., Bartel, B., Bartolome, A., Barve, G. R., Basagoudanavar, S. H., Bassham, D. C., Bast, R. C., Basu, A., Batoko, H., Batten, I., Baulieu, E. E., Baumgarner, B. L., Bayry, J., Beale, R., Beau, I., Beaumatin, F., Bechara, L. R. G., Beck, G. R., Beers, M. F., Begun, J., Behrends, C., Behrens, G. M. N., Bei, R., Bejarano, E., Bel, S., Behl, C., Belaid, A., Belgareh-Touze, N., Bellarosa, C., Belleudi, F., Bello Perez, M., Bello-Morales, R., Beltran, J. S. D. O., Beltran, S., Benbrook, D. M., Bendorius, M., Benitez, B. A., Benito-Cuesta, I., Bensalem, J., Berchtold, M. W., Berezowska, S., Bergamaschi, D., Bergami, M., Bergmann, A., Berliocchi, L., Berlioz-Torrent, C., Bernard, A., Berthoux, L., Besirli, C. G., Besteiro, S., Betin, V. M., Beyaert, R., Bezbradica, J. S., Bhaskar, K., Bhatia-Kissova, I., Bhattacharya, R., Bhattacharya, S., Bhattacharyya, S., Bhuiyan, M. S., Bhutia, S. K., Bi, L., Bi, X., Biden, T. J., Bijian, K., Billes, V. A., Binart, N., Bincoletto, C., Birgisdottir, A. B., Bjorkoy, G., Blanco, G., Blas-Garcia, A., Blasiak, J., Blomgran, R., Blomgren, K., Blum, J. S., Boada-Romero, E., Boban, M., Boesze-Battaglia, K., Boeuf, P., Boland, B., Bomont, P., Bonaldo, P., Bonam, S. R., Bonfili, L., Bonifacino, J. S., Boone, B. A., Bootman, M. D., Bordi, M., Borner, C., Bornhauser, B. C., Borthakur, G., Bosch, J., Bose, S., Botana, L. M., Botas, J., Boulanger, C. M., Boulton, M. E., Bourdenx, M., Bourgeois, B., Bourke, N. M., Bousquet, G., Boya, P., Bozhkov, P. V., Bozi, L. H. M., Bozkurt, T. O., Brackney, D. E., Brandts, C. H., Braun, R. J., Braus, G. H., Bravo-Sagua, R., Bravo-San Pedro, J. M., Brest, P., Bringer, M. -A., Briones-Herrera, A., Broaddus, V. C., Brodersen, P., Brodsky, J. L., Brody, S. L., Bronson, P. G., Bronstein, J. M., Brown, C. N., Brown, R. E., Brum, P. C., Brumell, J. H., Brunetti-Pierri, N., Bruno, D., Bryson-Richardson, R. J., Bucci, C., Buchrieser, C., Bueno, M., Buitrago-Molina, L. E., Buraschi, S., Buch, S., Buchan, J. R., Buckingham, E. M., Budak, H., Budini, M., Bultynck, G., Burada, F., Burgoyne, J. R., Buron, M. I., Bustos, V., Buttner, S., Butturini, E., Byrd, A., Cabas, I., Cabrera-Benitez, S., Cadwell, K., Cai, J., Cai, L., Cai, Q., Cairo, M., Calbet, J. A., Caldwell, G. A., Caldwell, K. A., Call, J. A., Calvani, R., Calvo, A. C., Calvo-Rubio Barrera, M., Camara, N. O. S., Camonis, J. H., Camougrand, N., Campanella, M., Campbell, E. M., Campbell-Valois, F. -X., Campello, S., Campesi, I., Campos, J. C., Camuzard, O., Cancino, J., Candido de Almeida, D., Canesi, L., Caniggia, I., Canonico, B., Canti, C., Cao, B., Caraglia, M., Carames, B., Carchman, E. H., Cardenal-Munoz, E., Cardenas, C., Cardenas, L., Cardoso, S. M., Carew, J. S., Carle, G. F., Carleton, G., Carloni, S., Carmona-Gutierrez, D., Carneiro, L. A., Carnevali, O., Carosi, J. M., Carra, S., Carrier, A., Carrier, L., Carroll, B., Carter, A. B., Carvalho, A. N., Casanova, M., Casas, C., Casas, J., Cassioli, C., Castillo, E. F., Castillo, K., Castillo-Lluva, S., Castoldi, F., Castori, M., Castro, A. F., Castro-Caldas, M., Castro-Hernandez, J., Castro-Obregon, S., Catz, S. D., Cavadas, C., Cavaliere, F., Cavallini, G., Cavinato, M., Cayuela, M. L., Cebollada Rica, P., Cecarini, V., Cecconi, F., Cechowska-Pasko, M., Cenci, S., Ceperuelo-Mallafre, V., Cerqueira, J. J., Cerutti, J. M., Cervia, D., Cetintas, V. B., Cetrullo, S., Chae, H. -J., Chagin, A. S., Chai, C. -Y., Chakrabarti, G., Chakrabarti, O., Chakraborty, T., Chami, M., Chamilos, G., Chan, D. W., Chan, E. Y. W., Chan, E. D., Chan, H. Y. E., Chan, H. H., Chan, H., Chan, M. T. V., Chan, Y. S., Chandra, P. K., Chang, C. -P., Chang, C., Chang, H. -C., Chang, K., Chao, J., Chapman, T., Charlet-Berguerand, N., Chatterjee, S., Chaube, S. K., Chaudhary, A., Chauhan, S., Chaum, E., Checler, F., Cheetham, M. E., Chen, C. -S., Chen, G. -C., Chen, J. -F., Chen, L. L., Chen, L., Chen, M., Chen, M. -K., Chen, N., Chen, Q., Chen, R. -H., Chen, S., Chen, W., Chen, X. -M., Chen, X. -W., Chen, X., Chen, Y., Chen, Y. -G., Chen, Y. -J., Chen, Y. -Q., Chen, Z. S., Chen, Z., Chen, Z. -H., Chen, Z. J., Cheng, H., Cheng, J., Cheng, S. -Y., Cheng, W., Cheng, X., Cheng, X. -T., Cheng, Y., Cheng, Z., Cheong, H., Cheong, J. K., Chernyak, B. V., Cherry, S., Cheung, C. F. R., Cheung, C. H. A., Cheung, K. -H., Chevet, E., Chi, R. J., Chiang, A. K. S., Chiaradonna, F., Chiarelli, R., Chiariello, M., Chica, N., Chiocca, S., Chiong, M., Chiou, S. -H., Chiramel, A. I., Chiurchiu, V., Cho, D. -H., Choe, S. -K., Choi, A. M. K., Choi, M. E., Choudhury, K. R., Chow, N. S., Chu, C. T., Chua, J. P., Chua, J. J. E., Chung, H., Chung, K. P., Chung, S., Chung, S. -H., Chung, Y. -L., Cianfanelli, V., Ciechomska, I. A., Cifuentes, M., Cinque, L., Cirak, S., Cirone, M., Clague, M. J., Clarke, R., Clementi, E., Coccia, E. M., Codogno, P., Cohen, E., Cohen, M. M., Colasanti, T., Colasuonno, F., Colbert, R. A., Colell, A., Colic, M., Coll, N. S., Collins, M. O., Colombo, M. I., Colon-Ramos, D. A., Combaret, L., Comincini, S., Cominetti, M. R., Consiglio, A., Conte, A., Conti, F., Contu, V. R., Cookson, M. R., Coombs, K. M., Coppens, I., Corasaniti, M. T., Corkery, D. P., Cordes, N., Cortese, K., Costa, M. D. C., Costantino, S., Costelli, P., Coto-Montes, A., Crack, P. J., Crespo, J. L., Criollo, A., Crippa, V., Cristofani, R., Csizmadia, T., Cuadrado, A., Cui, B., Cui, J., Cui, Y., Culetto, E., Cumino, A. C., Cybulsky, A. V., Czaja, M. J., Czuczwar, S. J., D'Adamo, S., D'Amelio, M., D'Arcangelo, D., D'Lugos, A. C., D'Orazi, G., da Silva, J. A., Dafsari, H. S., Dagda, R. K., Dagdas, Y., Daglia, M., Dai, X., Dai, Y., Dal Col, J., Dalhaimer, P., Dalla Valle, L., Dallenga, T., Dalmasso, G., Damme, M., Dando, I., Dantuma, N. P., Darling, A. L., Das, H., Dasarathy, S., Dasari, S. K., Dash, S., Daumke, O., Dauphinee, A. N., Davies, J. S., Davila, V. A., Davis, R. J., Davis, T., Dayalan Naidu, S., De Amicis, F., De Bosscher, K., De Felice, F., De Franceschi, L., De Leonibus, C., de Mattos Barbosa, M. G., De Meyer, G. R. Y., De Milito, A., De Nunzio, C., De Palma, C., De Santi, M., De Virgilio, C., De Zio, D., Debnath, J., Debosch, B. J., Decuypere, J. -P., Deehan, M. A., Deflorian, G., Degregori, J., Dehay, B., Del Rio, G., Delaney, J. R., Delbridge, L. M. D., Delorme-Axford, E., Delpino, M. V., Demarchi, F., Dembitz, V., Demers, N. D., Deng, H., Deng, Z., Dengjel, J., Dent, P., Denton, D., Depamphilis, M. L., Der, C. J., Deretic, V., Descoteaux, A., Devis, L., Devkota, S., Devuyst, O., Dewson, G., Dharmasivam, M., Dhiman, R., di Bernardo, D., Di Cristina, M., Di Domenico, F., Di Fazio, P., Di Fonzo, A., Di Guardo, G., Di Guglielmo, G. M., Di Leo, L., Di Malta, C., Di Nardo, A., Di Rienzo, M., Di Sano, F., Diallinas, G., Diao, J., Diaz-Araya, G., Diaz-Laviada, I., Dickinson, J. M., Diederich, M., Dieude, M., Dikic, I., Ding, S., Ding, W. -X., Dini, L., Dinic, J., Dinic, M., Dinkova-Kostova, A. T., Dionne, M. S., Distler, J. H. W., Diwan, A., Dixon, I. M. C., Djavaheri-Mergny, M., Dobrinski, I., Dobrovinskaya, O., Dobrowolski, R., Dobson, R. C. J., Dokic, J., Dokmeci Emre, S., Donadelli, M., Dong, B., Dong, X., Dong, Z., Dorn II, G. W., Dotsch, V., Dou, H., Dou, J., Dowaidar, M., Dridi, S., Drucker, L., Du, A., Du, C., Du, G., Du, H. -N., Du, L. -L., du Toit, A., Duan, S. -B., Duan, X., Duarte, S. P., Dubrovska, A., Dunlop, E. A., Dupont, N., Duran, R. V., Dwarakanath, B. S., Dyshlovoy, S. A., Ebrahimi-Fakhari, D., Eckhart, L., Edelstein, C. L., Efferth, T., Eftekharpour, E., Eichinger, L., Eid, N., Eisenberg, T., Eissa, N. T., Eissa, S., Ejarque, M., El Andaloussi, A., El-Hage, N., El-Naggar, S., Eleuteri, A. M., El-Shafey, E. S., Elgendy, M., Eliopoulos, A. G., Elizalde, M. M., Elks, P. M., Elsasser, H. -P., Elsherbiny, E. S., Emerling, B. M., Emre, N. C. T., Eng, C. H., Engedal, N., Engelbrecht, A. -M., Engelsen, A. S. T., Enserink, J. M., Escalante, R., Esclatine, A., Escobar-Henriques, M., Eskelinen, E. -L., Espert, L., Eusebio, M. -O., Fabrias, G., Fabrizi, C., Facchiano, A., Facchiano, F., Fadeel, B., Fader, C., Faesen, A. C., Fairlie, W. D., Falco, A., Falkenburger, B. H., Fan, D., Fan, J., Fan, Y., Fang, E. F., Fang, Y., Fanto, M., Farfel-Becker, T., Faure, M., Fazeli, G., Fedele, A. O., Feldman, A. M., Feng, D., Feng, J., Feng, L., Feng, Y., Feng, W., Fenz Araujo, T., Ferguson, T. A., Fernandez, A. F., Fernandez-Checa, J. C., Fernandez-Veledo, S., Fernie, A. R., Ferrante, A. W., Ferraresi, A., Ferrari, M. F., Ferreira, J. C. B., Ferro-Novick, S., Figueras, A., Filadi, R., Filigheddu, N., Filippi-Chiela, E., Filomeni, G., Fimia, G. M., Fineschi, V., Finetti, F., Finkbeiner, S., Fisher, E. A., Fisher, P. B., Flamigni, F., Fliesler, S. J., Flo, T. H., Florance, I., Florey, O., Florio, T., Fodor, E., Follo, C., Fon, E. A., Forlino, A., Fornai, F., Fortini, P., Fracassi, A., Fraldi, A., Franco, B., Franco, R., Franconi, F., Frankel, L. B., Friedman, S. L., Frohlich, L. F., Fruhbeck, G., Fuentes, J. M., Fujiki, Y., Fujita, N., Fujiwara, Y., Fukuda, M., Fulda, S., Furic, L., Furuya, N., Fusco, C., Gack, M. U., Gaffke, L., Galadari, S., Galasso, A., Galindo, M. F., Gallolu Kankanamalage, S., Galluzzi, L., Galy, V., Gammoh, N., Gan, B., Ganley, I. G., Gao, F., Gao, H., Gao, M., Gao, P., Gao, S. -J., Gao, W., Gao, X., Garcera, A., Garcia, M. N., Garcia, V. E., Garcia-Del Portillo, F., Garcia-Escudero, V., Garcia-Garcia, A., Garcia-Macia, M., Garcia-Moreno, D., Garcia-Ruiz, C., Garcia-Sanz, P., Garg, A. D., Gargini, R., Garofalo, T., Garry, R. F., Gassen, N. C., Gatica, D., Ge, L., Ge, W., Geiss-Friedlander, R., Gelfi, C., Genschik, P., Gentle, I. E., Gerbino, V., Gerhardt, C., Germain, K., Germain, M., Gewirtz, D. A., Ghasemipour Afshar, E., Ghavami, S., Ghigo, A., Ghosh, M., Giamas, G., Giampietri, C., Giatromanolaki, A., Gibson, G. E., Gibson, S. B., Ginet, V., Giniger, E., Giorgi, C., Girao, H., Girardin, S. E., Giridharan, M., Giuliano, S., Giulivi, C., Giuriato, S., Giustiniani, J., Gluschko, A., Goder, V., Goginashvili, A., Golab, J., Goldstone, D. C., Golebiewska, A., Gomes, L. R., Gomez, R., Gomez-Sanchez, R., Gomez-Puerto, M. C., Gomez-Sintes, R., Gong, Q., Goni, F. M., Gonzalez-Gallego, J., Gonzalez-Hernandez, T., Gonzalez-Polo, R. A., Gonzalez-Reyes, J. A., Gonzalez-Rodriguez, P., Goping, I. S., Gorbatyuk, M. S., Gorbunov, N. V., Gorgulu, K., Gorojod, R. M., Gorski, S. M., Goruppi, S., Gotor, C., Gottlieb, R. A., Gozes, I., Gozuacik, D., Graef, M., Graler, M. H., Granatiero, V., Grasso, D., Gray, J. P., Green, D. R., Greenhough, A., Gregory, S. L., Griffin, E. F., Grinstaff, M. W., Gros, F., Grose, C., Gross, A. S., Gruber, F., Grumati, P., Grune, T., Gu, X., Guan, J. -L., Guardia, C. M., Guda, K., Guerra, F., Guerri, C., Guha, P., Guillen, C., Gujar, S., Gukovskaya, A., Gukovsky, I., Gunst, J., Gunther, A., Guntur, A. R., Guo, C., Guo, H., Guo, L. -W., Guo, M., Gupta, P., Gupta, S. K., Gupta, S., Gupta, V. B., Gupta, V., Gustafsson, A. B., Gutterman, D. D., H. B, R., Haapasalo, A., Haber, J. E., Hac, A., Hadano, S., Hafren, A. J., Haidar, M., Hall, B. S., Hallden, G., Hamacher-Brady, A., Hamann, A., Hamasaki, M., Han, W., Hansen, M., Hanson, P. I., Hao, Z., Harada, M., Harhaji-Trajkovic, L., Hariharan, N., Haroon, N., Harris, J., Hasegawa, T., Hasima Nagoor, N., Haspel, J. A., Haucke, V., Hawkins, W. D., Hay, B. A., Haynes, C. M., Hayrabedyan, S. B., Hays, T. S., He, C., He, Q., He, R. -R., He, Y. -W., He, Y. -Y., Heakal, Y., Heberle, A. M., Hejtmancik, J. F., Helgason, G. V., Henkel, V., Herb, M., Hergovich, A., Herman-Antosiewicz, A., Hernandez, A., Hernandez, C., Hernandez-Diaz, S., Hernandez-Gea, V., Herpin, A., Herreros, J., Hervas, J. H., Hesselson, D., Hetz, C., Heussler, V. T., Higuchi, Y., Hilfiker, S., Hill, J. A., Hlavacek, W. S., Ho, E. A., Ho, I. H. T., Ho, P. W. -L., Ho, S. -L., Ho, W. Y., Hobbs, G. A., Hochstrasser, M., Hoet, P. H. M., Hofius, D., Hofman, P., Hohn, A., Holmberg, C. I., Hombrebueno, J. R., Yi-Ren Hong, C. -W. H., Hooper, L. V., Hoppe, T., Horos, R., Hoshida, Y., Hsin, I. -L., Hsu, H. -Y., Hu, B., Hu, D., Hu, L. -F., Hu, M. C., Hu, R., Hu, W., Hu, Y. -C., Hu, Z. -W., Hua, F., Hua, J., Hua, Y., Huan, C., Huang, C., Huang, H., Huang, K., Huang, M. L. H., Huang, R., Huang, S., Huang, T., Huang, X., Huang, Y. J., Huber, T. B., Hubert, V., Hubner, C. A., Hughes, S. M., Hughes, W. E., Humbert, M., Hummer, G., Hurley, J. H., Hussain, S., Hussey, P. J., Hutabarat, M., Hwang, H. -Y., Hwang, S., Ieni, A., Ikeda, F., Imagawa, Y., Imai, Y., Imbriano, C., Imoto, M., Inman, D. M., Inoki, K., Iovanna, J., Iozzo, R. V., Ippolito, G., Irazoqui, J. E., Iribarren, P., Ishaq, M., Ishikawa, M., Ishimwe, N., Isidoro, C., Ismail, N., Issazadeh-Navikas, S., Itakura, E., Ito, D., Ivankovic, D., Ivanova, S., Iyer, A. K. V., Izquierdo, J. M., Izumi, M., Jaattela, M., Jabir, M. S., Jackson, W. T., Jacobo-Herrera, N., Jacomin, A. -C., Jacquin, E., Jadiya, P., Jaeschke, H., Jagannath, C., Jakobi, A. J., Jakobsson, J., Janji, B., Jansen-Durr, P., Jansson, P. J., Jantsch, J., Januszewski, S., Jassey, A., Jean, S., Jeltsch-David, H., Jendelova, P., Jenny, A., Jensen, T. E., Jessen, N., Jewell, J. L., Ji, J., Jia, L., Jia, R., Jiang, L., Jiang, Q., Jiang, R., Jiang, T., Jiang, X., Jiang, Y., Jimenez-Sanchez, M., Jin, E. -J., Jin, F., Jin, H., Jin, L., Jin, M., Jin, S., Jo, E. -K., Joffre, C., Johansen, T., Johnson, G. V. W., Johnston, S. A., Jokitalo, E., Jolly, M. K., Joosten, L. A. B., Jordan, J., Joseph, B., Ju, D., Ju, J. -S., Ju, J., Juarez, E., Judith, D., Juhasz, G., Jun, Y., Jung, C. H., Jung, S. -C., Jung, Y. K., Jungbluth, H., Jungverdorben, J., Just, S., Kaarniranta, K., Kaasik, A., Kabuta, T., Kaganovich, D., Kahana, A., Kain, R., Kajimura, S., Kalamvoki, M., Kalia, M., Kalinowski, D. S., Kaludercic, N., Kalvari, I., Kaminska, J., Kaminskyy, V. O., Kanamori, H., Kanasaki, K., Kang, C., Kang, R., Kang, S. S., Kaniyappan, S., Kanki, T., Kanneganti, T. -D., Kanthasamy, A. G., Kanthasamy, A., Kantorow, M., Kapuy, O., Karamouzis, M. V., Karim, M. R., Karmakar, P., Katare, R. G., Kato, M., Kaufmann, S. H. E., Kauppinen, A., Kaushal, G. P., Kaushik, S., Kawasaki, K., Kazan, K., Ke, P. -Y., Keating, D. J., Keber, U., Kehrl, J. H., Keller, K. E., Keller, C. W., Kemper, J. K., Kenific, C. M., Kepp, O., Kermorgant, S., Kern, A., Ketteler, R., Keulers, T. G., Khalfin, B., Khalil, H., Khambu, B., Khan, S. Y., Khandelwal, V. K. M., Khandia, R., Kho, W., Khobrekar, N. V., Khuansuwan, S., Khundadze, M., Killackey, S. A., Kim, D., Kim, D. R., Kim, D. -H., Kim, D. -E., Kim, E. Y., Kim, E. -K., Kim, H. -R., Kim, H. -S., Hyung-Ryong, Kim, Kim, J. H., Kim, J. K., Kim, J. -H., Kim, J., Kim, K. I., Kim, P. K., Kim, S. -J., Kimball, S. R., Kimchi, A., Kimmelman, A. C., Kimura, T., King, M. A., Kinghorn, K. J., Kinsey, C. G., Kirkin, V., Kirshenbaum, L. A., Kiselev, S. L., Kishi, S., Kitamoto, K., Kitaoka, Y., Kitazato, K., Kitsis, R. N., Kittler, J. T., Kjaerulff, O., Klein, P. S., Klopstock, T., Klucken, J., Knaevelsrud, H., Knorr, R. L., Ko, B. C. B., Ko, F., Ko, J. -L., Kobayashi, H., Kobayashi, S., Koch, I., Koch, J. C., Koenig, U., Kogel, D., Koh, Y. H., Koike, M., Kohlwein, S. D., Kocaturk, N. M., Komatsu, M., Konig, J., Kono, T., Kopp, B. T., Korcsmaros, T., Korkmaz, G., Korolchuk, V. I., Korsnes, M. S., Koskela, A., Kota, J., Kotake, Y., Kotler, M. L., Kou, Y., Koukourakis, M. I., Koustas, E., Kovacs, A. L., Kovacs, T., Koya, D., Kozako, T., Kraft, C., Krainc, D., Kramer, H., Krasnodembskaya, A. D., Kretz-Remy, C., Kroemer, G., Ktistakis, N. T., Kuchitsu, K., Kuenen, S., Kuerschner, L., Kukar, T., Kumar, A., Kumar, D., Kumar, S., Kume, S., Kumsta, C., Kundu, C. N., Kundu, M., Kunnumakkara, A. B., Kurgan, L., Kutateladze, T. G., Kutlu, O., Kwak, S., Kwon, H. J., Kwon, T. K., Kwon, Y. T., Kyrmizi, I., La Spada, A., Labonte, P., Ladoire, S., Laface, I., Lafont, F., Lagace, D. C., Lahiri, V., Lai, Z., Laird, A. S., Lakkaraju, A., Lamark, T., Lan, S. -H., Landajuela, A., Lane, D. J. R., Lane, J. D., Lang, C. H., Lange, C., Langel, U., Langer, R., Lapaquette, P., Laporte, J., Larusso, N. F., Lastres-Becker, I., Lau, W. C. Y., Laurie, G. W., Lavandero, S., Law, B. Y. K., Law, H. K. -W., Layfield, R., Le, W., Le Stunff, H., Leary, A. Y., Lebrun, J. -J., Leck, L. Y. W., Leduc-Gaudet, J. -P., Lee, C., Lee, C. -P., Lee, D. -H., Lee, E. B., Lee, E. F., Lee, G. M., Lee, H. -J., Lee, H. K., Lee, J. M., Lee, J. S., Lee, J. -A., Lee, J. -Y., Lee, J. H., Lee, M., Lee, M. G., Lee, M. J., Lee, M. -S., Lee, S. Y., Lee, S. -J., Lee, S. B., Lee, W. H., Lee, Y. -R., Lee, Y. -H., Lee, Y., Lefebvre, C., Legouis, R., Lei, Y. L., Lei, Y., Leikin, S., Leitinger, G., Lemus, L., Leng, S., Lenoir, O., Lenz, G., Lenz, H. J., Lenzi, P., Leon, Y., Leopoldino, A. M., Leschczyk, C., Leskela, S., Letellier, E., Leung, C. -T., Leung, P. S., Leventhal, J. S., Levine, B., Lewis, P. A., Ley, K., Li, B., Li, D. -Q., Li, J., Li, K., Li, L., Li, M., Li, P. -L., Li, M. -Q., Li, Q., Li, S., Li, T., Li, W., Li, X., Li, Y. -P., Li, Y., Li, Z., Lian, J., Liang, C., Liang, Q., Liang, W., Liang, Y., Liao, G., Liao, L., Liao, M., Liao, Y. -F., Librizzi, M., Lie, P. P. Y., Lilly, M. A., Lim, H. J., Lima, T. R. R., Limana, F., Lin, C., Lin, C. -W., Lin, D. -S., Lin, F. -C., Lin, J. D., Lin, K. M., Lin, K. -H., Lin, L. -T., Lin, P. -H., Lin, Q., Lin, S., Lin, S. -J., Lin, W., Lin, X., Lin, Y. -X., Lin, Y. -S., Linden, R., Lindner, P., Ling, S. -C., Lingor, P., Linnemann, A. K., Liou, Y. -C., Lipinski, M. M., Lipovsek, S., Lira, V. A., Lisiak, N., Liton, P. B., Liu, C., Liu, C. -H., Liu, C. -F., Liu, C. H., Liu, F., Liu, H., Liu, H. -S., Liu, H. -F., Liu, J., Liu, L., Liu, M., Liu, Q., Liu, W., Liu, X. -H., Liu, X., Liu, Y., Livingston, J. A., Lizard, G., Lizcano, J. M., Ljubojevic-Holzer, S., Lleonart, M. E., Llobet-Navas, D., Llorente, A., Lo, C. H., Lobato-Marquez, D., Long, Q., Long, Y. C., Loos, B., Loos, J. A., Lopez, M. G., Lopez-Domenech, G., Lopez-Guerrero, J. A., Lopez-Jimenez, A. T., Lopez-Perez, O., Lopez-Valero, I., Lorenowicz, M. J., Lorente, M., Lorincz, P., Lossi, L., Lotersztajn, S., Lovat, P. E., Lovell, J. F., Lovy, A., Low, P., Lu, G., Lu, H., Lu, J. -H., Lu, J. -J., Lu, M., Lu, S., Luciani, A., Lucocq, J. M., Ludovico, P., Luftig, M. A., Luhr, M., Luis-Ravelo, D., Lum, J. J., Luna-Dulcey, L., Lund, A. H., Lund, V. K., Lunemann, J. D., Luningschror, P., Luo, H., Luo, R., Luo, S., Luo, Z., Luparello, C., Luscher, B., Luu, L., Lyakhovich, A., Lyamzaev, K. G., Lystad, A. H., Lytvynchuk, L., Ma, A. C., Ma, C., Ma, M., Ma, N. -F., Ma, Q. -H., Ma, X., Ma, Y., Ma, Z., Macdougald, O. A., Macian, F., Macintosh, G. C., Mackeigan, J. P., Macleod, K. F., Maday, S., Madeo, F., Madesh, M., Madl, T., Madrigal-Matute, J., Maeda, A., Maejima, Y., Magarinos, M., Mahavadi, P., Maiani, E., Maiese, K., Maiti, P., Maiuri, M. C., Majello, B., Major, M. B., Makareeva, E., Malik, F., Mallilankaraman, K., Malorni, W., Maloyan, A., Mammadova, N., Man, G. C. W., Manai, F., Mancias, J. D., Mandelkow, E. -M., Mandell, M. A., Manfredi, A. A., Manjili, M. H., Manjithaya, R., Manque, P., Manshian, B. B., Manzano, R., Manzoni, C., Mao, K., Marchese, C., Marchetti, S., Marconi, A. M., Marcucci, F., Mardente, S., Mareninova, O. A., Margeta, M., Mari, M., Marinelli, S., Marinelli, O., Marino, G., Mariotto, S., Marshall, R. S., Marten, M. R., Martens, S., Martin, A. P. J., Martin, K. R., Martin, S., Martin-Segura, A., Martin-Acebes, M. A., Martin-Burriel, I., Martin-Rincon, M., Martin-Sanz, P., Martina, J. A., Martinet, W., Martinez, A., Martinez, J., Martinez Velazquez, M., Martinez-Lopez, N., Martinez-Vicente, M., Martins, D. O., Martins, J. O., Martins, W. K., Martins-Marques, T., Marzetti, E., Masaldan, S., Masclaux-Daubresse, C., Mashek, D. G., Massa, V., Massieu, L., Masson, G. R., Masuelli, L., Masyuk, A. I., Masyuk, T. V., Matarrese, P., Matheu, A., Matoba, S., Matsuzaki, S., Mattar, P., Matte, A., Mattoscio, D., Mauriz, J. L., Mauthe, M., Mauvezin, C., Maverakis, E., Maycotte, P., Mayer, J., Mazzoccoli, G., Mazzoni, C., Mazzulli, J. R., Mccarty, N., Mcdonald, C., Mcgill, M. R., Mckenna, S. L., Mclaughlin, B., Mcloughlin, F., Mcniven, M. A., Mcwilliams, T. G., Mechta-Grigoriou, F., Medeiros, T. C., Medina, D. L., Megeney, L. A., Megyeri, K., Mehrpour, M., Mehta, J. L., Meijer, A. J., Meijer, A. H., Mejlvang, J., Melendez, A., Melk, A., Memisoglu, G., Mendes, A. F., Meng, D., Meng, F., Meng, T., Menna-Barreto, R., Menon, M. B., Mercer, C., Mercier, A. E., Mergny, J. -L., Merighi, A., Merkley, S. D., Merla, G., Meske, V., Mestre, A. C., Metur, S. P., Meyer, C., Meyer, H., Mi, W., Mialet-Perez, J., Miao, J., Micale, L., Miki, Y., Milan, E., Milczarek, M., Miller, D. L., Miller, S. I., Miller, S., Millward, S. W., Milosevic, I., Minina, E. A., Mirzaei, H., Mirzaei, H. R., Mirzaei, M., Mishra, A., Mishra, N., Mishra, P. K., Misirkic Marjanovic, M., Misasi, R., Misra, A., Misso, G., Mitchell, C., Mitou, G., Miura, T., Miyamoto, S., Miyazaki, M., Miyazaki, T., Miyazawa, K., Mizushima, N., Mogensen, T. H., Mograbi, B., Mohammadinejad, R., Mohamud, Y., Mohanty, A., Mohapatra, S., Mohlmann, T., Mohmmed, A., Moles, A., Moley, K. H., Molinari, M., Mollace, V., Moller, A. B., Mollereau, B., Mollinedo, F., Montagna, C., Monteiro, M. J., Montella, A., Montes, L. R., Montico, B., Mony, V. K., Monzio Compagnoni, G., Moore, M. N., Moosavi, M. A., Mora, A. L., Mora, M., Morales-Alamo, D., Moratalla, R., Moreira, P. I., Morelli, E., Moreno, S., Moreno-Blas, D., Moresi, V., Morga, B., Morgan, A. H., Morin, F., Morishita, H., Moritz, O. L., Moriyama, M., Moriyasu, Y., Morleo, M., Morselli, E., Moruno-Manchon, J. F., Moscat, J., Mostowy, S., Motori, E., Moura, A. F., Moustaid-Moussa, N., Mrakovcic, M., Mucino-Hernandez, G., Mukherjee, A., Mukhopadhyay, S., Mulcahy Levy, J. M., Mulero, V., Muller, S., Munch, C., Munjal, A., Munoz-Canoves, P., Munoz-Galdeano, T., Munz, C., Murakawa, T., Muratori, C., Murphy, B. M., Murphy, J. P., Murthy, A., Myohanen, T. T., Mysorekar, I. U., Mytych, J., Nabavi, S. M., Nabissi, M., Nagy, P., Nah, J., Nahimana, A., Nakagawa, I., Nakamura, K., Nakatogawa, H., Nandi, S. S., Nanjundan, M., Nanni, M., Napolitano, G., Nardacci, R., Narita, M., Nassif, M., Nathan, I., Natsumeda, M., Naude, R. J., Naumann, C., Naveiras, O., Navid, F., Nawrocki, S. T., Nazarko, T. Y., Nazio, F., Negoita, F., Neill, T., Neisch, A. L., Neri, L. M., Netea, M. G., Neubert, P., Neufeld, T. P., Neumann, D., Neutzner, A., Newton, P. T., Ney, P. A., Nezis, I. P., Ng, C. C. W., Ng, T. B., Nguyen, H. T. T., Nguyen, L. T., Ni, H. -M., Ni Cheallaigh, C., Ni, Z., Nicolao, M. C., Nicoli, F., Nieto-Diaz, M., Nilsson, P., Ning, S., Niranjan, R., Nishimune, H., Niso-Santano, M., Nixon, R. A., Nobili, A., Nobrega, C., Noda, T., Nogueira-Recalde, U., Nolan, T. M., Nombela, I., Novak, I., Novoa, B., Nozawa, T., Nukina, N., Nussbaum-Krammer, C., Nylandsted, J., O'Donovan, T. R., O'Leary, S. M., O'Rourke, E. J., O'Sullivan, M. P., O'Sullivan, T. E., Oddo, S., Oehme, I., Ogawa, M., Ogier-Denis, E., Ogmundsdottir, M. H., Ogretmen, B., Oh, G. T., Oh, S. -H., Oh, Y. J., Ohama, T., Ohashi, Y., Ohmuraya, M., Oikonomou, V., Ojha, R., Okamoto, K., Okazawa, H., Oku, M., Olivan, S., Oliveira, J. M. A., Ollmann, M., Olzmann, J. A., Omari, S., Omary, M. B., Onal, G., Ondrej, M., Ong, S. -B., Ong, S. -G., Onnis, A., Orellana, J. A., Orellana-Munoz, S., Ortega-Villaizan, M. D. M., Ortiz-Gonzalez, X. R., Ortona, E., Osiewacz, H. D., Osman, A. -H. K., Osta, R., Otegui, M. S., Otsu, K., Ott, C., Ottobrini, L., Ou, J. -H. J., Outeiro, T. F., Oynebraten, I., Ozturk, M., Pages, G., Pahari, S., Pajares, M., Pajvani, U. B., Pal, R., Paladino, S., Pallet, N., Palmieri, M., Palmisano, G., Palumbo, C., Pampaloni, F., Pan, L., Pan, Q., Pan, W., Pan, X., Panasyuk, G., Pandey, R., Pandey, U. B., Pandya, V., Paneni, F., Pang, S. Y., Panzarini, E., Papademetrio, D. L., Papaleo, E., Papinski, D., Papp, D., Park, E. C., Park, H. T., Park, J. -M., Park, J. -I., Park, J. T., Park, J., Park, S. C., Park, S. -Y., Parola, A. H., Parys, J. B., Pasquier, A., Pasquier, B., Passos, J. F., Pastore, N., Patel, H. H., Patschan, D., Pattingre, S., Pedraza-Alva, G., Pedraza-Chaverri, J., Pedrozo, Z., Pei, G., Pei, J., Peled-Zehavi, H., Pellegrini, J. M., Pelletier, J., Penalva, M. A., Peng, D., Peng, Y., Penna, F., Pennuto, M., Pentimalli, F., Pereira, C. M. F., Pereira, G. J. S., Pereira, L. C., Pereira de Almeida, L., Perera, N. D., Perez-Lara, A., Perez-Oliva, A. B., Perez-Perez, M. E., Periyasamy, P., Perl, A., Perrotta, C., Perrotta, I., Pestell, R. G., Petersen, M., Petrache, I., Petrovski, G., Pfirrmann, T., Pfister, A. S., Philips, J. A., Pi, H., Picca, A., Pickrell, A. M., Picot, S., Pierantoni, G. M., Pierdominici, M., Pierre, P., Pierrefite-Carle, V., Pierzynowska, K., Pietrocola, F., Pietruczuk, M., Pignata, C., Pimentel-Muinos, F. X., Pinar, M., Pinheiro, R. O., Pinkas-Kramarski, R., Pinton, P., Pircs, K., Piya, S., Pizzo, P., Plantinga, T. S., Platta, H. W., Plaza-Zabala, A., Plomann, M., Plotnikov, E. Y., Plun-Favreau, H., Pluta, R., Pocock, R., Poggeler, S., Pohl, C., Poirot, M., Poletti, A., Ponpuak, M., Popelka, H., Popova, B., Porta, H., Porte Alcon, S., Portilla-Fernandez, E., Post, M., Potts, M. B., Poulton, J., Powers, T., Prahlad, V., Prajsnar, T. K., Pratico, D., Prencipe, R., Priault, M., Proikas-Cezanne, T., Promponas, V. J., Proud, C. G., Puertollano, R., Puglielli, L., Pulinilkunnil, T., Puri, D., Puri, R., Puyal, J., Qi, X., Qi, Y., Qian, W., Qiang, L., Qiu, Y., Quadrilatero, J., Quarleri, J., Raben, N., Rabinowich, H., Ragona, D., Ragusa, M. J., Rahimi, N., Rahmati, M., Raia, V., Raimundo, N., Rajasekaran, N. -S., Ramachandra Rao, S., Rami, A., Ramirez-Pardo, I., Ramsden, D. B., Randow, F., Rangarajan, P. N., Ranieri, D., Rao, H., Rao, L., Rao, R., Rathore, S., Ratnayaka, J. A., Ratovitski, E. A., Ravanan, P., Ravegnini, G., Ray, S. K., Razani, B., Rebecca, V., Reggiori, F., Regnier-Vigouroux, A., Reichert, A. S., Reigada, D., Reiling, J. H., Rein, T., Reipert, S., Rekha, R. S., Ren, H., Ren, J., Ren, W., Renault, T., Renga, G., Reue, K., Rewitz, K., Ribeiro de Andrade Ramos, B., Riazuddin, S. A., Ribeiro-Rodrigues, T. M., Ricci, J. -E., Ricci, R., Riccio, V., Richardson, D. R., Rikihisa, Y., Risbud, M. V., Risueno, R. M., Ritis, K., Rizza, S., Rizzuto, R., Roberts, H. C., Roberts, L. D., Robinson, K. J., Roccheri, M. C., Rocchi, S., Rodney, G. G., Rodrigues, T., Rodrigues Silva, V. R., Rodriguez, A., Rodriguez-Barrueco, R., Rodriguez-Henche, N., Rodriguez-Rocha, H., Roelofs, J., Rogers, R. S., Rogov, V. V., Rojo, A. I., Rolka, K., Romanello, V., Romani, L., Romano, A., Romano, P. S., Romeo-Guitart, D., Romero, L. C., Romero, M., Roney, J. C., Rongo, C., Roperto, S., Rosenfeldt, M. T., Rosenstiel, P., Rosenwald, A. G., Roth, K. A., Roth, L., Roth, S., Rouschop, K. M. A., Roussel, B. D., Roux, S., Rovere-Querini, P., Roy, A., Rozieres, A., Ruano, D., Rubinsztein, D. C., Rubtsova, M. P., Ruckdeschel, K., Ruckenstuhl, C., Rudolf, E., Rudolf, R., Ruggieri, A., Ruparelia, A. A., Rusmini, P., Russell, R. R., Russo, G. L., Russo, M., Russo, R., Ryabaya, O. O., Ryan, K. M., Ryu, K. -Y., Sabater-Arcis, M., Sachdev, U., Sacher, M., Sachse, C., Sadhu, A., Sadoshima, J., Safren, N., Saftig, P., Sagona, A. P., Sahay, G., Sahebkar, A., Sahin, M., Sahin, O., Sahni, S., Saito, N., Saito, S., Saito, T., Sakai, R., Sakai, Y., Sakamaki, J. -I., Saksela, K., Salazar, G., Salazar-Degracia, A., Salekdeh, G. H., Saluja, A. K., Sampaio-Marques, B., Sanchez, M. C., Sanchez-Alcazar, J. A., Sanchez-Vera, V., Sancho-Shimizu, V., Sanderson, J. T., Sandri, M., Santaguida, S., Santambrogio, L., Santana, M. M., Santoni, G., Sanz, A., Sanz, P., Saran, S., Sardiello, M., Sargeant, T. J., Sarin, A., Sarkar, C., Sarkar, S., Sarrias, M. -R., Sarmah, D. T., Sarparanta, J., Sathyanarayan, A., Sathyanarayanan, R., Scaglione, K. M., Scatozza, F., Schaefer, L., Schafer, Z. T., Schaible, U. E., Schapira, A. H. V., Scharl, M., Schatzl, H. M., Schein, C. H., Scheper, W., Scheuring, D., Schiaffino, M. V., Schiappacassi, M., Schindl, R., Schlattner, U., Schmidt, O., Schmitt, R., Schmidt, S. D., Schmitz, I., Schmukler, E., Schneider, A., Schneider, B. E., Schober, R., Schoijet, A. C., Schott, M. B., Schramm, M., Schroder, B., Schuh, K., Schuller, C., Schulze, R. J., Schurmanns, L., Schwamborn, J. C., Schwarten, M., Scialo, F., Sciarretta, S., Scott, M. J., Scotto, K. W., Scovassi, A. I., Scrima, A., Scrivo, A., Sebastian, D., Sebti, S., Sedej, S., Segatori, L., Segev, N., Seglen, P. O., Seiliez, I., Seki, E., Selleck, S. B., Sellke, F. W., Selsby, J. T., Sendtner, M., Senturk, S., Seranova, E., Sergi, C., Serra-Moreno, R., Sesaki, H., Settembre, C., Setty, S. R. G., Sgarbi, G., Sha, O., Shacka, J. J., Shah, J. A., Shang, D., Shao, C., Shao, F., Sharbati, S., Sharkey, L. M., Sharma, D., Sharma, G., Sharma, K., Sharma, P., Sharma, S., Shen, H. -M., Shen, H., Shen, J., Shen, M., Shen, W., Shen, Z., Sheng, R., Sheng, Z., Sheng, Z. -H., Shi, J., Shi, X., Shi, Y. -H., Shiba-Fukushima, K., Shieh, J. -J., Shimada, Y., Shimizu, S., Shimozawa, M., Shintani, T., Shoemaker, C. J., Shojaei, S., Shoji, I., Shravage, B. V., Shridhar, V., Shu, C. -W., Shu, H. -B., Shui, K., Shukla, A. K., Shutt, T. E., Sica, V., Siddiqui, A., Sierra, A., Sierra-Torre, V., Signorelli, S., Sil, P., Silva, B. J. D. A., Silva, J. D., Silva-Pavez, E., Silvente-Poirot, S., Simmonds, R. E., Simon, A. K., Simon, H. -U., Simons, M., Singh, A., Singh, L. P., Singh, R., Singh, S. V., Singh, S. K., Singh, S. B., Singh, S., Singh, S. P., Sinha, D., Sinha, R. A., Sinha, S., Sirko, A., Sirohi, K., Sivridis, E. L., Skendros, P., Skirycz, A., Slaninova, I., Smaili, S. S., Smertenko, A., Smith, M. D., Soenen, S. J., Sohn, E. J., Sok, S. P. M., Solaini, G., Soldati, T., Soleimanpour, S. A., Soler, R. M., Solovchenko, A., Somarelli, J. A., Sonawane, A., Song, F., Song, H. K., Song, J. -X., Song, K., Song, Z., Soria, L. R., Sorice, M., Soukas, A. A., Soukup, S. -F., Sousa, D., Sousa, N., Spagnuolo, P. A., Spector, S. A., Srinivas Bharath, M. M., S, t. Clair D., Stagni, V., Staiano, L., Stalnecker, C. A., Stankov, M. V., Stathopulos, P. B., Stefan, K., Stefan, S. M., Stefanis, L., Steffan, J. S., Steinkasserer, A., Stenmark, H., Sterneckert, J., Stevens, C., Stoka, V., Storch, S., Stork, B., Strappazzon, F., Strohecker, A. M., Stupack, D. G., Su, H., Su, L. -Y., Su, L., Suarez-Fontes, A. M., Subauste, C. S., Subbian, S., Subirada, P. V., Sudhandiran, G., Sue, C. M., Sui, X., Summers, C., Sun, G., Sun, J., Sun, K., Sun, M. -X., Sun, Q., Sun, Y., Sun, Z., Sunahara, K. K. S., Sundberg, E., Susztak, K., Sutovsky, P., Suzuki, H., Sweeney, G., Symons, J. D., Sze, S. C. W., Szewczyk, N. J., Tabecka-Lonczynska, A., Tabolacci, C., Tacke, F., Taegtmeyer, H., Tafani, M., Tagaya, M., Tai, H., Tait, S. W. G., Takahashi, Y., Takats, S., Talwar, P., Tam, C., Tam, S. Y., Tampellini, D., Tamura, A., Tan, C. T., Tan, E. -K., Tan, Y. -Q., Tanaka, M., Tang, D., Tang, J., Tang, T. -S., Tanida, I., Tao, Z., Taouis, M., Tatenhorst, L., Tavernarakis, N., Taylor, A., Taylor, G. A., Taylor, J. M., Tchetina, E., Tee, A. R., Tegeder, I., Teis, D., Teixeira, N., Teixeira-Clerc, F., Tekirdag, K. A., Tencomnao, T., Tenreiro, S., Tepikin, A. V., Testillano, P. S., Tettamanti, G., Tharaux, P. -L., Thedieck, K., Thekkinghat, A. A., Thellung, S., Thinwa, J. W., Thirumalaikumar, V. P., Thomas, S. M., Thomes, P. G., Thorburn, A., Thukral, L., Thum, T., Thumm, M., Tian, L., Tichy, A., Till, A., Timmerman, V., Titorenko, V. I., Todi, S. V., Todorova, K., Toivonen, J. M., Tomaipitinca, L., Tomar, D., Tomas-Zapico, C., Tomic, S., Tong, B. C. -K., Tong, C., Tong, X., Tooze, S. A., Torgersen, M. L., Torii, S., Torres-Lopez, L., Torriglia, A., Towers, C. G., Towns, R., Toyokuni, S., Trajkovic, V., Tramontano, D., Tran, Q. -G., Travassos, L. H., Trelford, C. B., Tremel, S., Trougakos, I. P., Tsao, B. P., Tschan, M. P., Tse, H. -F., Tse, T. F., Tsugawa, H., Tsvetkov, A. S., Tumbarello, D. A., Tumtas, Y., Tunon, M. J., Turcotte, S., Turk, B., Turk, V., Turner, B. J., Tuxworth, R. I., Tyler, J. K., Tyutereva, E. V., Uchiyama, Y., Ugun-Klusek, A., Uhlig, H. H., Ulamek-Koziol, M., Ulasov, I. V., Umekawa, M., Ungermann, C., Unno, R., Urbe, S., Uribe-Carretero, E., Ustun, S., Uversky, V. N., Vaccari, T., Vaccaro, M. I., Vahsen, B. F., Vakifahmetoglu-Norberg, H., Valdor, R., Valente, M. J., Valko, A., Vallee, R. B., Valverde, A. M., Van den Berghe, G., van der Veen, S., Van Kaer, L., van Loosdregt, J., van Wijk, S. J. L., Vandenberghe, W., Vanhorebeek, I., Vannier-Santos, M. A., Vannini, N., Vanrell, M. C., Vantaggiato, C., Varano, G., Varela-Nieto, I., Varga, M., Vasconcelos, M. H., Vats, S., Vavvas, D. G., Vega-Naredo, I., Vega-Rubin-de-Celis, S., Velasco, G., Velazquez, A. P., Vellai, T., Vellenga, E., Velotti, F., Verdier, M., Verginis, P., Vergne, I., Verkade, P., Verma, M., Verstreken, P., Vervliet, T., Vervoorts, J., Vessoni, A. T., Victor, V. M., Vidal, M., Vidoni, C., Vieira, O. V., Vierstra, R. D., Vigano, S., Vihinen, H., Vijayan, V., Vila, M., Vilar, M., Villalba, J. M., Villalobo, A., Villarejo-Zori, B., Villarroya, F., Villarroya, J., Vincent, O., Vindis, C., Viret, C., Viscomi, M. T., Visnjic, D., Vitale, I., Vocadlo, D. J., Voitsekhovskaja, O. V., Volonte, C., Volta, M., Vomero, M., Von Haefen, C., Vooijs, M. A., Voos, W., Vucicevic, L., Wade-Martins, R., Waguri, S., Waite, K. A., Wakatsuki, S., Walker, D. W., Walker, M. J., Walker, S. A., Walter, J., Wandosell, F. G., Wang, B., Wang, C. -Y., Wang, C., Wang, D., Wang, F., Wang, G., Wang, H., Wang, H. -G., Wang, J., Wang, K., Wang, L., Wang, M. H., Wang, M., Wang, N., Wang, P., Wang, Q. J., Wang, Q., Wang, Q. K., Wang, Q. A., Wang, W. -T., Wang, W., Wang, X., Wang, Y., Wang, Y. -Y., Wang, Z., Warnes, G., Warnsmann, V., Watada, H., Watanabe, E., Watchon, M., Wawrzynska, A., Weaver, T. E., Wegrzyn, G., Wehman, A. M., Wei, H., Wei, L., Wei, T., Wei, Y., Weiergraber, O. H., Weihl, C. C., Weindl, G., Weiskirchen, R., Wells, A., Wen, R. H., Wen, X., Werner, A., Weykopf, B., Wheatley, S. P., Whitton, J. L., Whitworth, A. J., Wiktorska, K., Wildenberg, M. E., Wileman, T., Wilkinson, S., Willbold, D., Williams, B., Williams, R. S. B., Williams, R. L., Williamson, P. R., Wilson, R. A., Winner, B., Winsor, N. J., Witkin, S. S., Wodrich, H., Woehlbier, U., Wollert, T., Wong, E., Wong, J. H., Wong, R. W., Wong, V. K. W., Wong, W. W. -L., Wu, A. -G., Wu, C., Wu, J., Wu, K. K., Wu, M., Wu, S. -Y., Wu, S., Wu, W. K. K., Wu, X., Wu, Y. -W., Wu, Y., Xavier, R. J., Xia, H., Xia, L., Xia, Z., Xiang, G., Xiang, J., Xiang, M., Xiang, W., Xiao, B., Xiao, G., Xiao, H., Xiao, H. -T., Xiao, J., Xiao, L., Xiao, S., Xiao, Y., Xie, B., Xie, C. -M., Xie, M., Xie, Y., Xie, Z., Xilouri, M., Xu, C., Xu, E., Xu, H., Xu, J., Xu, L., Xu, W. W., Xu, X., Xue, Y., Yakhine-Diop, S. M. S., Yamaguchi, M., Yamaguchi, O., Yamamoto, A., Yamashina, S., Yan, S., Yan, S. -J., Yan, Z., Yanagi, Y., Yang, C., Yang, D. -S., Yang, H., Yang, H. -T., Yang, J. -M., Yang, J., Yang, L., Yang, M., Yang, P. -M., Yang, Q., Yang, S., Yang, S. -F., Yang, W., Yang, W. Y., Yang, X., Yang, Y., Yao, H., Yao, S., Yao, X., Yao, Y. -G., Yao, Y. -M., Yasui, T., Yazdankhah, M., Yen, P. M., Yi, C., Yin, X. -M., Yin, Y., Yin, Z., Ying, M., Ying, Z., Yip, C. K., Yiu, S. P. T., Yoo, Y. H., Yoshida, K., Yoshii, S. R., Yoshimori, T., Yousefi, B., Yu, B., Yu, H., Yu, J., Yu, L., Yu, M. -L., Yu, S. -W., Yu, V. C., Yu, W. H., Yu, Z., Yuan, J., Yuan, L. -Q., Yuan, S., Yuan, S. -S. F., Yuan, Y., Yuan, Z., Yue, J., Yue, Z., Yun, J., Yung, R. L., Zacks, D. N., Zaffagnini, G., Zambelli, V. O., Zanella, I., Zang, Q. S., Zanivan, S., Zappavigna, S., Zaragoza, P., Zarbalis, K. S., Zarebkohan, A., Zarrouk, A., Zeitlin, S. O., Zeng, J., Zeng, J. -D., Zerovnik, E., Zhan, L., Zhang, B., Zhang, D. D., Zhang, H., Zhang, H. -L., Zhang, J., Zhang, J. -P., Zhang, K. Y. B., Zhang, L. W., Zhang, L., Zhang, M., Zhang, P., Zhang, S., Zhang, W., Zhang, X., Zhang, X. -W., Zhang, X. D., Zhang, Y., Zhang, Y. -D., Zhang, Y. -Y., Zhang, Z., Zhao, H., Zhao, L., Zhao, S., Zhao, T., Zhao, X. -F., Zhao, Y., Zheng, G., Zheng, K., Zheng, L., Zheng, S., Zheng, X. -L., Zheng, Y., Zheng, Z. -G., Zhivotovsky, B., Zhong, Q., Zhou, A., Zhou, B., Zhou, C., Zhou, G., Zhou, H., Zhou, J., Zhou, K., Zhou, R., Zhou, X. -J., Zhou, Y., Zhou, Z. -Y., Zhou, Z., Zhu, B., Zhu, C., Zhu, G. -Q., Zhu, H., Zhu, W. -G., Zhu, Y., Zhuang, H., Zhuang, X., Zientara-Rytter, K., Zimmermann, C. M., Ziviani, E., Zoladek, T., Zong, W. -X., Zorov, D. B., Zorzano, A., Zou, W., Zou, Z., Zuryn, S., Zwerschke, W., Brand-Saberi, B., Dong, X. C., Kenchappa, C. S., Lin, Y., Oshima, S., Rong, Y., Sluimer, J. C., Stallings, C. L., Tong, C. -K., and Centre National de la Recherche Scientifique (CNRS)
Subjects: 0301 basic medicine, Programmed cell death, Settore BIO/06, Autophagosome, Autolysosome, [SDV]Life Sciences [q-bio], lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Autophagy-Related Proteins, Review, Computational biology, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Biology, Settore MED/04, 03 medical and health sciences, stress, Chaperone-mediated autophagy, ddc:570, Autophagy, LC3, Animals, Humans, cancer, Settore BIO/10, flux, lysosome, macroautophagy, neurodegeneration, phagophore, vacuole, Set (psychology), Molecular Biology, 030102 biochemistry & molecular biology, business.industry, Interpretation (philosophy), Autophagosomes, Cell Biology, Multicellular organism, 030104 developmental biology, Knowledge base, Biological Assay, Lysosomes, business, Biomarkers, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Contains fulltext : 232759.pdf (Publisher’s version ) (Closed access) In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.
Published: 2021

26. An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis

Author: Martha Zakrzewski, Katherine Hanigan, Gillian Mahy, Miles P. Sparrow, Graham L. Radford-Smith, James D. Doecke, Ian C. Lawrance, Susan J. Connor, Peter A. Bampton, Richard B. Gearry, Jake Begun, Sally Bell, Anton Lord, Jane M. Andrews, Alissa Walsh, Krupa Krishnaprasad, Timothy H Florin, Grant W. Montgomery, Lisa A. Simms, and Sally Mortlock
Subjects: medicine.medical_specialty, Genetic heterogeneity, business.industry, Incidence (epidemiology), Gastroenterology, Disease, Odds ratio, Human leukocyte antigen, General Medicine, medicine.disease, Inflammatory bowel disease, Ulcerative colitis, Internal medicine, medicine, Age of onset, business
Abstract: Ulcerative colitis (UC) is a major form of inflammatory bowel disease with increasing global incidence. There is significant phenotypic heterogeneity defined by a range of clinical variables including age of onset and disease extent. Clinical outcomes range from long-term remission on minimal therapy to surgical resection. Close to 70% of UC risk can be attributed to genetics and understanding the genetic mechanisms contributing to this risk and disease heterogeneity is vital for understanding disease pathogenesis and improving patient outcomes through targeted screening and therapies. This study aims to characterise the genetic heterogeneity of UC by identifying genomic risk variants specific to mild and/or severe forms of UC, exploring variations in the effect size of known risk variants and assessing the clinical value of a genetic risk score (GRS). We conducted genome-wide association (GWA) analyses in 287 patients with mild UC, 311 patients with severe UC and 583 age- and gender-matched controls. Odds ratios (OR) for mild vs control, severe vs control and combined mild and severe UC vs control were calculated. Using the combined UC data, two independent loci in the HLA region reached genome-wide significance. An additional genome-wide significant signal on chromosome 1 was identified in severe cases only. OR for known risk loci varied between mild and severe patients and were similar to previously published results. Effect estimates from the most recent UC GWA meta-analysis were used to calculate a GRS for each individual. A higher mean GRS was observed in both mild and severe UC cases compared to controls however, there was no difference between the mean GRS for mild and severe UC. Heterogeneity in effect sizes of UC associated variants between mild and severe disease burden suggests the presence of genetically distinct signatures. While large consortium data are needed to identify genome-wide significant variants, additional risk loci may be identified by targeted recruitment of individuals with a history of severe disease.Author SummaryUlcerative colitis (UC) is a chronic and often debilitating form of inflammatory bowel disease affecting approximately 0.3% of the population in industrialized economies. The disease displays significant clinical heterogeneity including age at presentation, disease severity, and the propensity to develop disease-related complications. Several previous studies have demonstrated the heritability of UC, identifying over 30 loci specific to the disease. The majority of these loci have small to modest effect sizes other than those within the Human Leucocyte Antigen (HLA) region on chromosome 6. Using stringent clinical criteria for defining mild and severe forms of UC in an extremes of phenotype approach, we undertook a genome wide association study in a dataset of 1222 participants to investigate genetic heterogeneity in this disease. We demonstrated substantial differences in genetic associations in severe UC as compared to mild UC. While over 2,000 SNPs achieved genome-wide significance in the severe UC analysis, none reached significance for mild UC. These results were reflected in significant differences in odds ratios. We identified Complement Factor B (CFB) as a potential susceptibility gene for severe UC in the Caucasian population with additional tissue gene expression demonstrating a positive correlation with disease severity.
Published: 2021

27. Innovative Economy And Environmental Safety Management Of Enterprises

Author: I. A. Dmitrieva, O. V. Begun, L. P. Mileshko, N. A. Ivanova, and A. I. Vasyutchenko
Subjects: Environmental safety, Business, Industrial organization
Published: 2021

28. MP67-08 UROLOGY PATIENT PERCEPTIONS OF RESIDENT CULTURAL COMPETENCY IN A PILOT LOCAL GLOBAL HEALTH CURRICULUM

Author: Dinah Diab, Cheryl T. Lee, Tasha Posid, Lily Kaufman, Frank P. Begun, Michael Sourial, Alicia Scimeca, David Sharp, Sabrina Amin, and Kerestina Khalil
Subjects: Medical education, Patient perceptions, business.industry, Urology, Global health, Medicine, business, Cultural competence, Curriculum
Abstract: INTRODUCTION AND OBJECTIVE:Physicians increasingly face the challenge of managing clinical encounters with patients from a range of cultural backgrounds. Cross-cultural training serves as a means t...
Published: 2021

29. PD24-02 BIASES IN RESIDENCY MATCH INTERVIEWS: 2-YEAR COMPARISON AND HOW UROLOGY STACKS UP

Author: Dinah Diab, Hayat Mohammed, Kathleen Puttmann, Alicia Scimeca, Erika Garza, Frank P. Begun, Nicolette Payne, Vivian Wong, Tasha Posid, and Steven Goldenthal
Subjects: Medical education, Matching (statistics), business.industry, Urology, Medicine, Program code, business
Abstract: INTRODUCTION AND OBJECTIVE:Despite the development of the National Resident Matching Program code of conduct, evidence suggests that “illegal or coercive” interview questions were still being asked...
Published: 2021

30. IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease

Author: Rabina Giri, Renee J. Robb, Philip Hugenholtz, Geoffrey R. Hill, Rachel D. Kuns, Motoko Koyama, Steven W. Lane, Kate H. Gartlan, Kate L Bowerman, Ram Savan, Adriana Forero, Andrea S. Henden, Karshing Chang, Jakob Begun, Mariapia A. Degli-Esposti, Antiopi Varelias, Bruce R. Blazar, Sergei V. Kotenko, Kathleen S. Ensbey, Andrew D. Clouston, Nicole Waddell, and Stephen H. Kazakoff
Subjects: Gastrointestinal Diseases, Immunology, Graft vs Host Disease, chemical and pharmacologic phenomena, digestive system, Biochemistry, Severity of Illness Index, Mice, Immunopathology, Organoid, Medicine, Humans, Animals, Transplantation, Homologous, Bone Marrow Transplantation, Receptors, Interferon, Mice, Knockout, Gastrointestinal tract, Transplantation, business.industry, Interleukins, LGR5, Hematopoietic Stem Cell Transplantation, Cell Biology, Hematology, medicine.disease, Gastrointestinal Tract, surgical procedures, operative, Graft-versus-host disease, Apoptosis, Cytokines, Stem cell, Signal transduction, business, Signal Transduction
Abstract: Common approaches to alleviate acute graft-versus-host disease (aGvHD) focus on inducing immune tolerance by directly targeting immune cells. However, protecting key target tissues such as the gastrointestinal tract from immune-mediated damage may also reduce aGvHD severity. Using murine aGvHD models, Henden and colleagues present compelling evidence that interferon λ (IFN- λ) limits intestinal stem cell loss and promotes regeneration of gut epithelia, preserving mucosal barrier function. They propose IFN- λ therapy as a novel strategy to boost tissue protection., Key Points IFN-λ receptor signaling protects against lethal acute GI GVHD.Recombinant IL-29 treatment in the peri-transplant period promotes gut epithelial regeneration and is a promising therapy to limit GVHD., Visual Abstract, Immunopathology and intestinal stem cell (ISC) loss in the gastrointestinal (GI) tract is the prima facie manifestation of graft-versus-host disease (GVHD) and is responsible for significant mortality after allogeneic bone marrow transplantation (BMT). Approaches to prevent GVHD to date focus on immune suppression. Here, we identify interferon-λ (IFN-λ; interleukin-28 [IL-28]/IL-29) as a key protector of GI GVHD immunopathology, notably within the ISC compartment. Ifnlr1−/− mice displayed exaggerated GI GVHD and mortality independent of Paneth cells and alterations to the microbiome. Ifnlr1−/− intestinal organoid growth was significantly impaired, and targeted Ifnlr1 deficiency exhibited effects intrinsic to recipient Lgr5+ ISCs and natural killer cells. PEGylated recombinant IL-29 (PEG-rIL-29) treatment of naive mice enhanced Lgr5+ ISC numbers and organoid growth independent of both IL-22 and type I IFN and modulated proliferative and apoptosis gene sets in Lgr5+ ISCs. PEG-rIL-29 treatment improved survival, reduced GVHD severity, and enhanced epithelial proliferation and ISC-derived organoid growth after BMT. The preservation of ISC numbers in response to PEG-rIL-29 after BMT occurred both in the presence and absence of IFN-λ–signaling in recipient natural killer cells. IFN-λ is therefore an attractive and rapidly testable approach to prevent ISC loss and immunopathology during GVHD.
Published: 2021

31. Osteoradionecrosis of the hyoid presenting as acute airway compromise

Author: Luke Stanisce, Sherrie Wang, Yekaterina Koshkareva, Nadir Ahmad, Traeden Wilson, Gregory J. Kubicek, and Zoe R. Begun
Subjects: medicine.medical_specialty, medicine.diagnostic_test, Osteoradionecrosis, business.industry, medicine.medical_treatment, Hyoid bone, Laryngoscopy, Head and neck cancer, respiratory system, medicine.disease, Airway Compromise, Radiation therapy, stomatognathic system, Otorhinolaryngology, medicine, Radiology, Complication, Airway, business
Abstract: Background Osteoradionecrosis (ORN) of the mandible is a well-known complication of radiation therapy for head and neck cancer. However, few reports have described hyoid bone ORN and its clinical implications. Methods We describe a retrospective case series of previously irradiated patients who were seen with sudden airway compromise, found to have underlying pathological hyoid fractures secondary to osteoradionecrosis. Results Six patients within postchemoradiation period (3-9 months) for oropharyngeal squamous cell carcinoma were seen with acute-onset dyspnea. Computed topography (CT) imaging was remarkable for severe airway luminal narrowing and pathological hyoid fractures. All six patients required urgent intervention with direct laryngoscopy and tracheostomy. Intraoperatively, five patients were seen with exposed necrotic hyoid bones. Conclusion The hyoid and its associated musculature strongly influence upper airway patency. ORN may compromise its physiological function and leads to acute airway compromise. Hyoid ORN may hold significant and imperative clinical implications in head and neck cancer post-treatment surveillance.
Published: 2021

32. RISK ASSESSMENT OF CATARACT SURGERY COMPLICATIONS

Author: D. N. Begun, A. D. Chuprov, A. N. Kazennov, Aleksandr O. Lositskiy, and E. L. Borshchuk
Subjects: medicine.medical_specialty, business.industry, Health Policy, General surgery, medicine.medical_treatment, Public Health, Environmental and Occupational Health, Medicine, Cataract surgery, business, Risk assessment
Published: 2019

33. Luminal Clinical

Author: Ecushla C Linedale, Yoon-Kyo An, Fergus W. Gardiner, David Prince, Susan J. Connor, Jane M. Andrews, and Jakob Begun
Subjects: medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Meta-analysis, Gastroenterology, medicine, Calprotectin, business, Feces
Published: 2019

34. Incidence and Morbidity of Radiation-Induced Hemorrhagic Cystitis in Prostate Cancer

Author: Mohammed T. Azaiza, Mazen Abdelhady, Eglal Samir, Steven Allegro, Sarah Martin, and Evan Begun
Subjects: Male, medicine.medical_specialty, Blood transfusion, Urology, medicine.medical_treatment, 030232 urology & nephrology, Hemorrhage, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Cystitis, Humans, Medicine, Radiation Injuries, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Fulguration, Incidence, Incidence (epidemiology), Acute kidney injury, Prostatic Neoplasms, Retrospective cohort study, Middle Aged, medicine.disease, Radiation therapy, 030220 oncology & carcinogenesis, Morbidity, business, Hemorrhagic cystitis
Abstract: OBJECTIVE To determine if reported incidence rates of hemorrhagic cystitis after radiation therapy for prostate cancer are accurate, to investigate the effect of different radiation modalities on the development of hemorrhagic cystitis and to assess its morbidity and treatment. MATERIALS AND METHODS A retrospective chart review was completed of 709 patients at 2 Detroit Medical Center hospitals who underwent radiation therapy for prostate cancer between January 2000 and September 2015. In patients who developed hemorrhagic cystitis, we analyzed the incidence, radiation modality, morbidity, treatment, and complications. RESULTS The incidence rate of hemorrhagic cystitis after radiation for prostate cancer was 11.1%. There was no significant difference between external beam and intensity-modulated radiation therapy and the development of hemorrhagic cystitis (P = .18). Patients developed hemorrhagic cystitis an average of 79.1 months (4-230 months) after radiation. The average number of admissions was 2.5 (1-9) with an average length of stay of 7.6 days (1-42 days). Fifty-two percent of patients required blood transfusion with an average of 4.3 units transfused per patient (1-33U). The most common treatment was cystoscopy with fulguration/clot evacuation in 86% of patients. Complications included urinary tract infection, acute kidney injury, urosepsis, and even death. CONCLUSION The incidence of hemorrhagic cystitis following radiation therapy for prostate cancer is under-reported in the literature. Hemorrhagic cystitis is associated with high morbidity and complications for patients, requiring multiple hospitalizations, blood transfusions, and procedures. Advances in radiation have not significantly reduced the risk of developing hemorrhagic cystitis.
Published: 2019

35. Determinants of Community-Related Expenses of US Tax-Exempt Hospitals, 2013

Author: James W. Begun and Hanh Q. Trinh
Subjects: medicine.medical_specialty, Community building, Uncompensated Care, Tax Exemption, Hospitals, Community, Population health, 03 medical and health sciences, 0302 clinical medicine, Acute care, medicine, Humans, Community Health Services, 030212 general & internal medicine, Social determinants of health, Operating expense, health care economics and organizations, 030505 public health, Health Policy, Public health, Public Health, Environmental and Occupational Health, Per capita income, United States, Community health, Linear Models, Demographic economics, Business, 0305 other medical science
Abstract: Context Tax-exempt hospitals in the United States are required to report community benefit expenses on their federal tax forms. Two categories of expenses critical to the public health mission of hospitals are the "community health improvement" and "community-building" expense categories. The community health improvement expenses formally qualify as a community benefit, whereas community-building expenses do not. Increasing both types of spending would be consistent with the growing evidence on the effects of social determinants on population health. Objective To identify characteristics associated with the level of community health improvement and community-building expenses reported by tax-exempt hospitals. Design The general acute care hospital is the unit of analysis. We utilize secondary data for all US general acute care hospitals that filed their own Internal Revenue Service Form 990 Schedule H for 2013 (n = 1508). We apply linear regression analysis to an explanatory model with 8 independent variables. Measures The primary dependent variables are percentage of operating expenses devoted to community health improvement and to community building. The independent variables include 4 hospital-level measures, 3 county-level measures, and a measure of state requirements for community benefit. Results The level of community health improvement expenses is positively associated with bed size, system membership, profit margin, and urban location. In states where tax-exempt hospitals are required to demonstrate community benefit to the state, there is lower community health improvement spending. Teaching hospitals also demonstrate lower community health improvement spending. Results for community-building expenses mirror those for community health improvement except that teaching hospital status and per capita income lose significance and hospital competition gains significance in the negative direction. Conclusions Leaders among tax-exempt hospitals in community-related spending are hospitals that are larger, more profitable, members of systems, and located in urban areas and in states that do not have community benefit requirements.
Published: 2019

36. Clinical decision support improves quality of care in patients with ulcerative colitis

Author: Jake Begun, Leonid Churilov, Belinda D Jackson, Kathleen Gray, Simon R. Knowles, Danny Liew, and Peter De Cruz
Subjects: Adult, Male, medicine.medical_specialty, Decision support system, Decision Making, MEDLINE, Clinical decision support system, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Pharmacology (medical), Prospective Studies, 030212 general & internal medicine, Prospective cohort study, Quality of Health Care, Hepatology, business.industry, Australia, Gastroenterology, Middle Aged, Decision Support Systems, Clinical, medicine.disease, Ulcerative colitis, Clinical research, Emergency medicine, Cohort, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, business
Abstract: Background Decision support tools may facilitate shared decision-making and improve quality of care. Aim To assess the effectiveness of a decision support tool on improving quality of care in ulcerative colitis. Methods A prospective quality of care intervention was conducted at two Australian hospitals comparing out-patient-based ulcerative colitis care with, and without, a tablet-based decision support tool. This included questions on disease activity management; psychological well-being; and preventive care, with 13 process indicators relevant to each domain. Participants included adult out-patients with mild-to-moderate ulcerative colitis and their clinicians who were divided into two cohorts. The first cohort were followed up immediately after their clinical review to check whether their clinician had discussed the 13 process indicators during the consultation. The second cohort of patients used the decision support tool immediately prior to their consultation which then generated a suggested management plan for the patient and clinician to discuss during the consultation. Management between the 2 cohorts was compared to assess the effectiveness of the decision support tool in improving the primary outcome, defined as the proportion of quality process indicators used for ulcerative colitis care, with and without the decision support tool. Results Thirteen physicians and 100 patients participated. Fifty patients were managed without the decision support tool using standard care (median age 40; 44% male), and 50 patients used the decision support tool (median age 40; 46% male) over a 20-week period. Increase in the median use of process indicators overall was observed following use of the decision support tool (27% vs 100%; P < 0.001). Improvements were seen in psychological well-being management (30% vs 100%; P < 0.001), preventive care (16% vs 100%; P < 0.001) and process indicators related to disease activity management (50% vs 100%; P < 0.001). The decision support tool was found to be usable and acceptable. Shared decision-making was greater in the post-intervention group (mean decision conflict score of 18.0 vs 33.5; P = 0.002). Conclusions The decision support tool substantially improved the quality of the delivery of care. Decision support tools have the potential to minimise errors of omission via a standardised approach to care.
Published: 2019

37. Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey

Author: Todd M Tuttle, Schelomo Marmor, Ariella M. Altman, Scott Kizy, Jane Yuet Ching Hui, James W. Begun, and Bonnie Jerome-D'Emilia
Subjects: Adult, Cancer Research, medicine.medical_specialty, Adolescent, Biopsy, Lobular carcinoma, Breast Neoplasms, Logistic regression, California, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Risk Factors, Epidemiology, Humans, Medicine, Breast, 030212 general & internal medicine, Risk factor, Aged, Aged, 80 and over, New Jersey, medicine.diagnostic_test, business.industry, Obstetrics, Public health, Endocrine therapy, Middle Aged, medicine.disease, Oncology, 030220 oncology & carcinogenesis, Female, Breast Carcinoma In Situ, business
Abstract: The diagnosis of lobular carcinoma in situ (LCIS) is a strong risk factor for breast cancer. Endocrine therapy (ET) for LCIS has been shown to decrease breast cancer risk substantially. The purpose of this study was to evaluate the trends of ET use for LCIS in two large geographic locations. We identified women, ages 18 through 75, with a microscopic diagnosis of LCIS in California (CA) and New Jersey (NJ) from 2004 to 2014. We evaluated trends in unadjusted ET rates during the study period and used logistic regression to evaluate the relationship between patient, tumor, and treatment characteristics, and ET use. We identified 3,129 patients in CA and 2,965 patients in NJ. The overall use of ET during the study period was 14%. For the combined sample, women in NJ were significantly less likely to utilize ET then their counterparts in CA (OR 0.77, CI 0.66–0.90, NJ vs. CA). In addition, patients in the later year period (OR 1.27, CI 1.01–1.59, 2012–2014 vs. 2004–2005) and women who received an excisional biopsy (OR 2.35, CI 1.74–3.17), were more likely to utilize ET. Uninsured women were less likely to receive ET (OR 0.61, CI 0.44–0.84, non-insured vs. insured status). We observed that an increasing proportion of women are using ET for LCIS management, but geographical differences exist. Health insurance status played an important role in the underutilization of ET. Further research is needed to assess patient outcomes given the variations in management of LCIS.
Published: 2019

38. Blood coagulation in venous thrombosis, complicating treatment of children, adolescents and young adults with lymphomas

Author: V. V. Dmitriev, A. S. Fedorova, N. V. Lipay, I. V. Begun, I. A. Dunaev, and E. V. Dmitriev
Subjects: medicine.medical_specialty, hodgkin lymphoma, non-hodgkin lymphoma, 030204 cardiovascular system & hematology, Fibrinogen, Gastroenterology, blood clotting, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Diseases of the blood and blood-forming organs, Young adult, Vein, Internal jugular vein, anticoagulant therapy, business.industry, Warfarin, Hematology, medicine.disease, Thrombosis, Lymphoma, Venous thrombosis, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, venous thrombosis, RC633-647.5, business, medicine.drug
Abstract: Objective of the study was to compare blood clotting parameters in lymphoma patients with or without venous thrombosis (VT), as well as to analyze the duration and outcome of anticoagulant therapy in children, adolescents and young adults with lymphoma, whose program treatment was complicated by VT.Materials and methods . The analysis included 28 patients with lymphoma (Hodgkin lymphoma – 5, non-Hodgkin lymphoma – 23), aged from 2 to 25 years (median – 16.0 years), whose program treatment in 2005–2017 was complicated by VT. The case-control study was carried out to compare the parameters of blood coagulation. The control group consisted of 22 patients, aged from 2 to 20 years (median – 15.5 years) with the same diagnosis, age, therapy protocol and phase of treatment who had no thrombotic complications. The comparison group consisted of 35 healthy children aged from 3 to 18 years (median – 14.0 years).Results . There was no difference in majority of blood clotting parameters in lymphoma patients with or without VT. Hyperfibrinogenemia and an increased D-dimers level distinguished patients with lymphoma, regardless of the presence or absence of thrombosis, from healthy children of the same age (рA gene of the factor II takes warfarin continuously for a long time after relapse of VT. Complete recanalization of the thrombosed vessel occurred within the first 3 months in 9 patients, within 4–6 months – in 1, within 7–12 months ‒ in 4. Partial recanalization within 3–12 months was confirmed in 8 patients. Vein obliteration, mainly the internal jugular vein, as the outcome of VT occurred in 6 patients within 4–12 months.Conclusion . Detection of routine blood clotting parameters does not allow identifying patients with thrombosis among children, adolescents and young adults with lymphoma. Fibrinogen and D-dimers levels were significantly higher in lymphoma patients, than in healthy children. Anticoagulant therapy for 3–12 months led to the complete or partial recanalization of VT in 79 % of patients. To detect blood clotting parameters by thrombosis development, as well as to reveal and monitor transient and permanent risk factors are necessary to specify the cause of VT and to determine the appropriate anticoagulant therapy.
Published: 2019

39. Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones

Author: Melek Simsek, Rupa Banerjee, Javier P. Gisbert, Adriaan A. van Bodegraven, Rupert W. Leong, Azhar Ansari, Graham L. Radford-Smith, Vineet Ahuja, Margien L. Seinen, Richard B. Gearry, Timothy H. Florin, David P. Epstein, Nanne K. H. de Boer, Jean-Frederic Colombel, Sven Almer, Chris J. J. Mulder, Jake Begun, Murray L. Barclay, Miles P. Sparrow, Markus F. Neurath, Gastroenterology and hepatology, AGEM - Digestive immunity, AII - Inflammatory diseases, and Amsterdam Reproduction & Development (AR&D)
Subjects: medicine.medical_specialty, Hepatology, Thiopurine methyltransferase, biology, business.industry, Gastroenterology, MEDLINE, Inflammatory Bowel Diseases, Azathioprine, Friends, Internal medicine, medicine, biology.protein, Humans, business, medicine.drug
Published: 2019

40. 'It seems kinda like a different language to us': Homeless youths’ attitudes and experiences pertaining to condoms and contraceptives

Author: Msw Stephanie Begun Ph.D., Msw Kimberly Bender Ph.D., Katie Massey Combs Ph.D. Candidate, Msw, Msph, and Michaela Torrie Msw
Subjects: Male, Health Knowledge, Attitudes, Practice, Adolescent, Sexual Behavior, Population, Human sexuality, Vulnerable Populations, law.invention, Developmental psychology, Condoms, Homeless Youth, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Contraceptive Agents, Homeless youths, Condom, Pregnancy, law, Health care, Humans, 030212 general & internal medicine, education, Contraception Behavior, Reproductive health, Community and Home Care, High rate, education.field_of_study, 030505 public health, business.industry, Pregnancy, Unplanned, Psychiatry and Mental health, Contraceptive use, Socioeconomic Factors, Female, 0305 other medical science, business, Psychology
Abstract: Homeless youth become pregnant or involved in pregnancies at high rates. There are many ways by which unintended pregnancies may be prevented, including the use of condoms and other contraceptives. However, there is a dearth of research regarding contraceptive use among this vulnerable youth population, and especially through lenses that consider homeless youths' diverse gender identities, expressions, and sexualities. This study qualitatively explores homeless youths' attitudes and experiences regarding condom and other contraceptive use. Data were obtained from interviews with 30 youth experiencing homelessness, ages 18-21. Youth reported inconsistent use of condoms and other contraceptives, which youth often attributed to their perceptions of contraceptive inaccessibility and exorbitant cost. Most youth also did not know where to obtain contraceptive information and services, and reported transportation barriers and fear of being stigmatized in health care settings, particularly in relation to their gender identities and sexualities. Findings suggest that reproductive and sexual health information and services are urgently needed by all homeless young people, and from low-barrier, non-judgmental, and empathetic sources.
Published: 2018

41. A taxonomy of hospitals based on partnerships for population health management

Author: James W. Begun, Eunjeong Noh, and Sandra J. Potthoff
Subjects: Leadership and Management, Strategy and Management, partnership, Population health, 03 medical and health sciences, Surveys and Questionnaires, 0502 economics and business, Humans, Cooperative Behavior, health care economics and organizations, Features, Strategic options, community health, Community level, business.industry, 030503 health policy & services, Health Policy, 05 social sciences, Public relations, Classification, Hospitals, United States, General partnership, Population Health Management, Public Health, 0305 other medical science, business, 050203 business & management, cluster analysis
Abstract: Background: Hospitals face growing pressures and opportunities to engage with partner organizations in efforts to improve population health at the community level. Variation has been observed in the degree to which hospitals develop such partnerships. Purpose: The aim of this study was to generate a taxonomy of hospitals based on their partnerships with external organizations, employing the theoretical notion of organizations’ focus on exploration versus exploitation. Methodology: With 1,238 valid cases from the 2015 American Hospital Association Population Health Survey, our study uses items asking about the level of partnership strength for 36 named partner types. Excluding three variables with low reliability, 33 variables are classified into six partner groups by factor analysis. Then, cluster analysis is conducted to generate a taxonomy of hospitals based on their partnerships with the six partner groups. Findings: Of 1,238 hospitals, 26.1% are classified as exploratory hospitals that develop more collaborative relationships with partners outside the medical sector. Exploitative hospitals (18.3%) focus on relationships with traditional medical sector partners. Ambidextrous hospitals (27.0%) develop partnerships both in and outside the medical sector. Finally, independent hospitals (28.6%) do not establish strong partnerships. Larger hospitals, not-for-profit hospitals, and teaching hospitals are more likely to be classified as exploratory. Practice Implications: The four-cluster taxonomy can provide hospital and health system leaders and managers with a better understanding of the wide variation in partnerships that hospitals establish and insights into their different strategic options with regard to partnership development.
Published: 2018

42. SARS-CoV-2 vaccination in patients with inflammatory bowel disease

Author: Robert V Bryant, John Halliday, Britt Christensen, Mark G. Ward, Peter Lewindon, Aysha H Al-Ani, Ralley E Prentice, Jacob Begun, Simon Ghaly, Clarissa Rentsch, Susan J. Connor, Douglas F Johnson, and Eva Zhang
Subjects: medicine.medical_specialty, Crohn's disease, immunosuppression, business.industry, Context (language use), Review Article, medicine.disease, Vaccine efficacy, vaccination, Inflammatory bowel disease, SARS‐CoV‐2, Review article, Vaccination, immunocompromised, COVID‐19, inflammatory bowel disease, Pandemic, medicine, Intensive care medicine, business, Contraindication, ulcerative colitis
Abstract: Background The current COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has drastically impacted societies worldwide. Vaccination against SARS-CoV-2 is expected to play a key role in the management of this pandemic. Inflammatory conditions such as inflammatory bowel disease (IBD) often require chronic immunosuppression, which can influence vaccination decisions. Aim This review article aims to describe the most commonly available SARS-CoV-2 vaccination vectors globally, assess the potential benefits and concerns of vaccination in the setting of immunosuppression and provide medical practitioners with guidance regarding SARS-CoV-2 vaccination in patients with IBD. Methods All published Phase 1/2 and/or Phase 3 and 4 studies of SARS-CoV-2 vaccinations were reviewed. IBD international society position papers, safety registry data and media releases from pharmaceutical companies as well as administrative and medicines regulatory bodies were included. General vaccine evidence and recommendations in immunosuppressed patients were reviewed for context. Society position papers regarding special populations, including immunosuppressed, pregnant and breast-feeding individuals were also evaluated. Literature was critically analysed and summarised. Results Vaccination against SARS-CoV-2 is supported in all adult, non-pregnant individuals with IBD without contraindication. There is the potential that vaccine efficacy may be reduced in those who are immunosuppressed; however, medical therapies should not be withheld in order to undertake vaccination. SARS-CoV-2 vaccines are safe, but data specific to immunosuppressed patients remain limited. Conclusions SARS-CoV-2 vaccination is essential from both an individual patient and community perspective and should be encouraged in patients with IBD. Recommendations must be continually updated as real-world and trial-based evidence emerges.
Published: 2021

43. So many therapies-So little data: How to choose? Session two summary

Author: Jakob Begun
Subjects: Evidence-Based Medicine, Hepatology, business.industry, Tumor Necrosis Factor-alpha, Gastroenterology, Adalimumab, Anti-Inflammatory Agents, Antibodies, Monoclonal, Humanized, Inflammatory Bowel Diseases, World Wide Web, Treatment Outcome, Gastrointestinal Agents, Medicine, Humans, Session (computer science), Molecular Targeted Therapy, Safety, business, Randomized Controlled Trials as Topic
Published: 2021

44. Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas

Author: Miles P. Sparrow, Dougal J M Brown, Wa Cheung, Nik S. Ding, Yoon-Kyo An, Robert B Gilmore, Peter De Cruz, Numan Kutaiba, Ashish Srinivasan, Susan J. Connor, Matthew Bastian-Jordan, Michael De Gregorio, Allan Lee, Bonita Gu, Gregory Amos, Alexander J. Thompson, Jan F. Gerstenmaier, Daniel R. van Langenberg, Christopher J Welman, Jakob Begun, Nira Borok, Tanya Lee, Gillian Mahy, Eric Yong, Lena Thin, Lauren E. Gilbert, and Krupa Krishnaprasad
Subjects: medicine.medical_specialty, Fistula, Gastroenterology, Crohn Disease, Interquartile range, Internal medicine, Adalimumab, medicine, Clinical endpoint, Humans, Rectal Fistula, Retrospective Studies, Hepatology, medicine.diagnostic_test, business.industry, Tumor Necrosis Factor-alpha, Magnetic resonance imaging, Odds ratio, medicine.disease, Infliximab, Cross-Sectional Studies, Treatment Outcome, Therapeutic drug monitoring, Tumor Necrosis Factor Inhibitors, business, medicine.drug
Abstract: BACKGROUND & AIMS: Higher anti-tumor necrosis factor-α (TNF) drug levels are associated with improved clinical healing of Crohn's perianal fistulas. It is unclear whether this leads to improved healing on radiologic assessment. We aimed to evaluate the association between anti-TNF drug levels and radiologic outcomes in perianal fistulising Crohn's disease. METHODS: A cross-sectional retrospective multicenter study was undertaken. Patients with perianal fistulising Crohn's disease on maintenance infliximab or adalimumab, with drug levels within 6 months of perianal magnetic resonance imaging were included. Patients receiving dose changes or fistula surgery between drug level and imaging were excluded. Radiologic disease activity was scored using the Van Assche Index, with an inflammatory subscore calculated using indices: T2-weighted imaging hyperintensity, collections >3 mm diameter, rectal wall involvement. Primary endpoint was radiologic healing (inflammatory subscore ≤6). Secondary endpoint was radiologic remission (inflammatory subscore =0). RESULTS: Of 193 patients (infliximab, n = 117; adalimumab, n = 76), patients with radiologic healing had higher median drug levels compared with those with active disease (infliximab 6.0 vs 3.9 μg/mL; adalimumab 9.1 vs 6.2 μg/mL; both P < .05). Patients with radiologic remission also had higher median drug levels compared with those with active disease (infliximab 7.4 vs 3.9 μg/mL; P < .05; adalimumab 9.8 vs 6.2 μg/mL; P = .07). There was a significant incremental reduction in median inflammatory subscores with higher anti-TNF drug level tertiles. CONCLUSIONS: Higher anti-TNF drug levels were associated with improved radiologic outcomes on magnetic resonance imaging in perianal fistulising Crohn's disease, with an incremental improvement at higher drug level tertiles for both infliximab and adalimumab.
Published: 2021

45. Abstract P432: Large Scale, CTEvaluation Can Improve Screening for Multi-Center Stroke Trials

Author: Tammy Stinson, Brian T. Jankowitz, Dina Begun, and Jason M Davies
Subjects: Advanced and Specialized Nursing, medicine.medical_specialty, business.industry, medicine.disease, Triage, law.invention, Randomized controlled trial, Prospective trial, law, Scale (social sciences), Medicine, Medical physics, Neurology (clinical), Cardiology and Cardiovascular Medicine, business, Stroke
Abstract: Introduction: Artificial intelligence (AI) can automate the detection and triage of ICH. ENRICH is a RCT evaluating the efficacy of MIS for ICH. AI ENRICH is a prospective trial operating within and in parallel to the ENRICH trial that utilizes an AI application, Viz RECRUIT and ICH VOLUME to identify and segment ICH to quickly identify potentially eligible subjects. Methods: Non-contrast CT scans performed at 5 participating US hospitals were evaluated specifically for a parenchymal hemorrhage by Viz ICH VOLUME. Participating health care professionals downloaded a phone application that allowed one to be notified for any hemorrhage ≥ 5 mL. Time metrics included the onset of CT scan, phone alert, and user recognition of that alert. Results: Over a combined period of 220 days, 8714 CT scans were evaluated by the Viz ICH VOLUME application. Of these, 257 CT scans were determined to contain an ICH yielding a total of 45 patients that met ENRICH criteria for trial inclusion (30-80 mL). The median time from CT scan to cell phone notification was 2:52 minutes (IQR=0.002) . The median time from cell phone notification to the user viewing the CT scan was 3:00 minutes (IQR=55.5 minutes), which was altered by a few significant delays in recognizing the alert (e.g. coordination of alerts and call schedules). After segregating the 4 weeks after ENRICH restarted on 7/14/20 into 2 week blocks, recognition of an alert within 5 minutes increased from 9% to 61.5% at the first site and 36% to 61.5% at second site - demonstrating the ability of alerts to improve site engagement and active screening for new subjects. Conclusions: In conclusion, Viz ICH VOLUME can screen large numbers of CT scans and send alerts within minutes to medical professionals. Studies relying on radiographic selection criteria may benefit from automated screening, although participating health care providers need to make use of the technology in order to maximize benefit.
Published: 2021

46. Adverse Effects Associated with Diazoxide Use in Neonates

Author: Alla Kushnir, Evan Graber, and Zoe R. Begun
Subjects: Drug, Pediatrics, medicine.medical_specialty, business.industry, Recurrent hypoglycemia, media_common.quotation_subject, Hypoglycemia, medicine.disease, Pediatrics, Perinatology and Child Health, Diazoxide, medicine, business, Adverse effect, Hyperinsulinism, medicine.drug, media_common
Abstract: Background: Hyperinsulinism (HI) is the most common cause of persistent or recurrent hypoglycemia in infants. Diazoxide is the first-line treatment used to manage infants with hypoglycemia secondary to HI after initial stabilization of blood glucose. Recent changes in definition of and in guidelines for screening for hypoglycemia in neonates led to an increase in the number of infants being treated with diazoxide. Previous studies have noted various side effects of diazoxide. With the increased use of this drug in …
Published: 2021

47. Ultrasound support of central venous catheterization reduces the incidence of thrombotic complications in the pediatric oncology clinic

Author: D. A. Solonenko, I. V. Begun, R. A. Tarasevich, and I. I. Papkevich
Subjects: medicine.medical_specialty, Venous catheterization, business.industry, Incidence (epidemiology), Ultrasound, Medicine, Pediatric oncology clinic, business, Thrombotic complication, Surgery
Published: 2021

48. Multimodal ultrasound examination in the diagnosis of benign head and neck lesions

Author: I. V. Begun, R. A. Tarasevich, and I. I. Papkevich
Subjects: medicine.medical_specialty, business.industry, Ultrasound, medicine, Radiology, Head and neck, business
Published: 2021

49. Systematic Review and Meta-analysis of Immunomodulator and Biologic Therapies for Treatment of Chronic Pouchitis

Author: Yoon-Kyo An, Jakob Begun, Emi Khoo, Teresa Neeman, and Andrew Lee
Subjects: Response rate (survey), medicine.medical_specialty, business.industry, Proctocolectomy, medicine.medical_treatment, Pouchitis, medicine.disease, Vedolizumab, Discontinuation, Meta-analysis, Internal medicine, Ustekinumab, Medicine, business, Complication, medicine.drug
Abstract: SummaryBackgroundPouchitis is a common complication after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). Although antibiotics are the primary therapy for acute pouchitis, a proportion of patients developed chronic antibiotic-dependent pouchitis (CADP) or antibiotic-refractory pouchitis (CARP). The efficacy of second line immunomodulator and biologic therapies for chronic pouchitis remain undefined. We performed a systematic review and metanalysis of published studies to assess their efficacy.MethodThe online EMBASE database was searched for full-text articles describing the treatment of chronic pouchitis meeting our criteria. Post-induction clinical and endoscopic response and remission rates were extracted and combined for meta-analyses. The rate of treatment discontinuation and safety profiles were also assessed.ResultsA total of 21 full-text articles were included in this meta-analysis representing 491 patients. The overall clinical response rate was 49% with clinical remission rate of 34%. The overall endoscopic response and remission rates were 53% and 36% respectively. The safety profile of individual agents was reassuring, but vedolizumab appears to have a more favorable safety profile.ConclusionThis review and meta-analysis identified the effectiveness of vedolizumab and ustekinumab in achieving clinical and endoscopic response in chronic pouchitis, with a reassuring safety profile. There is limited data regarding use of immunomodulators and no conclusion can be drawn. Further studies are required to define the comparative effectiveness of available treatments of CADP or CARP.
Published: 2021

50. IgM and IgA augmented autoantibody signatures improve early‐stage detection of colorectal cancer prior to nodal and distant spread

Author: Jakob Begun, Yonghua Sheng, Christopher W. Schmidt, Karen Lawler, Catharine Lanagan, Saiful Islam Roney, Gregor Kijanka, and Nam-Trung Nguyen
Subjects: medicine.medical_specialty, IgM, autoantibodies, Colorectal cancer, Immunology, colorectal cancer, Gastroenterology, Antigen, Internal medicine, medicine, Immunology and Allergy, early detection, General Nursing, Survival analysis, Receiver operating characteristic, business.industry, Proportional hazards model, Autoantibody, Cancer, Original Articles, RC581-607, medicine.disease, biomarker, Biomarker (medicine), Original Article, Immunologic diseases. Allergy, business, IgA
Abstract: Objectives Tumor‐associated autoantibodies (AAbs) in individuals with cancer can precede clinical diagnosis by several months to years. The objective of this study was to determine whether the primary immune response in form of IgM and gut mucosa‐associated IgA can aid IgG AAbs in the detection of early‐stage colorectal cancer (CRC). Methods We developed a novel protein array comprising 492 antigens seropositive in CRC. The array was used to profile IgG, IgM and IgA antibody signatures in 99 CRC patients and 99 sex‐ and age‐matched non‐cancer controls. A receiver operating curve (ROC), Kaplan–Meier survival analysis and univariate and multivariate Cox regression analyses were conducted. Results We identified a panel of 16 multi‐isotype AAbs with a cumulative sensitivity of 91% and specificity of 74% (AUC 0.90, 95% CI: 0.850–0.940) across all CRC stages. IgM and IgG isotypes were conversely associated with disease stage with IgM contributing significantly to improved stage I and II sensitivity of 96% at 78% specificity (AUC 0.928, 95% CI: 0.884–0.973). A single identified IgA AAb reached an overall sensitivity of 5% at 99% specificity (AUC 0.520, 95% CI: 0.440–0.601) balanced across all CRC stages. Kaplan–Meier analysis revealed that se33‐1 (ZNF638) IgG AAbs were associated with reduced 5‐year overall survival (log‐rank test, P = 0.012), whereas cumulative IgM isotype signatures were associated with improved 5‐year overall survival (log‐rank test, P = 0.024). Conclusion IgM AAbs are associated with early‐stage colorectal cancer. Combining IgG, IgM and IgA AAbs is a novel strategy to improve early diagnosis of cancers., Early‐stage detection of colorectal cancer is critical for patient survival. We have conducted a multi‐isotype autoantibody (AAbs) screen using a 492‐feature CRC protein array. Our study shows that IgM AAbs are associated with early‐stage disease and IgA AAbs, although stage‐independent, encompass humoral responses associated with mucosal surfaces. Combining IgG, IgM and IgA AAbs is a novel strategy for early disease detection and improvement of patient outcomes.
Published: 2021

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

311 results on '"Begun A"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources